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ABSTRACT 
Eosinophils recruited to the lungs, in response to respiratory syncytial 
virus (RSV) infection, have been associated with, the pathophysiological sequel 
of infection and more recently, with accelerated virus clearance. Heparan 
sulfates (HS), on the cell surface, are utilised by RSV to initiate infection, 
making HS a potential therapeutics target. As there is no effective RSV vaccine 
currently available, controlling RSV has remained a formidable challenge. 
The aims of this thesis were to investigate: (1) in vitro RSV effect on 
eosinophil morphology and eosinophil antiviral activity against RSV; (2) in vivo 
eosinophil antiviral activity expressed by four distinct mouse models following 
RSV infection and re-infection; and (3) the efficacy of HS mimetics treatment on 
RSV infection in vitro and in vivo. 
Firstly, transmission electron microscopy analysis, major basic protein 
and eosinophil peroxidase assays, eosinophil chemotaxis and RSV kinetics 
assays were used to examine aim 1. In vitro findings indicated human RSV 
pathogen inability to infect murine eosinophils however; eosinophil exposure to 
RSV antigen or RSV infected HEp-2 supernatant resulted in eosinophil 
activation, degranulation and chemotaxis. 
Secondly, four genetically modified BALB/s strains were infected and re-
infected. Analysis of bronchoalveolar lavage (BALF), blood and lung histology 
was used to elucidate aim 2. These in vivo results revealed significant 
eosinophil mediated reduction in viral load following RSV primary infection of IL-
5 Tg and IL-5 Tg Rag 2"/" BALB/c. However, following the RSV re-infection, 
eosinophils in addition to NK cells and type 2 innate lymphoid cells (ILC) were 
unable to provide the same antiviral protection in both, Rag 27" and IL-5 Tg Rag 
27" BALB/c mice. Results of cell adoptive transfer demonstrated a 
significant reduction of viral load recovered from IL-5 Tg Rag 27" BALB/c mice 
re-infected with RSV. 
Lastly, the antiviral potential of 53 HS mimetics was tested in vitro under 
four clinically relevant conditions. Following the in wfro findings, six HS mimetics 
were tested in vivo as a post RSV infection treatment and as a prophylactic 
treatment of RSV infection. Results revealed the first HS mimetic study 
examining and reporting on 53 HS mimetics RSV antiviral activity in vitro 
followed by HS mimetics effect on viral load reduction in vivo. Moreover, HS 
228 was found to be the best performing compound, both, as post RSV 
infection HS treatment and prophylactic treatment of RSV infection, while 
reducing RSV disease pathology in vivo. 
Taken together, the findings of this thesis identify that RSV induced 
eosinophil activation results in targeted eosinophil response in vitro and in vivo; 
however, that eosinophil recruitment and activation following RSV re-infection 
appears to be dependent on stimulation by RSV-specific memory Th2 cells 
and/or sufficient cellular response Involving NK cells and/or type 2 ILCs. In 
addition, exhaustive HS mimetics analysis has resulted in a comprehensive list 
of potential antiviral compounds that could be targeted for RSV therapeutic 
development. Furthermore, HS mimetics tested were found to activate an 
immune response even In the absence of viral infection, suggesting their 
potential in pre-emptive immune activation and modulation. 
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Chapter 1. GENERAL INTRODUCTION 
1.1 RESPIRATORY SYNCYTIAL VIRUS (RSV) 
Respiratory syncytial virus (RSV) is responsible for one of the most 
important pathogenic infections of childhood and is associated with significant 
morbidity and mortality (McNamara and Smyth, 2002). In 2005, RSV was found 
to be responsible for almost 34 million lower respiratory tract infections in 
children under 5 years of age worldwide, with 10% of infections requiring 
hospitalisation and as many as 199,000 deaths (Nair et ai, 2010). 
Approximately 99% of these deaths occur in developing countries, reflecting 
both a greater population of infants and the unjust consequences of inadequate 
resources. These morbidity and mortality numbers are most likely under-
estimated, as RSV testing is generally incomplete and undercounted globally 
(Nair et al., 2010). 
Despite extensive RSV research covering epidemiology, clinical 
manifestations, diagnostic techniques, animal models and the immunobiology of 
infection, there is not yet a convincing and safe vaccine available. Numerous 
approaches to the development of RSV vaccines are being evaluated, as are 
the use of newer antiviral agents to mitigate disease. More research is urgently 
required to elucidate the mechanisms of RSV infection and pathogenesis to 
reduce the worldwide impact of this viral infection. 
1.2 R S V DISEASE 
1.2.1 History and RSV impact on society 
Human RSV was first isolated in 1955 from a captive chimpanzee with 
upper respiratory tract illness (Morris et al., 1956). It was quickly identified as a 
human virus and since 1956 RSV has been defined as a major paediatric 
respiratory pathogen causing serious lower respiratory tract infection in infants 
and young children worldwide (Chanock and Finberg, 1957; Chanock et al., 
1957). RSV also causes disease in adults, particularly in the elderly and in the 
immunocompromised (Walsh, 2011). 
The World Health Organisation (WHO) estimates approximately 4 million 
deaths each year from infections that are transmitted via the respiratory tract, 
most of which occur in childhood (WHO, 2004). Viral infections of the 
respiratory tract are particularly serious during infancy and viral bronchiolitis is 
the most common cause of infantile hospitalisation in the developed world 
(Henrickson et a!., 2004). It has been estimated to cause 91,000 hospital 
admissions per year in the USA alone, with associated hospitalisation costs 
adding up to $300,000,000 per year. RSV accounts for approximately 70% of all 
cases of viral bronchiolitis (Openshaw, 2002). 
1.2.2 Epidemiology and evolution 
RSV is a highly contagious virus and infects an individual multiple times 
throughout the life, resulting In w/orldwide epidemics of respiratory disease each 
year (Graham et al., 2000). Humans are the only natural host for RSV, however 
the virus has been found to infect and cause severe disease in non-human 
primates (Kondgen et al., 2008; Morris et al., 1956). RSV occurs most 
frequently in areas experiencing greater seasonal temperature changes with 
RSV infections peaking in the winter months and extending into the spring 
(Arbiza et al., 2005; Bolisetty et al., 2005; Galiano et al., 2005; Kuroiwa et al., 
2005; Mufson et al., 1991; Wang et al., 1995; Watson et al., 2006; White et al., 
2005). 
Circulating human RSV isolates have been classified into two antigenic 
groups, A and B (Mufson et al., 1985) representing genetic divergence that has 
occurred approximately 350 years ago (Zlateva et al., 2005). Multiple genotypes 
within subgroups A and B have been identified to co-circulate within the same 
season and community, with one or two dominant genotypes being replaced in 
successive years (Cane, 2001; Johnson et al., 1987a). In addition, there can be 
shifts in the predominance of subgroup A versus B occurring in 1-2 year cycles 
(Waris, 1991). This reflects a modest advantage of the heterogeneous strain in 
evading previously induced immunity (White et al., 2005). As a result, the RSV 
evolutionary pattern does not resemble that of influenza A virus, in which a 
strong immune selection dictates the fast replacement worldwide of dominant 
strains in a linear manner. Instead, RSV evolution resembles that of influenza B 
viruses, in which a less strong immune selection favours slower co-evolution of 
several branches of viruses (Rota etal., 1992). 
RSV A and B often co-circulate during an outbreak, however, group A is 
found to be associated with more severe disease (Domachowske and 
Rosenberg, 1999; McConnochie etal., 1990). A study has shown that among all 
infants, RSV strain A was 2.84 times more likely to cause severe disease than 
group B (Walsh et al., 1997). Most children are infected by RSV during the first 
year of life and virtually all are infected by the age of two (McNamara and 
Smyth, 2002). 
Re-infection is frequent during the first few years of life and is 
independent of antigenic differences in RSV isolates. Of the children who had 
been infected during the first year of life, 47% and 45% were re-infected during 
the second and third years of their life, respectively (Glezen etal., 1986). Lower 
respiratory tract infection can occur during the first or second infections; 
however a considerable reduction in disease severity was observed with 
subsequent infections indicative of increasing protective immunity (Henderson 
etal., 1979). 
1.2.3 Groups at risk of RSV Infection 
The incidence of RSV is greatest at the extremes of age, in infants and 
elderly (Openshaw and Tregoning, 2005). Children under 1 year of age are the 
most affected, with peak incidence between 2 to 4 months of age (Openshaw et 
al., 2003). In children younger than 2 years of age, RSV infection is the most 
common cause of asthma attacks and is frequently associated with acute 
wheezing and respiratory distress (Zhao et a!., 2002). A number of factors can 
contribute to the risk of severe RSV disease early in life, including prematurity, 
low titres of maternal antibodies or lack of previous RSV infection (Cunningham 
et al., 1991), underlying cardiopulmonary disease (Groothuis et al., 1988; 
MacDonald et al., 1982) and immunosuppression or immunodeficiency 
disorders (Fishaut etal., 1980; Mcintosh etal., 1984). However, it is important 
to note that more than half of RSV hospitalisations occur in previously healthy, 
full term individuals (Falsey, 2007; Falsey etal., 2005). 
RSV re-infects healthy adults at a rate of approximately 5-10% per year, 
a rate that increases with increased exposure to the virus, such as with health 
care personnel (Falsey, 2007; Falsey et al., 2005). Hospitalisation due to RSV 
in othenwise healthy non-elderly adults is rare, but RSV is considered second 
only to seasonal influenza as a cause of medically significant respiratory tract 
disease in adulthood. Morbidity and mortality due to RSV is substantially 
increased in the elderly, presumably due in part to immune senescence 
(Thompson et al., 2003). In countries that are more affluent, deaths due to RSV 
are more frequent in the elderly than in the paediatric population, whereas in 
less affluent countries the paediatric burden is greater. 
Another group at risk are immunosuppressed individuals, including 
patients with an immune defect (e.g. complement deficiency, human 
immunodeficiency virus (HIV)) and patients who have undergone bone marrow 
transplantation (e.g. leukaemia patients) (Openshaw and Tregoning, 2005). 
Morbidity and mortality due to RSV is substantially increased in adults with 
underlying pulmonary or cardiac disease or immunosuppression (Falsey, 2007; 
Falsey et al., 2005; Whimbey and Ghosh, 2000). In particular, the mortality rate 
associated with severe RSV infection in adults with profound 
immunosuppression due to leukaemia or hematopoietic stem cell transplant can 
be as high as 80-100% (Whimbey and Ghosh, 2000). 
1.2.4 RSV disease and clinical symptoms 
RSV is transmitted by respiratory secretions and by direct contact with 
contaminated surfaces or materials. Viral entry is usually through the 
nasopharynx and the eyes, thus the most common way of RSV transmission is 
by hand-to-hand, hand-to-mouth or hand-to-eye contact (Hall, 1983; Hall et al., 
1976; Tripp, 2004). Infection occurs in the lung epithelial tissue (Adams et al., 
2006; Openshaw, 2002) resulting in upper rather than lower respiratory tract 
infections (Openshaw, 2002). In addition, another path of transmission is 
through viral persistence where the host serves as a reservoir for transmission 
or re-infection. This path of infection contributes to the pathogenesis of asthma 
and chronic wheezing in children who have experienced bronchiolitis 
(Mahalingam et a/., 2006). 
Clinical symptoms of RSV infected young children range from mild 
respiratory problems to severe cough, bronchiolitis and pneumonia (van den 
Hoogen et al., 2001). These symptoms are usually followed by high fever, 
myalgia (muscle pain) and vomiting (van den Hoogen et al., 2001). RSV 
infection is characterised by a slow, progressive increase in viral protein 
synthesis, where viral proteins first become detectable by 8 hours post infection 
and increase to a maximum by 18-24 hours, followed by the peak of virion 
morphogenesis (Collins et al., 1996). Severe RSV infection has been strongly 
associated with childhood asthma and repeated episodes of bronchospastic 
bronchitis which can continue into adulthood (Rosenberg etal., 2007). 
During early months of life, bronchiolitis may cause severe insult to the 
lungs and can cause long-term effects by delaying or preventing normal 
postnatal pulmonary changes. Consequently, this viral infection may lead to 
smaller underdeveloped lungs, which are more susceptible to disease later in 
life. Alternatively, neonatal infection may cause long-lasting changes in host 
immunity (Adams et a!., 2006). 
It is thought that RSV disease arises from both direct viral damage and 
the host immune response, but the relative contributions of each remain 
controversial. However, it is generally accepted that there is a positive 
correlation between the level of virus replication and disease severity 
(DeVincenzo et al., 2010; DeVincenzo et ai, 2005; Karron et al., 1997b; Martin 
et al., 2008), even though this was not observed in some studies (Bennett et al., 
2007; Hall etal., 1976; Wright etal., 2002). 
In in vivo models, duhng an infection of several weeks, there was little 
visible damage to the tissue except that ciliary beating was usually impaired, in 
contrast to the rapid tissue destruction observed with influenza A virus (Wright 
et al., 2005; Zhang et al., 2002). This suggests that RSV is not inherently a 
highly cytopathic virus, although its effect on ciliary function facilitates the 
airway obstruction, which is characteristic of RSV disease. 
RSV has also been shown to exacerbate asthma. Asthma is a chronic, 
episodic inflammatory disease of the airways where inflammation causes airway 
hyperreactivity (AHR) associated with narrowing of the small ainways (known as 
bronchioles) and variable airflow response to triggering events such as 
allergens, viral infections and exposure to airway irritants (Beasley et al., 2001). 
The asthmatic response is characterised by elevated production of 
immunoglobulin (Ig) E, cytokines, mucus hypersecretion, airway obstruction, 
eosinophil infiltration (eosinophilia) and enhanced AHR to spasmogens 
(Rothenberg, 1998; Zimmermann et al., 2003). Episodes of virus induced 
exacerbations of asthma are accompanied by increased numbers of eosinophils 
in respiratory secretions and there is evidence of eosinophil degranulation 
(Handzel et al., 1998). Eosinophil degranulation in ainway tissues is thought to 
significantly contribute to asthma pathogenesis, nasal polyposis, allergic rhinitis 
and eosinophilic pneumonia through the release of cytotoxic proteins (Walsh, 
2001). Overexpression of interleukin (IL)-13 has also been found to induce 
multiple features of asthma, including eosinophilia, mucus overproduction and 
AHR (Pope et a!., 2005). The involvement of eosinophils in RSV infection will be 
discussed in more detail later on in this literature review. 
The incubation period of RSV in vivo is typically 2 to 8 days, with virus 
replication spreading from the upper respiratory tract to the lower respiratory 
tract (Easton et a!., 2004; Wennergren and Kristjansson, 2001). In infants 
suffering from lower respiratory tract infection, signs of infection usually appear 
1-3 days after the onset of rhinorrhoea, representing the viral spread into the 
bronchi and bronchioles. Clinical recovery from RSV bronchiolitis may occur 
during the continuous viral shedding from the upper respiratory tract. However, 
virus shedding stops with the emergence of specific secretory IgA at the time of 
clinical recovery (Domachowske and Rosenberg, 1999). Prolonged virus 
shedding from the respiratory tract is observed in immunocompromised 
individuals, which suggests that functional cell-mediated immunity is very 
important in the clearance of RSV infection (Domachowske and Rosenberg, 
1999). 
1.3 R S V VIRUS AND VIRAL GENOME 
RSV is an enveloped, non-segmented, negative sense single stranded 
ribonucleic acid (RNA), cytoplasmic virus (Domachowske and Rosenberg, 
1999; Olmsted and Collins, 1989; Spann et al., 2004) with a genome of 15.2 
kllobases (kb) in length (Olmsted and Collins, 1989; Teng et al., 2001). The 
genome is comprised of ten genes which encode for eleven viral proteins 
(Collins et al., 1996; Collins and Melero, 2011; Teng et al., 2001) (Figure 1.1). 
These are; the major nucleocapsid (N) protein, phosphoprotein (P), large (L) 
polymerase protein, the non-glycosylated envelope associated matrix (M) 
protein, the fusion (F) glycoprotein, the attachment (G) glycoprotein, non-
structural (NS1 and NS2) proteins, small hydrophobic (SH) membrane protein 
and internal virion protein (M2 (M2-1 and M2-2)) (Collins et al., 1996; Olmsted 
and Collins, 1989). The viral replication cycle in vitro Is relatively long (30-48 
hours) (Collins and Graham, 2008) (Figure 1.2). 
3 ' H H H 2 B d Z Z K Z X K 
Figure 1.1. Genome structure of the Respiratory Syncytial Virus (RSV) 
The RSV genome consists of 15,222 nucleotides. RSV ten major genes encode for eleven 
different viral proteins and these are: non-structural (NS1 and NS2) proteins, nucleocapsid (N) 
protein, phosphoprotein (P), matrix (M) protein, small hydrophobic (SH) membrane protein, 
attachment glycoprotein (G), fusion (F) glycoprotein, internal virion protein (M2 (M2-1 and M2-2)) 
and large (L) polymerase protein. Adapted from (McNamara and Smyth, 2002). 
The respiratory syncytial virion is composed of the nucleocapsid 
enclosed within a lipid envelope (Easton etal., 2004; Fields etal., 1996; Smyth, 
2002). The lipid envelope is derived from the plasma membrane of the host cell 
into which the three virus glycoproteins: F, G and SH, are embedded (Figure 
1.2). The F and G proteins contribute to the 10- to 14-nm spikes present on the 
virion surface (Easton et a!., 2004). 
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Figure 1.2. Schematic presentation of respiratory syncytial virus (RSV) 
virion structure and its replication cycle 
A) RSV virion. The nucleocapsid of the RSV genome consists of the nucleocapsid protein (N), 
the phosphoprotein (P) and the large polymerase (L) protein. The nucleocapsid structure is 
surrounded by the matrix (M) protein, which forms a link between the nucleocapsid and the lipid 
membrane of the virus particle. Three virus glycoproteins are embedded in the lipid membrane, 
these are the attachment (G) glycoprotein, the fusion (F) protein and the small hydrophobic (SH) 
protein. B) The RSV replication cycle. The virus enters by direct fusion at the plasma 
membrane, and releases the encapsulated genome ribonucleic acid (RNA) and RNA dependent 
RNA polymerase into the cytoplasm. The polymerase uses the genome as a template to produce 
capped and polyadenylated messenger RNAs (mRNA), which are translated into viral proteins, 
and encapsulated antigenome and genome RNAs. The resulting encapsulated genomes are 
assembled with other viral proteins and bud from the plasma membrane to produce progeny virus 
particles. Adapted from (Bawage et al., 2013; Jianrong and Yu, 2012). 
1.3.1 Viral proteins 
1.3.1.1 Nucleocapsid-associated proteins 
The RSV L protein is thought to be the major component of the viral 
RNA-dependent RNA polymerase complex, responsible for the synthesis of all 
viral RNA, including mRNA, replicative intermediates and the progeny RNA 
genomes. The L protein contains 2,165 amino acids (Easton et a!., 2004). The 
last two RSV genes, M2 and L, overlap by 68 nucleotides. During transcription 
this overlap results in initiation at the L gene-start signal and termination at the 
M2 (M2-1 and M2-2) gene-end signal, yielding a short, truncated L mRNA as 
the major transcription product of the L gene (Fearns and Collins, 1999). 
The M2 gene has two overlapping open reading frames (ORFs), which 
encode for two proteins, M2-1 and M2-2, involved in the viral RNA synthesis 
process (Blondot et al., 2012). The RSV M2-1 is a transcription anti-termination 
factor important for the efficient synthesis of full-length mRNAs (Collins et a!., 
1996). The M2-2 protein accumulates during infection and shifts RNA synthesis 
from transcription to RNA replication (Bermingham and Collins, 1999). 
Therefore, the M2-1 protein is essential for full viral transcription, while the M2-2 
protein is responsible for viral replication (Cheng et al., 2005). 
The P protein is a key component of the viral RNA-dependent RNA 
polymerase complex (Lu et al., 2002). Interaction of the RSV P protein with the 
N, L and M2-1 proteins promotes the formation of a transcriptase complex that 
is essential for viral RNA transcription and replication (Asenjo et al., 2006; 
Garcia-Barreno et a!., 1996; Khattar et al., 2001). As it has been determined 
with other paramyxovirus P proteins, the P protein of RSV likely acts as a 
cofactor that serves both to stabilise the L protein and to place the polymerase 
complex on the N protein RNA template (Horikami et al., 1992). An in vitro study 
has also shown that P protein phosphorylation affects RSV budding and 
replication (Lu et al., 2002). Another study found that interactions of P with M2-1 
and RNA with M2-1 are required for efficient transcription activation by M2-1. 
M2-1 association with P is strictly required for recruitment to the viral RNA 
synthesis site (Blondot et al., 2012). 
The N protein forms an integral part of the nucleocapsid complex of the 
virion and is an essential component of the polymerase complex. It plays a 
critical role in folding the genome into a semi-stable RNA helix. Recent studies 
have revealed novel w/ays that RSV prevents activation of cellular defences in 
response to infection. Studies have revealed that the RSV N protein uses 
multiple novel methods to inhibit induction and signalling of pro-inflammatory 
cytokines, the induction of apoptosis, and other aspects of cellular defence 
against infection (Groskreutz e/ a/., 2010; Valarcher etal., 2003). 
1.3.1.2 Non-structural proteins 
The NS1 and NS2 proteins are relatively small, with the NS1 and NS2 
proteins being 139 and 124 amino acids in length, respectively (Easton et al., 
2004). Deletion of the genes coding for NS1 and NS2, results in reduced viral 
replication in immune cells. These proteins play a very important role in 
attenuating host immune response. The NS1 and NS2 also activate pro-survival 
pathways in the infected cell, prolonging its survival and increasing viral yield 
(Bitko etal., 2007). 
1.3.1.3 Ma trix protein 
The viral nucleocapsid is surrounded by the M protein. Recent study, 
with other members of the Paramyxoviridae family, has shown that M protein at 
the later stages of infection is predominantly accumulated in the cytoplasm 
where it is able to bind to viral RNA. This finding suggests that the M protein 
may be capable of silencing viral RNA synthesis in preparation for packaging 
(Ghildyal et al., 2003) as well as inhibition of the nuclear gene transcription 
(Ghildyal et al., 2005). As previously mentioned the N, P and L proteins were 
also found to be necessary for RNA replication (Collins et al., 1996). 
1.3.1.4 Viral envelope proteins 
The SH protein is a small integral membrane protein. The SH protein of 
RSV is the smallest of all Pneumoviruses, with a length of 64 amino acids 
(Easton et al., 2004; Teng et al., 2001). The function of the SH protein in RSV 
infection Is unclear, however, it has been suggested that its role may be in 
evading the host's immune system or in providing an ancillary role in virus-
mediated cell fusion (Rixon etal., 2005). A study has shown that in the absence 
of G protein, the SH gene has enhanced the rate of virion entry, cell-to-cell 
fusion and plaque size (Techaarpornkul et al., 2001). The SH protein shares 
structural features with a class of small hydrophobic proteins, the viroporins 
(Gonzalez and Carrasco, 2003), that insert themselves into the membrane of 
infected cells and induce permeability to ions and small molecules. In line with 
this hypothesis, SH increases membrane permeability when expressed in 
bacteria (Perez et al., 1997) and when incorporated into artificial membranes it 
forms pentameric and hexameric pore-like structures with cation channel-like 
activity (Carter et al., 2010; Gan etal., 2008). 
The G protein is an attachment protein responsible for binding of RSV to 
the cell (Karron et al., 1997a). The G protein is heavily glycosylated and helps 
the virus to evade host immune response by preventing the virus from being 
recognised as a foreign antigen (Domachowske and Rosenberg, 1999). An un-
glycosylated region in the centre of the protein contains four cysteines held 
together by disulfide bonds in a cysteine noose (Gorman et al., 1997; Johnson 
et al., 1987b; Langedijk et a!., 1996), followed by a heparin-binding domain 
(HBD) (Feldman et al., 2000; Feldman et al., 1999). While in the endoplasmic 
reticulum (ER), RSV G protein is modified by the addition of multiple N-linked 
carbohydrate chains resulting in an increase in the molecular mass of G protein 
from 32 kilodaltons (kDa) to 60kDa. Maturation of the N-linked carbohydrates of 
the G protein occurs in the Golgi compartment, where a large number of O-
linked carbohydrate chains are added, resulting in an 84-92kDa mature protein 
(Fernie etal., 1985; Lambert, 1988; Levine etal., 1987; Wertz etal., 1985). The 
size variation of the G protein is presumed to be, in part, due to the difficulty in 
sizing heavily glycosylated molecules and variations in molecular mass 
markers. It is possible that a sheath of host-specified carbohydrate helps shield 
the G protein from immune recognition. Whether due to carbohydrates, its 
unfolded structure, or some other reason, G is a less efficient neutralisation and 
protective antigen compared to F (Olmsted et al., 1986), and most individual 
monoclonal antibodies against G do not neutralise infectivity (Martinez et al., 
1997). The N- and 0-linked glycosylation sites are clustered in two regions of 
the G protein, with amino acid content reminiscent of mucins. These two mucin-
like domains in G are highly variable and contain multiple epitopes that are 
poorly conserved between strains. These two domains are separated by a 
central region to which conserved epitopes have been mapped (Martinez et al., 
1997). This conserved region includes a segment of 13 highly conserved amino 
acids that overlaps with a segment containing four closely spaced, invariant 
cysteine residues that are disulfide-bonded to form a cysteine noose (Gorman 
et a/., 1997; Johnson et al., 1987b). The downstream pair of cysteine residues 
conform to a CX3C motif that is embedded to the CXC3 chemol<ine fractalkine 
sequence (Tripp et al., 2001). 
Studies in the mouse model comparing wild type with a mutant RSV 
lacking the CX3C motif revealed that fractalkine mimicry reduces the pulmonary 
influx of immune cells involved in innate and adaptive responses to RSV 
infection (Harcourt et al., 2006; Tripp et al., 2000; Tripp et al., 2001). In addition, 
the cysteine-rich domain of G was shown to inhibit activation of toll-like receptor 
(TLR)-2, 4, and 9 in human monocytes, thus suppressing innate immune 
response (Polack et al., 2005). In addition to these immune evasion strategies 
G protein in its secreted form, functions as an antigen decoy to help the virus 
escape neutralising antibodies and reducing antibody-mediated clearance by 
immune cells (Bukreyev et al., 2008). Taken together these immune evasion 
strategies benefit not only virus replication but also viral persistence (Li et al., 
2006). 
The F protein fuses the viral envelope with the host membrane, allowing 
the entrance of the viral nucleocapsid into the cell cytoplasm. It is also 
responsible for cell-to-cell fusion and the formation of syncytia (Walsh and 
Hruska, 1983). Syncytia are a mass of cytoplasm within a cell membrane, 
containing multiple nuclei and resulting from cell-to-cell fusion. Fusion of the 
virus to the cell membrane and formation of syncytia, are characteristic 
cytopathic effect of RSV, and are mediated by the viral F protein. It is still 
unclear what advantage RSV gains from forming syncytia through cell-to-cell 
fusion. However, it is believed that RSV may use syncytium formation to enable 
quick spread to neighbouring cells and/or to evade host defence mechanisms 
(Gower et al., 2005). While penetrating through the cell membrane, RSV causes 
changes in the surface morphology of infected cells (Krzyzaniak et al., 2013). As 
a result, the cell surface is covered with filamentous protrusions, which are 
coated with the viral envelope proteins F and G, suggesting a potential role for 
both proteins in forming cell-to-cell contact and syncytium formation (Gower et 
al., 2005; Yao and Compans, 2000). The RSV F protein is necessary for 
infection, as mutant RSV lacking F protein cannot Infect cells on Its own but 
rather requires a helper virus to gain entry into cells (Batonick et al., 2008). The 
F protein is post-synthetically cleaved and has other structural similarities to the 
F proteins of other paramyxoviruses. In addition, some monoclonal antibodies 
directed to the F protein inhibit syncytium formation (Walsh and Hruska, 1983), 
confirming its role in fusion. The RSV-F protein has been shown to interact with 
intercellular adhesion molecule (ICAM)-1 expressed on the cell surface. 
Al though it has not been definitively shown to be essential in viral fusion, ICAM-
1 has been reported to bind the F protein and as such may still have a role in 
fusion (Behera etal., 2001). 
1.3.2 RSV receptors 
RSV binding and entry is hypothesised to be a two-step process: the first 
involving the attachment of the virus to the cell membrane, which may be 
enhanced by electrostatic interactions with cellular glycoproteins/heparin and 
the viral G protein, and the second involving fusion to the cell membrane 
mediated by the viral F protein and a specific cellular fusion receptor (Tayyarl et 
al., 2011). Proposed RSV receptors Include ICAM-1 (Behera et ai, 2001), 
heparin (Krusat and Streckert, 1997), annexin II (Krusat and Streckert, 1997), 
TLR-4 (Marr and Turvey, 2012) and fractalkine receptor, CX3CR1 (Harcourt et 
al., 2006). 
Binding of viral G protein in an electrostatic fashion to the cell surface 
may be the first step in efficient viral attachment prior to fusion via nucleolin. 
First described in 1973, nucleolin is a multifunctional protein found throughout 
the cell and primarily localised within the nucleolus (Bugler et al., 1982; Orrick et 
al., 1973). Nucleolin is involved in diverse biological processes including cell 
proliferation, growth, cytokinesis, replication, embryogenesis and nucleogenesis 
and is considered necessary for cell survival and proliferation (Srivastava and 
Pollard, 1999). Al though nucleolin is typically thought of first and foremost as an 
intranuclear protein (Tajrishi et al., 2011), there is abundant evidence that it can 
also be found within the cytoplasm and on the cell surface and may play the 
role of a "molecular shuttle" between these compartments (Hovanesslan et al., 
2010; Srivastava and Pollard, 1999). The actin cytoskeleton modulates the 
entry of substances via nucleolin into the cytoplasm (Hovanesslan et al., 2010). 
Nucleolin also plays a role In viral replication and intracellular trafficking of viral 
components. For example nucleolin is required for herpes simplex virus (HSV) 1 
DNA replication (Calle et al., 2008) and also for trafficking of the herpes simplex 
virus US11 protein (small HSV phosphoprotein) out of the nucleus (Greco et al., 
2012). 
Viruses initially activate the innate immune system, which recognises 
viral components such as genomic DNA, single-stranded RNA and viral proteins 
through pattern-recognition receptors (PRRs) (Diebold et al., 2004; Hell et al., 
2004). One group of PPRs involved in RSV infection are TLRs that are 
important for the production of type I interferons (IFNs) (Edelmann et al., 2004; 
Ishii et al., 2006; Stetson and Medzhitov, 2006). Detection of viral components 
by TLRs in immune cells activates intracellular signalling cascades result which 
in turn in secretion of type I IFNs, proinflammatory chemokines and increased 
expression of costimulatory molecules such as CD (cluster of differentiation) 40, 
CD80 and CD86 (Hochrein etal., 2004; Hoebe etal., 2003; Honda etai, 2003). 
TLRs can be divided into subfamilies primarily recognising related pathogen-
associated molecular patterns; TLR-1, TLR-2, TLR-4, and TLR-6 recognise 
lipids, whereas TLR-3, TLR-7, TLR-8, and TLR-9 recognise nucleic acids (Akira 
et al., 2006; Latz et al., 2007). Intriguingly, some TLRs are endowed with the 
capacity to recognise structurally and biochemically unrelated ligands, as 
exemplified by the ability of TLR-4 to recognise such divergent structures such 
as liposaccharide, the fusion protein of RSV (Akira et al., 2006). The most 
important cell types expressing TLRs are antigen presenting cells (ARCs), 
including macrophages, dendritic cells (DCs) and B lymphocytes (Janssens and 
Beyaert, 2003). Recently, transcripts encoding TLR-1, TLR-4, TLR-7, TLR-9, 
and TLR-10, all of which coordinate innate and acquired immune responses, 
were shown to be expressed constitutively by eosinophils (Nagase et al., 2003) 
which as previously mentioned play very important role in RSV infection. 
Although TLR-3 and TLR-7 both recognise viral RNA, TLR-3 uses toll-
interleukin receptor domain-containing adaptor-inducing IFN-P (TRIF) and does 
not require myeloid differentiation primary response gene 88 (MyD88), while 
TLR-7 signalling is MyDSS dependent (Diebold et al., 2004). These differences 
in adaptor usage, along with the activation of different IFN regulatory factors 
(IRFs), are proposed to provide specificity in functional outcome (O'Neill et al., 
2003). In addition, the molecular characterisation of eosinophils supports the 
concept that these cells may contribute to the regulation of both, the innate and 
the adaptive immunity. As there is only limited direct evidence demonstrating 
eosinophil functional role in controlling of viral infection (Domachowske et al., 
1998a; Rosenberg and Domachowske, 2001), more research is required to 
elucidate the role of eosinophils in RSV infection. 
Feldman et al. (2000) have reported in their study that cp-52, the RSV 
mutant lacking its SH and G genes, binds to glycosaminoglycan (GAGs) on the 
cell surface of the target cell in a manner similar to wild type RSV (Feldman et 
al., 2000). Furthermore, they found that the RSV F protein, like its G protein, 
binds to heparin-agarose, though the relative affinities were not explored. These 
results suggest that in the absence of the G protein, the F protein may be able 
to attach the virion to cellular GAGs initiating viral infection, highlighting the 
importance of heparan sulfate (HS) as an RSV receptor enabling RSV 
propagation. Li et al. (2006) have also show/n that RSV is capable of infecting 
neuronal cells in the lungs of mice, however the RSV infection was reduced in 
the absence of the RSV G protein and the G protein CX3C motif (Li et al., 
2006). 
1.3.2.1 Viral interaction with GAGs 
1.3.2.1.1 Proteoglycans and GAGs 
Proteoglycans (PGs) are important components in the extracellular 
matrix (ECM) and on the cell surface. They are composed of a core protein with 
one or more covalently O-linked GAG chain(s) (Bernfield et al., 1999; Kjellen 
and Lindahl, 1991). GAGs are linear polysaccharide composed of repeating 
disaccharide units (Yamada and Kawasaki, 2005). The GAGs are divided into 
four classes: 1. HS/heparin; 2. Chondroitin sulfate (OS) and dermatan sulfate 
(DS); 3. Keratan sulfate (KS); 4. Hyaluronan (Figure 1.3) (Kjellen and Lindahl, 
1991). 
HS and heparin are composed of repeating disaccharide units of 
hexuronic acid (HexA) and glucosamine (GlcN) in -HexA/1,4-GlcN1,4- structure 
with sulfation at various positions (Lindahl and Li, 2009). Heparin, an 
intracellular GAG, is synthesised and stored in mast cells. Heparin shares high 
similarity with HS in structure, but is more sulfated. The biological functions of 
heparin in mast cells are not entirely clear, however it is known that heparin is 
crucial for expression and storage of histamine, proteases and other 
inflammatory mediators within mast cells granules (Kolset and Zernichow, 
2008). HS is generally attached to core proteins, forming heparan sulfate 
proteoglycan (HSPG). In this form, HS binds to a variety of protein ligands 
regulating a wide variety of biological processes including angiogenesis, blood 
coagulation, tumour metastasis and viral attachment (Jones et a!., 2005; 
Nangia-Makker et al., 2000). 
on HNR' OR HNAc 
Heparan sulfate/Heparin Chondroitin sultate/Dermatan sulfate 
Cf^R CH,OR CH^ OH 
5h m^ Ac OH HNAc 
Keratan sulfate Hyaluronan 
Figure 1.3. Disaccharide structure of glycoaminoglycans 
R represents H or SO -^, R' represents H, COCH3 or SO^-; GIcA of heparan sulfate/heparin and 
chondroitin sulfate can be epimerised to IdoA (in grey) (Kjellen and Lindahl, 1991). 
GAGs found in the intracellular vesicles and on the outer face of the 
plasma membrane, are found to act as virus receptors. Several studies have 
show/n that some bacteria and viruses use GAGs, particularly HS for attachment 
to, and entry into, cultured immortalised cells (Baldassarri et al., 2005; 
Bousarghin eta!., 2005; Jones ef a/., 2005; Rue and Ryan, 2002). 
A number of viruses have demonstrated a great affinity for cell HSPGs, 
playing important roles in virus attachment and entry (Lee et al., 2006). HS has 
been shown to bind the RSV G protein (Krusat and Streckert, 1997) on the cell 
surface of the human epidermoid cancer derived (HEp-2) cells, however it turns 
out that human airway epithelium does not express HS on the apical surface, 
the site of RSV attachment and cellular entry (Duan et al., 1998). Therefore, the 
binding to heparin by the G protein may simply serve to demonstrate that the G 
protein has a general affinity for negatively charged carbohydrates on the cell 
surface (Guo et al., 2008). Peptides from a conserved region of the G protein 
bind to heparin and to target cells, partially inhibiting viral infection (Feldman et 
al., 2000). Furthermore, the G protein has been shown to bind immobilised 
heparin (Krusat and Streckert, 1997). These findings further support the idea 
that the G protein is the RSV attachment protein and point to cell surface GAGs 
as the llgand. RSV infection is mediated partly by an initial interaction between 
attachment glycoprotein and highly sulfated heparln-like GAGs located on the 
cell surface (Grim et al., 2007; Techaarpornkul et al., 2002). Also, it has been 
suggested that the presence of cell surface GAGs containing iduronic acid, 
such as HS and chondroitin B, is required for efficient RSV infection in cell 
culture (Dong ef a/., 2013; Hallak etal., 2000b). 
HS mimetics, mimicking the role of heparin and heparan sulfate, have 
the ability to inhibit the virus binding to cells and their antiviral efficiency 
depends on their molecular w/eight and number of sulphated groups present. A 
study has used low molecular weight HS mimetics such as PI-88, a mixture of 
highly sulphated mannose containing di- to hexa-saccharides, to inhibit HSV 
infection of cells and cell-to-cell spread (Nyberg et al., 2004). Heparin, which is 
approximately six times larger than PI-88, appeared to be a better inhibitor of 
HSV infectivity, whilst PI-88 performed more efficiently in reduction of cell-to-cell 
spread of the virus (Nyberg et al., 2004). This is indicative of the importance 
that the size of the HS mimetics compound has on the Inhibition of intracellular 
transmission of HSV. PI-88 appears to inhibit HSV infection of cells by blocking 
the binding of the viral attachment glycoproteins to the cell surface (Nyberg et 
al., 2004). 
RSV interactions with cellular GAGs, cp-52 in particular, share 
similarities with other viruses, including alphaviruses (Byrnes and Griffin, 1998), 
flaviviruses (Chen et al., 1997), and herpes viruses (Neyts et al., 1992). 
Therefore, consideration of the model that was proposed for dengue virus 
binding to cells by Putnak et al. (1997) is appropriate (Putnak et al., 1997). This 
model suggests that the initial interaction of the dengue virus E glycoprotein 
with cell surface GAGs provokes a conformational change allowing E 
glycoprotein to interact with a putative high-affinity receptor, triggering 
endocytosis. In a similar scenario, RSV-F interaction with cellular GAGs could 
result in a conformational change that exposes the fusion peptide or allows 
RSV-F to interact with a putative high-affinity receptor required for fusion. RhoA 
is a small GTPase of the Ras superfamily that has been shown to interact with 
RSV-F both in vitro and in vivo (Pastey et al., 1999). Another study has shown 
that RhoA facilitates virus induced syncytium formation; however, whether 
RhoA is expressed on the cell surface and serves as the RSV receptor, remains 
unclear. Also, their preliminary findings suggest that an RSV mutant lacking G-
protein can still infect CHOpgs>4-745 cells, which are 99% GAG deficient, 
indicating that RSV F protein alone can infect cells by interacting with cellular 
membrane components other than GAGs (Feldman etal., 2000). 
In addition, dengue virus, a human pathogen that has re-emerged as an 
increasingly important public health threat, has been found to use HS for viral 
attachment (Chen et al., 1997). Heparin and the polysulfonate pharmaceutical 
suramin have been found to effectively prevent dengue virus infection of target 
cells, indicating that the envelope protein-target cell receptor interaction is a 
critical determinant of infectivity (Chen et al., 1997). 
Developing pharmaceuticals that inhibit target cell binding to the virus 
may also be an effective strategy for the treatment of RSV infection. These 
could harness the similarities observed in the cell binding mechanisms between 
dengue virus and RSV, specifically the interactions with cellular GAGs (Chen et 
al., 1997). 
1.4 IMMUNE RESPONSE TO R S V INFECTION 
Viral detection, clearance and the process of recovery from viral 
respiratory tract infection (as well as resistance to re-infection) is mediated by 
both the innate and adaptive host immune responses with cellular and humoral 
immune responses, acting directly to orchestrate viral clearance (Braciale et al., 
2012; Graham and Braciale, 1997). In animal models of RSV infection, both 
cytotoxic T cells and antibody responses play a pivotal role in RSV clearance 
from the lung (Braciale et al., 2012; Yoo et al., 2013). 
1.4.1 Adaptive immunity 
1.4.1.1 Cell-mediated immunity and T cell deficiency 
Cell-mediated immune response plays an important role in RSV 
clearance (Domachowske and Rosenberg, 1999). It is classified according to 
the expression of lymphocyte surface antigens into, CD8^ cytotoxic T 
lymphocytes (CTL) and CD4'- T helper (Th) cells. Both types of cells possess 
antiviral and immunogenic capabilities. 
CD4'' Th cells are subdivided into Th1, Th2 and Th17 lymphocytes based 
on their cytokine production profile. The Th1 subset is characterised by the 
production of IFN-y, IL-2, IL-12 and tumour necrosis factor alpha (TNF-a), while 
Th2-cells are characterised by the production of IL-4, IL-5, IL-10 and IL-13 
(McNamara and Smyth, 2002). In the murine model, induction of different CD4'' 
T cell responses may be dependent on the RSV antigen. It has been found that 
when mice are primed with vaccinia expressing F protein, a strong Th1 CTL 
response is induced (Graham etal., 2000). However, when mice are immunised 
with RSV G protein, a Th2 response is generated which is associated with 
eosinophilic infiltration into the lung following subsequent RSV challenge 
resulting in increased clinical disease symptoms (Graham et al., 2000). The 
third subset of 004"^ Th cells, Th17, differs from the other two subsets in terms 
of their requirements for differentiation and expansion factors and in their target 
pathogens. Th17 lymphocyte are characterised by production of IL-17, which is 
known to induce mucus production in the respiratory tract and increase the 
expression of polymeric Ig receptors that facilitate the release of IgA and IgM 
antibodies into the respiratory tract (Jaffar et al., 2009). Of the other cytokines 
produced byTh17 lymphocytes, IL-21 promotes Th17 proliferation and antibody 
production by B lymphocytes (Mitsdoerffer et al., 2010). Th17 lymphocytes are 
present in the respiratory tract and there is evidence that they play a key role in 
responses to fungal infections. These cells, however, also contribute to 
inflammatory disorders that afflict the respiratory tract, such as asthma and 
chronic obstructive pulmonary disease (COPD). Increased production of the 
Th17-related cytokines, such as IL-17A, IL-22 and IL-23 in COPD patients 
reflects the involvement of Th17 lymphocytes in initiating and driving the 
disease process (Di Stefano etal., 2009; Vargas-Rojas etal., 2011). In addition, 
excess IL-17 production has been reported in animal models and human 
patients has been associated with neutrophil dominated asthma and with 
cortisone-resistant severe AHR (Wilson et al., 2009; Zhao et al., 2010). Th17 
lymphocytes have also been implicated in effector mechanisms triggered in 
response to RSV and other types of respiratory viral infections (Faber et al., 
2012; Mukherjee et al., 2011). Mukherjee et al. (2011) study found that blocking 
of IL-17 significantly decreased viral load and altered cytotoxic CDS T-cell 
marker expression (Mukherjee et al., 2011). 
CDS"^  T cells play a critical role in mediating RSV clearance. However, as 
RSV is a leading cause of severe virus induced respiratory disease in 
individuals over the age of 65, it is important to note that immune response 
varies depending on age. While it is clear that T cell immunity declines with age, 
it is not clear to what extent the CDS"^  T cell response to RSV is altered. A study 
has found a decrease in the capacity of aged mice to induce a high magnitude 
acute CDS"^  T cell response, resulting in prolonged viral replication. This would 
help explain the increased disease severity of RSV infection observed for aged 
individuals (Fulton et al., 2013). RSV-specific CD8'' lymphocytes are important 
in recovery and pathogenesis of RSV disease, however, a too vigorous 
response can be harmful (McNamara and Smyth, 2002). Therefore, the key to 
effective immunity is in T cells regulation (Braciale et al., 2012; Graham and 
Braciale, 1997). 
In a study of RSV-infected infants, no correlation was found between 
clinical disease parameters and the level of the virus specific CTL response in 
bronchoalveolar lavage (BAL) fluid or blood (Heidema et al., 2007). Moreover, 
only low numbers of T cells were detected in postmortem lung tissues of 
children with lethal RSV infections (Johnson et al., 2007; Welliver et al., 2007). 
In addition individuals with compromised T cell immunity can shed virus for 
months (Hall et al., 1986) with prolonged virus shedding also observed in nude 
or irradiated BALB/c mice (Cannon et al., 1987) and in mice depleted of both 
CD4^ and CD8'' cells (Graham et al., 1991). In wild type mice, an RSV-specific 
CDS'" T cell response provides protection against infection, but the effect is 
short-lived (Connors etal., 1991; Kulkarni etal., 1995). Experiments in the RSV 
mouse model have shown that T cells are necessary and sufficient for virus 
elimination and that T cell mediated immunopathology contributes significantly 
to the disease (Cannon et al., 1988; Graham et al., 1991; Ostler et al., 2002). 
However, RSV is not a natural pathogen of mice, and only a limited respiratory 
infection can be established after intranasal inoculation of virus at high titres 
(>10^ plaque forming units (pfu)) (Graham et al., 1988). The significance of 
these findings for human RSV infection is therefore unclear. 
Infection of mice with pneumonia virus of mice (PVM), a virus of the 
same genus as RSV, is increasingly used as a natural host experimental model 
for human RSV infection (Easton et al., 2004). PVM replicates to high titres in 
the mouse lung, causing a rapid onset of severe, and eventually fatal, 
granulocytic bronchiolitis at doses as low as lO^pfu (Domachowske et a!., 
2000a; Domachowske et al., 2002). Supporting a similarity in clinical 
presentation between RSV and PVM is evident in functional CTL inactivation 
observed in mice after PVM challenge (Bonville et al., 2003; Claassen et al., 
2005; Domachowske et al., 2001). A study using T cell deficient mice 
challenged with PVM showed that mice became chronic virus carriers in the 
absence of acute disease, illustrating the dual role of T cells for virus control 
and immunopathology (Frey et al., 2008). Controlled variation of host and viral 
parameters showed a tight balance between beneficial and detrimental effects 
of T cells but also revealed pathways of disease that appeared to be T cell 
Independent following high dose PVM infection (Frey et al., 2008). Earlier 
studies found that the innate immune response to PVM in C57BL/6 mice 
(Easton et al., 2004) resulted in a very poor pulmonary lymphocyte responses 
(Domachowske et al., 2000b) while in contrast analysis of BALB/c mice at later 
time points following infection showed significant CD8^ T-cell infiltrates 
(Claassen et al., 2005). This data indicates a potential PVM mediated functional 
inactivation of T cells as well varying responses depending on a genetic 
makeup. 
Analysis of the function of PVM specific T cells after re-stimulation with 
PVM infected APCs has resulted in a pulmonary T cell response to PVM that is 
comparable to other murine respiratory virus infections, including RSV (Ostler et 
al., 2001). This supports observations that functional silencing of T cells in the 
alveolar space may not be to impair virus control but represents a physiological 
mechanism to limit pulmonary inflammation rather than a viral escape strategy 
(Ostler and Ehl, 2002; Vallbracht et al., 2006). Frey et al. (2008) also showed 
that T cell deficient or T cell depleted mice could not eliminate PVM15 during an 
observation period of 49 days. They found that persisting virus titres in these 
chronically infected mice were almost 10-fold lower than peak titres, suggesting 
that T cell independent factors, e.g., components of the innate immune 
response, can provide some level of virus control but fail to eliminate the 
pathogen (Frey et al., 2008). These results mirror previous findings in human 
and murine RSV infection in that infants with congenital T cell deficiencies fail to 
eliminate RSV (El Saleeby et al., 2004; Fishaut et al., 1980; Hall et al., 1986), 
and depletion of T cells leads to persistent infection in BALB/c mice (Graham et 
a/., 1991). Adoptive transfer experiments have shown that T cells are necessary 
and sufficient to clear RSV from infected mice (Cannon et al., 1988; Cannon et 
al., 1987; Ostler et al., 2002). Similar to the RSV model (Graham et al., 1991), 
both CD4-' and CDS'" T cells contributed to the clearance of PVM from the lung 
and it w/ould be important to assess if this applies to human model as well. 
Limitations of the cell mediated immune response to RSV seem to be crucial to 
RSV evasion tactics of the immune system, short lived immunological memory 
and partial viral clearance. Further research into RSV infection using T cell 
deficient model is required to assess the degree of RSV inhibition of the 
adaptive immunity as well as if enabling of the enhanced innate immune 
response is able to compensate for the absence of adaptive immune 
components. 
1.4.1.2 Humoral immunity 
Humoral immunity is mediated by B lymphocytes, which are responsible 
for antibody production. The presence of maternal IgA antibodies, within 
colostrum, provides limited protection against RSV in breastfed infants 
(McNamara and Smyth, 2002). The amount of antibodies in the newborn is 
similar to maternal levels and declines slowly during the first month of life. 
Serum and secretory antibodies are produced in response to RSV infection 
however, the total amount of antibodies produced in infants is very low 
(Yamazaki et al., 1994). Antibody responses in young infants are often 
ineffective at neutralising virus as well as short lived compared to older 
individuals (Welliver et al., 1980). Immunologic immaturity contributes to limited 
innate and adaptive responses observed early on in life (Adkins et al., 2004; 
Levy, 2007). For example, the B cell response to RSV infection of young 
infants, which are less than 3 months of age, was found to have a biased 
antibody gene repertoire. Furthermore, it also expressed significantly reduced 
frequency of somatic mutations, limiting the host capacity to respond to new 
foreign antigens. These findings demonstrate how immature immunity 
contributes to the poor neutralising activity characteristic of responses in young 
infants (Williams et al., 2009). Furthermore, the immunosuppression by RSV 
specific maternal serum antibodies, present in young infants, have been shown 
to suppress both serum and secretory antibody responses to RSV infection, but 
did not suppress the cell mediated response or priming for a secondary 
antibody response (Crowe et al., 2001; Murphy et at., 1988). In contrast, a 
recent study examined a cohort of infants of less than 6 months of age with very 
low titres of RSV specific maternal antibodies and found that the titres of RSV 
neutralising serum antibodies, induced by primary RSV infection, were 
indistinguishable from those of individuals of 6-24 months of age (Shinoff et al., 
2008). This showed that, when the immunosuppressive effect of maternal 
antibodies is minimal, wild type RSV could induce a substantial antibody 
response even in young infants. 
1.4.2 Innate immune response 
The innate immunity is non-specific and provides the first line of defence 
against infection (Goldsby et al., 2003). The innate immune response recruits 
effector molecules and phagocytic cells rapidly to the site of infection through 
the release of cytokines and chemokines, however, it lacks immunological 
memory (McNamara and Smyth, 2002). In the lung, pulmonary surfactant is the 
first line of defence producing a surface active complex of lipids and proteins 
that lines the alveolar surface. However, it has been shown that the 
concentration of surfactant proteins (A, B and D) is significantly reduced in 
severe RSV infection (Kerr and Paton, 1999). Surfactant protein A mediates 
processes such as opsonisation and complement activation. In vitro, surfactant 
protein A has been shown to neutralise RSV by binding to the F protein 
(McNamara and Smyth, 2002). 
In RSV infection, the most important cells of the innate immune response 
are neutrophils, macrophages, DCs, eosinophils and natural killer (NK) cells. 
Literature suggests that DCs, as the primary APCs, are the first to encounter 
RSV and are likely to carry viral antigen from the respiratory tract to lymph 
nodes where DCs encounter and activate naive virus specific T cells (Braciale, 
2005). Macrophages and neutrophils are phagocytic cells whose main function 
is to engulf and destroy viruses and other foreign pathogens (Message and 
Johnston, 2001). Macrophages play an important role in controlling the immune 
response to viral infection. Both macrophages and epithelial cells encounter 
RSV in the airways (Kimpen, 2001b). Recent studies in mice showed that 
macrophages provide an immediate response of proinflammatory cytokines 
following RSV infection (Pribul et al., 2008), and are a major producer of type I 
I FN (Kumagai et al., 2007). Macrophages appear to be important both in 
restricting the virus and in clearing debris that othenwise can promote further 
damage and inflammation (Reed et a!., 2008). During RSV infection, 
macrophages secrete cytokines (e.g. IL-1p, IL-6, IL-8, IL-10, IL-12 and TNF-a) 
which further upregulate the immune response, increasing vascular permeabil i ty 
and recruiting and activating lymphocytes, neutrophils, natural killer cells and 
eosinophils to the site of infection (McNamara and Smyth, 2002). These 
activated cells have been found to secrete a number of chemokines whose 
primary function is the movement of cells within tissue and across endothelial 
barriers. Chemokines include monocyte chemoattractant protein (MCP)-3, 
MCP-4, regulated upon activation normal T-cell expressed and secreted 
(RANTES), macrophage inf lammatory protein 1a (MIP-1a) and eotaxin (Foster 
etal., 1996). 
Neutrophils are the predominant airway leukocytes in RSV bronchiolitis 
and they are activated in the presence of infection. A recent study of infants 
hospitalised for severe RSV disease showed that the appearance of neutrophil 
precursors in the peripheral blood, which precedes their influx into the lungs, 
closely fol lowed the peak of virus shedding and was coincident with clinical 
symptoms, implying possible roles both in protection and disease (Lukens etal., 
2010). 
Up until the last decade, NK cells were unique in being the only identified 
innate cell derived from a lymphoid progenitor. Recent developments have now 
classified NK cells as the earliest identified member of a family of hematopoietic 
effector cells termed innate lymphoid cells (ILCs) that are dependent on the 
transcription factor Id2. Currently, ILCs can be broadly classified into three 
groups: (a) NK cells, (b) the retinoic acid receptor-related orphan receptor y t 
(RorYt)-dependent ILCs (lymphoid tissue inducer (LTi) cells, ILC17, ILC22), and 
(c) ILC2 cells. These groups have recently been named ILC1, ILC3 and ILC2 
respectively. These various ILCs have now been implicated in protection 
against infectious organisms, organogenesis of lymphoid tissue, t issue 
remodell ing during wound healing and homeostasis in t issue stromal 
cells.(Cherrier et ai, 2012; Hwang and McKenzie, 2013; Moro et a!., 2010; Neill 
et ai, 2010; Price et al., 2010; Spits and Di Santo, 2011). Because the key 
cytokines secreted by some ILCs mirror those of various T helper cell 
populations, it has been proposed that ILCs may represent the innate 
counterparts of T helper lymphocytes, at least in terms of cytokine production 
(Cherrier et al., 2012; Spits and Di Santo, 2011). NK cells (or ILC1) are 
recruited locally during the initial phases of virus infection (Hussell and 
Openshaw, 1998). NK cells accumulate in the lung in the first few days of RSV 
infection and produce cytokines that activate specific T cells. In addition, NK 
cells are responsible for most of the early production of IFN-y, found to be 
important in preventing the development of lung eosinophilia (Hussel et al., 
1997a; Hussell and Openshaw, 1998). The main function of NK cells is to 
recognise and destroy virus infected cells on the basis of alterations that occur 
on the surface proteins on the normal cell (Message and Johnston, 2001). The 
ILC2 cells were independently discovered in 2010 by three separate groups, 
and were called nuocytes, natural helper cells (NHCs), and innate type 2 helper 
(Ih2) cells (Moro et al., 2010; Neill et al., 2010; Price et al., 2010). Using a 
combination of flow cytometry and microarray analyses, ILC2 cells were shown 
to lack the expression of lineage defining surface markers for T cells, B cells, 
natural killer T (NKT) cells, DCs, macrophages, neutrophils, eosinophils, mast 
cells, basophils, and lymphoid tissue inducer (LTi) cells. ILC2 cells share a 
number of surface and functional similarities (Saenz et al., 2010) and variability 
of surface expression markers may be attributed to the different tissues these 
ILC2 cells have been identified in: lungs, intestine, liver and bone marrow 
(Brickshawana etal., 2011; Chang etai, 2011; Mjosberg etal., 2011; Monticelli 
etal., 2011; Wong etal., 2012; Yasuda etal., 2012). All identified ILC2 cells are 
lineage negative, respond to treatment with either IL-25 and/ or IL-33, and can 
produce type 2 cytokines (IL-5 and/or IL-13). A report of particular interest by 
Mjosberg et al. (2001) characterised a possible human equivalent of mouse 
ILC2 cells (Mjosberg etal., 2011). These human type 2 ILC cells share a similar 
phenotype, function with mouse ILC2 cells, are found in the fetal and adult lung 
and gut tissues. They also found these cells present in the peripheral blood, 
expressing the chemokine receptor type (CCR) 6 however, not producing type 2 
cytokines. This suggests that human ILC2 cells may initially be released into the 
bloodstream in an inactivate form after which they home into the lung and gut 
tissue. There, they may mature, becoming activated in situ to start producing 
type 2 cytokines (Mjosberg et al., 2011). Type 2 cytokines, such as, IL-25 and 
IL-33, are important in ILC2 cells activation and subsequent effector cytokines 
production. IL-25 (IL-17E) is a member of the IL-17 family that is associated 
with Th2-like inflammation and disease (Fort et al., 2001; Lee et al., 2001). IL-
25 mRNA transcripts are produced in Th2 cells and lung epithelial cells while 
the protein has been reported to be produced by alveolar macrophages, mast 
cells, eosinophils, and basophils (Angkasekwinai etal., 2007; Ikeda etal., 2003; 
Kang et al., 2005). IL-25 upregulates the production of type 2 cytokines through 
the activation of eosinophils, mast cells, ILC2 and Th2 cells (Kondo et al., 2008; 
Neilland McKenzie, 2011). 
Eosinophils play a specialised role in innate host defence as the potential 
exists to mediate direct killing via the release of granule associated cytotoxic 
proteins and the eosinophil ribonucleases (RNases). Also, RSV infection of lung 
epithelial cells stimulates the expression of the eosinophil activating cytokines, 
IL-5 and IL-4 secreted by mucosal lymphocytes and chemokines such as 
eotaxin, RANTES and MIP-1 a secreted by RSV-infected epithelial cells 
(Matsuzaki et al., 1996; Olszewska-Pazdrak et al., 1998a). TLRs also play an 
important role in innate immunity and eosinophil activity, with eosinophils 
expressing TLR-1, TLR-4, TLR-7, TLR-9 and TLR-10 (Nagase et al., 2003). 
Figure 1.4 summarises the innate and adaptive immune response to RSV 
primary infection and re-infection, as discussed above. 
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Figure 1.4. Detailed innate immune response following respiratory 
syncytial virus (RSV) infection 
Upon entry into the lungs, RSV virion is met by the first line of immune defence, pulmonary 
surfactants. RSV virion can be eliminated at this point how/ever if it manages to evade this 
defence system, RSV infects epithelial cells. Infection induces the release of cytokines and 
chemokines resulting in eosinophil recruitment from the blood into the lung tissue. In the 
meantime, RSV virion is recognised by dendritic cell or eosinophil via Toll-like receptor (TLR)4 
interactions with RSV glycoproteins. T helper (Th) cells once activated differentiate into Th1 or 
Th2 cell. In the case of RSV infection, this usually leads to Th differentiation into Th2 cell. 
Activated Th2 cells also release cytokines and chemokines, which can be upregulated (in black 
letters) or downregulated (red letters), resulting in activation of other immune cells. This process 
leads to eosinophil degranulation resulting in a granular content release and antiviral activity. 
Abbreviations defined: Regulated on Activation, Normal T Cell Expressed and Secreted 
(RANTES), interleukin (IL), macrophage inflammatory protein (M\P)-: a, granulocyte-macrophage 
colony-stimulating factor (GM-CSF), innate lymphoid cell type 2 (ILC2), monocyte chemotactic 
protein 1 (MCP-l)interferon (IFN), tumour necrosis factor (TNF), eosinophil cationic protein 
(ECP), eosinophil derived neurotoxin protein (EDN), eosinophil peroxidase, major basic protein 
(MBP) and reactive oxygen species (ROS). 
1.5 EOSINOPHILS 
1.5.1 Eosinophil development and function 
Eosinophils are multifunctional leukocytes involved in a wide variety of 
inflammatory responses, as well as being modulators of innate and adaptive 
immunity (Rothenberg and Hogan 2005). These highly motile granulated 
leukocytes have bi-lobed nucleus (Figure 1.5.) and are derived from CD34^ 
haematopoietic progenitor cells in the bone marrow (Rothenberg, 2004). 
Eosinophils play an important role in biological processes such as; post-
pubertal mammary gland development (Gouon-Evans and Pollard, 2001), 
oestrus cycling (Gouon-Evans and Pollard, 2001), organ rejection (Nagral et al., 
1998), and allergic inflammatory responses (Wardlaw et al., 1986) protection 









Figure 1.5. Eosinophil structure 
The bi-lobed structure (in purple) represents the eosinophil nucleus containing the 
deoxyribonucleic acid, involved in transcription of information used for nnaintaining the role of 
eosinophils in innate Immunity. The other structures are cytoplasm, cell surface membrane and 
secretion granules: major basic protein (MBP), eosinophil cationic protein (ECP) eosinophil 
derived neurotoxin (EDN) and eosinophil peroxidase (EPO) (Rothenberg and Hogan, 2005), 
Eosinophils in the bone marrow mature for eight days under the control 
of transcription factors, erythroid transcription factors (GATA-1 and GATA-2) 
and CCAAT-enhancer-binding proteins (C/EBPs) (Rothenberg, 2004). A 
number of other inflammatory mediators have been implicated in regulating 
eosinophil accumulation at the site of infection and these include IL-1, IL-3, IL-4, 
IL-5, IL-13 and granulocyte-macrophage colony-stimulating factor (GM-CSF) as 
well as the chemokines; RANTES, MCP-3, MCP-4, MIP-1a, eotaxin-1, eotaxin-
2, eotaxln-3 and lipid mediators (platelet-activating factor (PAP) and leukotriene 
(LT) C4) (Foster etal., 1996). 
1.5.2 Adhesion and migration 
Recruitment of circulating eosinophils from the blood stream into the 
mucosa involves several steps tightly regulated by chemoattractants, cell 
adhesion molecules (selectins and integrins) and Ig-like adhesion molecules. 
Firstly, eosinophils are recruited from the blood by vascular endothelial selectins 
to the inflamed endothelium. This process is closely followed by the adherence 
of eosinophils to the vascular endothelium through the adhesion molecule 
activation. Eosinophils then migrate to the inflamed site (Desreumaux and 
Capron, 1996). Once recruited to sites of allergic inflammation, eosinophils 
become activated by signals produced through the Th2-mediated cascade and 
are thought to induce disease via the release of proinflammatory molecules and 
granular proteins (Foster et al., 2002). 
Adhesion of eosinophils also occurs in the presence of molecules from 
the integrin family such as very-late-antigen-4 (VLA-4) molecules, pi integrins 
and (32 integrins (Bochner and Schleimer, 1994). VLA-4 is a receptor expressed 
by eosinophils that binds to vascular cell adhesion molecule 1 (VCAM-1) on in 
the endothelium (Symon et al., 1994). VCAM-1 on endothelial cells Is 
upregulated by IL-4 and IL-13. These two cytokines play an Important role in 
allergic inflammation, and their increased expression was found to enhance 
eosinophil recruitment (Kita and Gleich, 1996). IL-13 is particularly important as 
it regulates multiple features of asthma, including IgE production, mucus 
overproduction, eosinophil recruitment and survival, AHR and expression of 
adhesion molecules and chemokines (Pope ef a/., 2005). 
1.5.3 Trafficking of eosinophils 
Of all the cytokines implicated in modulating leukocyte recruitment, only 
IL-5 and eotaxin selectively regulate eosinophil trafficking (Rankin et al., 2000). 
IL-5 regulates growth, differentiation, activation and survival of eosinophils. 
However, both IL-5 and eotaxin provide an essential signal for eosinophil 
expansion and mobilisation from the bone marrow into the lung following 
allergen exposure (Collins et al., 1995). The mature cells shed L-selectin and 
migrate from the bone marrow to the blood (Gleich, 2000). 
The finding that IL-4 and IL-13 are potent inducers of eotaxin by a signal 
transducers and activators of transcription (STAT)-6 dependent pathway 
provides an integrated mechanism to explain eosinophilia associated with Th2 
responses (Kaplan et a!., 1996; Takeda et al., 1996). Currently there is an 
increased focus on the importance of arachidonic acid metabolites, especially 
LTB4, LTC4, LTCD4 and LTE4, and prostaglandin (PG) D2, on eosinophil 
activation. Notably, the LT type 1-receptor antagonists (now approved for 
asthma therapy), have been shown to reduce blood and lung eosinophilia 
(Tager et a!., 2000). A study has shown that mice with the targeted deletion of 
the LTB4 receptor also have markedly reduced allergen-induced eosinophilia 
(Tager et al., 2000). Furthermore, eosinophils were also found to express high 
levels of the high-affinity PGD2 type II receptor. This receptor, also expressed 
by basophils and Th2 cells, appears to co-mediate Th2 cell and 
eosinophil/basophil recruitment. Eosinophils have also been shown to express 
high levels of histamine receptor 4 which mediates eosinophil chemoattraction 
and activation in vitro (O'Reilly etal., 2002). 
1.5.4 Proinflammatory and cytotoxic effects 
Eosinophils are a potent source of proinflammatory mediators. These 
include cytotoxic proteins stored in eosinophil granules, lipid mediators newly 
formed following eosinophil activation, cytokines, chemokines, various 
eosinophil proteases and components of the respiratory burst (rapid release of 
reactive oxygen species), including superoxide and hydrogen peroxide (Walsh, 
2001). 
Eosinophil peroxidase (EPO), an abundant heme protein secreted from 
activated eosinophils, plays a central role in oxidant production by eosinophils 
(MacPherson et al., 2001; Wu et al., 1999). It is a member of the mammalian 
peroxidase subfamily and amplifies the oxidising potential of hydrogen peroxide 
produced during the respiratory burst by using it as a co-substrate to generate 
cytotoxic oxidants (MacPherson etal., 2001; Wu etal., 1999). 
Eosinophil catlonic protein (ECP) Is a major component of the large 
secretory granules of human eosinophilic leukocytes (Domachowske et al., 
1998a). Gleich et al. (1986) were the first to note that the N-terminal of both 
ECP and eosinophil derived neurotoxin (EDN) showed distinct similarities to 
RNase A, a bovine ribonuclease that has since been identified as the prototype 
of the extensive gene superfamily (Beintema, 1997). Therefore, ECP and EDN 
are classified as ribonucleases having both neurotoxic and helminthotoxic 
activities, with EDN being more active than ECP (Gleich et al., 1986; Slifman et 
al., 1986). 
Major basic protein (MBP) is localised to the core of the eosinophil 
granule while EPO, ECP and EDN are localised to the eosinophil granule matrix 
(Gleich, 1996). MBP is a potent toxin which induces damage to various 
parasites, kills bacterial and nnammalian cells, causes histamine release from 
basophils and mast cells, and activates neutrophils, platelets and eosinophils 
themselves (Kita etal., 1995). 
Eosinophil cytotoxic proteins are released through one of the following 
three mechanisms: classical exocytosis, whereby secondary granules fuse 
directly with the plasma membrane of the cell, to release their entire contents 
into the extracellular environment (Nusse et al., 1990); piecemeal degranulation 
(PMD), whereby small vesicles bud from the secondary granules and 
subsequently transport a subset of the granule proteins to the cell surface, 
resulting in the progressive loss of secondary granule constituents (Dvorak et 
al., 1992; Dvorak et al., 1991); and cytolysis, a highly organised process of cell 
death, where loss of the plasma membranes integrity leads to the release of 
cellular contents (Erjefalt et al., 1998). The release of these cationic proteins 
and associated oxidants assists in the clearance of parasitic infection (Barnes et 
al., 1998; Gleich and Loegering, 1984) and may assist in the clearance of viral 
infections. Eosinophils also induce the release of an array of inflammatory 
mediators and cytokines (e.g. IL-2, IL-4, IL-5, and IFN-y) (Table 1.1) from 
epithelial cells, APGs or T cells, leading indirectly to cytotoxicity. 
Table 1.1. Key factors involved in eosinophil-mediated immunity 
Factors Full name of factors Key observations References 
PAF Platelet activating factor 
Enhanced leukotriene 
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Eosinophilia occurs in a variety of disorders (Table 1.2.) and can range 
from nnild, to severe. Tlie most common cause of eosinophilia worldwide is 
helminthic infections, and the most common cause in industrialised nations is 
atopic disease such as allergic asthma (Rothenberg, 1998). 




Examples of Causes 
Peripheral 
Blood Tissue 
Respiratory Present or absent Present 
Eosinophilic pneumonitis, asthma (Foster et 
ai, 1996) 
Gastrointestinal Present or absent Present 
Inflammatory bowel disease, eosinophilic 
gastroenteritis, allergic colitis (Beeken et 
al., 1987; Jose etal., 1994) 
Allergic Present or absent Present 
Allergic rhinoconjuctivitis, asthma, eczema 
(Ahlstrom-Emanuelsson etal., 2004; Fauci 
etal., 1982) 
Systemic Present Present Idiopathic hypereosinophilic syndrome, vasculitis (Fauci etal., 1982) 
Three processes lead to eosinophilia: eosinophil rolling, adhesion and 
migration however; degranulation, the forth process depicted in Figure 1.6, is a 
result of eosinophilia itself at the site of infection. As described in Table 1.2 
eosinophilia has been associated with several health conditions. Accumulation 
of eosinophils, limited to specific organs, is a characteristic of particular 
diseases, including eosinophilic cellulitis or Well's syndrome. Additionally, 
eosinophilic pneumonias and Loffler's syndrome are also characterised by 
eosinophil infiltration and accumulation in the lung. Shulman's syndrome, which 
typically occurs in young adults, is another disease with characteristic 
eosinophil accumulation, with patients developing scleroderma-like skin 
indurations, predominantly on the extremities with joint contractures (Cottin and 
Cordier, 2005; Mosconi etal., 2002; Van derStraaten etal., 2006). 
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Figure 1.6. Processes involved in eosinophilia 
Eosinophilia is initiated by T helper (Tti) 2-mediated and/or innate lympiioid cell type 2 (ILC2) 
signals, namely interleukin-5 and eotaxin, driving tiie proliferation of eosinopiiils via ttie 
differentiation of progenitor cells in tiie bone marrow. Prolonged stimulation induces eosinopiiil 
mobilisation into tiie blood. Eosinophil recruitment from the blood involves rolling, adhesion and 
extravasation through the vascular endothelium, processes mediated by cell-surface integrins, 
selectins and adhesion molecules on the vascular endothelium and Th2-mediated 
chemoattractants. Eosinophils are then directed to the site of inflammation by chemokines and 
leukotrienes and induced to degranulation (Rothenberg, 1998). 
Most importantly, eosinophils are best characterised by their role in 
parasitic infections (Rothenberg, 1998), allergic asthma (Kariyawasam and 
Robinson, 2007) and recently, by their role in tumour eradication (Simson et a!., 
2007). These cells have also been found at the site of viral infection (Barends et 
al., 2004), however w/hether they actively contribute to antiviral immunity or are 
mere bystanders, continues to be a source of debate. 
1.5.6 Role of eosinophils in asthma and AHR 
Eosinophil infiltration into the lung tissue is believed to play a major role 
in promoting the pathophysiology associated with allergic airway disease, 
including inflammation and AHR (Busse and Lemanske, 2001). The release of 
the eosinophil cellular contents in response to allergen challenge in atopic 
asthma has been identified to contribute to AHR, which is an important 
pathophysiological hallmark of asthmatic decease (Ahlstrom-Emanuelsson et 
al., 2004; Kephart etal., 2010). The eosinophil cationic proteins, MBP and EPO 
have been found to induce both bronchoconstriction and AHR in the airways 
(Gundel et al., 1991), with MBP found to play a role in neurogenic inflammation 
contributing to modulation of the smooth muscle response (Fryer et al., 1997). 
Eosinophils are also the main source of LTC4, which undergoes enzymatic 
cleavage to produce two metabolites LTD4 and LTE4. These products can 
induce mucus hypersecretion, AHR, oedema and bronchoconstriction 
(Kariyawasam and Robinson, 2007). These findings suggest that eosinophils 
play an important role in the pathogenesis of asthma. 
1.5.7 Role of eosinophils in RSV infection 
Eosinophils appear to have the potential to clear respiratory viruses, 
however they can also contribute to deleterious effects of viral infection as 
highlighted by their link to allergic ainways disease and asthma (Busse and 
Lemanske, 2001). In addition the clinical similarities between viral bronchiolitis 
and asthma have led to speculation that these two diseases could have similar 
pathophysiological mechanisms, brought about by eosinophils (Domachowske 
and Rosenberg, 1999). 
In the 1960s infants were immunised with formalin-inactivated (FI)-RSV 
vaccine (Kim et al., 1969). Many of the vaccinated children became severely ill 
during a subsequent winter RSV epidemic resulting in several deaths (Olson 
and Varga, 2007). The presence of eosinophils as a result of RSV infection 
became the main histological feature in the lungs and blood of the infants who 
died following FI-RSV vaccination and subsequent RSV infection (Lindemans et 
al., 2006; Openshaw, 1995; Openshaw etal., 2001). Laboratory-based research 
into this phenomenon using a mouse model confirmed that there was increased 
eosinophil influx in the lungs of mice following immunisation with FI-RSV and 
subsequent exposure to RSV (Openshaw et al., 2001). It was unclear whether 
eosinophils were part of the host defence or were a sign of the 
immunopathology observed in response to RSV infection. 
The recruitment of eosinophils to the lungs during RSV infection may be 
an initial immune response designed to reduce viral replication, since eosinophil 
cationic molecules, especially eosinophil RNases, have been shown to possess 
antiviral activity (Domachowske et al., 1998a; Domachowske et al., 1998b; 
Klebanoff and Coombs, 1996). Phipps et al. (2007) found that airway 
eosinophilia present in hypereosinophilic (IL-5 Tg) mice, or via transfer of 
eosinophils directly to the lungs, results in the enhanced clearance of RSV 
virions and a subsequent reduction in mucus hypersecretion and AHR (Phipps 
et al., 2007). Eosinophils have the potential to play a beneficial role in RSV 
disease by clearing viral infections however when over-recruited, they 
exacerbate RSV inflammation, and cause subsequent tissue damage. 
Further research studies have focused on elucidating the role of 
eosinophils in RSV infection and pathology. Studies by Garofalo et al. (1992) 
established that wheezing during RSV infection was associated with increased 
concentrations of LTC4 and ECP in respiratory secretions, both of which are 
mediators produced and secreted by activated eosinophils (Domachowske and 
Rosenberg, 1999; Garofalo et al., 1992). Eosinophils were found to contribute to 
the inflammatory response through their chemokine expression profile 
(Olszewska-Pazdrak et al., 1998a). Olszewska-Pazdrak etal. (1998) examined 
the secretion of chemokines by RSV-infected eosinophils in vitro and found that 
human eosinophils secreted significant amounts of RANTES and MIP-1a 
following their exposure to RSV (Olszewska-Pazdrak et al., 1998a). Rosenberg 
and Domachowske (2001) also showed that eosinophils mediated a dose-
dependent reduction in virus infectivity in the presence of the RSV-containing 
suspensions. They found that a 55kDa polypeptide ribonuclease inhibitor was 
binding to the eosinophil granule proteins, EDN and ECP, with great affinity, 
causing a significant decrease in eosinophil activity and increase in viral 
infectivity (Rosenberg and Donfiachowske, 2001). 
RSV infection induces expansion of virus-specific CD4-' Th2 cells, 
resulting in the release of proinflammatory cytokines that contribute to 
eosinophilic ainways inflammation (Openshaw et al., 1992). A mouse study 
revealed that the RSV viral attachment G glycoprotein was linked to the release 
of Th2 cytokines and the development of eosinophilic pulmonary infiltrates 
(Harcourt et al., 2004). This was also demonstrated by leukocyte chemotaxis 
experiments revealing G proteins ability to modulate the immune response and 
induce leukocyte migration via the CX3CR1-fractallne pathway. CX3CR1 is a 
chemokine receptor primarily expressed at the surface of the cytotoxic cells 
such as T cells, NK cells and monocytes/macrophages (Harcourt et al., 2006). 
The CX3CR1 receptor binds to the chemokine fractalkine in murine and human 
models (Combadiere et al., 1998). As fractalkine binds to the CX3CR1 
chemokine receptor, it causes leukocyte adhesion and migration as well as a 
Th i immune response (Harcourt et al., 2006; Lee et al., 2004). The RSV G 
protein contains a CX3C chemokine motif and it has been found to interact 
directly with the CX3CR1 receptor. Hence, the G protein is competing with 
fractalkine for binding to the CX3CR1 receptor. Upon binding, the RSV G 
protein is believed to modify the CX3CR1-fractalkine interaction resulting in a 
suppression of the Th i response and upregulation of the Th2 immune response 
(Harcourt etal., 2006) ultimately resulting in downstream eosinophil activation. 
1.5.8 Role of eosinophils in PVM infection 
PVM is the only virus of the family Paramyxoviridae and subfamily 
Pneumovirinae, which naturally infects mice and is the rodent pathogen most 
closely related to human RSV (Domachowske etal., 2000a; Garvey etal., 2005; 
Rosenberg and Domachowske, 2001). In 1939, Horsfall and Hahn (1939) were 
the first to identify PVM in mouse lungs (Horsfall and Hahn, 1939). In the 
absence of antiviral therapies, PVM infection results in increased viral 
replication and a profound inflammatory response which can lead to morbidity 
and mortality (Garvey etal., 2005; Rosenberg and Domachowske, 2001). 
Murine studies have found that eosinophils and neutrophils are among 
the earliest cellular responses to PVM infection (Domachowske et al., 2000a; 
Rosenberg and Domachowske, 2001). Pulmonary eosinophilia in mice 
precedes the onset of symptoms but is not detectable once symptoms become 
obvious as it dissipates over time (Harrison et al., 1999). Therefore, eosinophil 
products are more likely detectable earlier in infection (Rosenberg and 
Domachowske, 2001). Furthermore, although IL-5 normally recruits eosinophils 
to the site of infection, PVM infected mice appear to be completely devoid of IL-
5, even in the presence of eosinophilia. Viral challenge of TLR77- mice induces 
all of the cardinal pathophysiologic features of asthma, including tissue 
eosinophilia, mast cell hyperplasia, IgE production, airway smooth muscle 
alterations, and airways hyperreactivity in a memory CD4'' T cell-dependent 
manner (Kaiko et al., 2013). Moreover, as PVM infection induces the release of 
MIP-1a, there appears to be correlation between the released MIP-1a, 
eosinophil infiltration and viral replication (Domachowske et al., 2000a). PVM 
infection in MIP-1a and/or CCR3 deficient mice, which have no eosinophils and 
a reduced number of neutrophils detected in BAL fluid at the time of infection, 
resulted in minimal inflammatory response, increased viral load and accelerated 
mortality (Domachowske et al., 2000a). These results demonstrate e that in the 
absence of eosinophils, MIP-1a/CCR3 deficient mice are overwhelmed by viral 
replication and potential death, thus suggesting the importance of eosinophils 
and neutrophils in antiviral activity. 
Although PVM is the rodent pathogen most closely related to human 
RSV, a recent research study examining the role of eosinophilia in PVM 
infection has revealed some very interesting findings. A mouse study found that 
when mice are vaccinated with PVM they remained protected following virus 
challenge (Percopo et al., 2009). These results indicate that the presence of 
eosinophils in the lung tissue and airways are associated with protection against 
virus infection. The same study repeated the vaccination and challenge protocol 
in eosinophil-deficient mice and found that eosinophil deficiency resulted in no 
change in viral titres and no change in the overall clinical symptoms (Percopo et 
al., 2009). It is unclear as to why eosinophils did not promote viral clearance in 
PVM infection (Percopo et al., 2009), despite evidence that they do promote 
antiviral activity in RSV infection (Phipps et al., 2007). Most recent study by 
Percopo et al. (2014) has found that reduction in PVM viral load is dependent 
on eosinophil activation. This study shows that eosinophils recruited to the 
airways in response to Aspergillus fumigatus (or ovalbumin) sensltisation and 
challenge do not degranulate on their own, but do so in response to subsequent 
activation with PVM (Percopo et al., 2014). It is believed that this occurs in 
response to both, PVM replication in alveolar macrophages and bronchiolar 
epithelial cells as well as production of proinflammatory cytokines (Bern et al., 
2011; Dyer et al., 2012; Rosenberg et al., 2005).This is the first study to show 
that eosinophils have a profoundly antiviral role and promote survival in 
response to an otherwise lethal PVM infection (Percopo et al., 2014). Taken 
together, these studies reveal a very promising and positive role of eosinophils 
in PVM and potentially RSV infection. 
1.5.9 Eosinophils in Rliinovirus (RV) infection 
Rhinoviruses (RV) cause the common cold which, in some cases, results 
in the hospitalisation of infected infants, the development of pneumonia in 
immunosuppressed patients and the exacerbation of asthma (Bartlett et al., 
2008). Currently, there is no effective treatment available for RV infection. 
Clinical studies have shown that RV infection results in the infiltration of 
eosinophils, neutrophils and lymphocytes in nasal and bronchial mucosa, 
causing airway inflammation (Bardin et al., 1995; Levandowski et al., 1988). 
Due to the involvement of RV in the exacerbation of asthma, Bartlett et al. 
(2008) investigated the interactions between RV infection and allergic ainway 
inflammation using a mouse model. This study found that RV infection 
contributes to the exacerbation of eosinophilic ainway inflammation, airway 
hyper-responsiveness, mucus secretion and the production of Th1 and Th2 
cytokines. A Th2 immune response in a human system results in a release of 
cytokines such as IL-4, IL-5, IL-13 and GM-CSF. High levels of these cytokines 
can be correlated with increased eosinophil infiltration and greater disease 
severity (Kato et al., 2011; Sasaki et al., 2007). All of these responses appeared 
to be linked with a rhinovirus-induced exacerbation of asthma (Bartlett et al., 
2008). 
There are approximately 100 different rhinovirus serotypes and about 
90% of these, use the human ICAM-1 for cell attachment and entry. However, 
these viruses do not to bind to mouse ICAM-1 (Bartlett et al., 2008). In a mouse 
study, Sasaki et al. (2007) found that virally infected respiratory epithelial cells 
had increased expression of ICAM-1, resulting In eosinophil infiltration into the 
respiratory area. Moreover, the same study confirmed that the sites lacking 
ICAM-1 expression experienced less eosinophil infiltration (Sasaki eta!., 2007). 
Results from a study investigating ICAM-1 and RSV suggest that the regulation 
of ICAM-1 could potentially be used to inhibit rhinovirus infection (Traub et al., 
2013). Regulation of ICAM-1 could prevent cell adhesion and entry and at the 
same time reduce eosinophil infiltration, hence reducing the respiratory 
epithelium damage caused by cytotoxic proteins (e.g. MBP and EPO) released 
from the eosinophils. 
1.5.10 Eosinophils as antigen presenting cells in viral 
infection 
As early as 1960s, studies began documenting the capacity of 
eosinophils to Internalise administered antigens and rapidly traffic them to 
regional lymph nodes. These studies revealed that within one hour of antigen 
injection, eosinophils containing the labelled antigens were localised within 
regional lymph nodes (Litt, 1964; Roberts, 1966; Shi, 2004). Although these 
studies did not establish that eosinophils were acting as APCs, they did show 
that eosinophils can be Involved in the early uptake of antigen (Shi, 2004). 
Naive T lymphocytes require two signals from APCs to be activated. The 
first signal is provided through the interaction of the T cell receptor (TCR) with 
the MHC-II protein on APCs (Chambers and Allison, 1997; Linsley etal., 1990). 
Although blood eosinophils do not usually express MHC class II protein, they 
have been shown to express MHC II in response to activation (Akuthota et al., 
2012; Linsley et al., 1990). Allergen challenge has been shown to elicit an 
eosinophil influx into the ainways resulting In recruited eosinophils expressing 
human leukocyte antigen (HLA)-DR (MHC II family member), which was not 
found on otherwise activated blood eosinophils (Mengelers et al., 1994; 
Sedgwick et al., 1992; Shi, 2004). Eosinophils in the sputum of asthmatics and 
airway have been found to express HLA-DR, but this expression was not found 
In blood eosinophils in chronic eosinophilic pneumonia patients (Shi, 2004). 
To present antigen, a second co-stlmulatory signal must be provided by 
APCs for the activation of CD28 and inhibition of cytotoxic lymphocyte-
associated antigen (CTLA)-4 receptors on T cells (Shi, 2004). CD28 and CTLA-
4 are expressed by T cells and interact with the B7 molecules B7-1 (CD80) and 
B7-2 (CD86) (Freeman et al., 1993; Linsley et a!., 1990), providing co-
stimulatory signals necessary for T-cell activation. Blood eosinophils have no 
detectable levels of CD80 and CD86 while eosinophils extracted from IL-5 
transgenic (Tg) mice from the peritoneal cavity have been found to express both 
CD80 and CD86 (Tamura et al., 1996; Wang et al., 2007). In vitro incubation of 
these cells with GM-CSF was found to increase CD80 and CD86 expression 
(Wang et al., 2007). Hence, eosinophils appear to have the potential to act as 
APCs in allergic and viral infections. By activating rhinovirus-specific T cells, 
eosinophils may play an important role in the initiation of antiviral T cell 
responses, contributing to enhanced airway inflammation and increased asthma 
symptoms in susceptible individuals (Handzel etal., 1998). 
Although a number of studies support the role of eosinophils as potential 
APCs, there are studies that argue that even with MHC class II protein being 
expressed eosinophils are inefficient in activation of T cells by antigen 
(Mawhorter et al., 1994). Therefore, the role of eosinophils as APCs remains a 
controversial topic debated intensely in the literature. 
1.6 R S V PREVENTION AND TREATMENT 
1.6.1 Prevention 
Prevention is the most important aspect of healthcare; it can lead to 
reduction in morbidity and mortality, and lower the economic burden of RSV 
disease. Currently, there is no effective vaccine against RSV. Direct or indirect 
contact with the nasopharyngeal secretions or droplets (sneezing, coughing and 
kissing), fomites, and food from RSV infected patients can potentially transmit 
RSV as live virus can survive on surfaces for several hours (Hall, 1983; White et 
al., 2005). Several approaches have been considered for developing an 
effective vaccine against RSV, however human immunisation against RSV has 
unfortunately failed (Graham et al., 2000). In the 1960's a number of infants 
were immunised with a FI-RSV vaccine, who following the natural RSV infection 
experienced pulmonary eosinophilia, several deaths and high rate of 
hospitalisation (Graham et al., 2000; Rakes et al., 1999). An efficient RSV 
vaccine would be one with proper balance between immunogenicity and 
protection without any allergic response (Hacking and Hull, 2002). RSV F 
protein has widely been accepted as the vaccine candidate due to its conserved 
nature among various strains as well as among the other paramyxoviruses 
(Hacking and Hull, 2002; Openshaw and Tregoning, 2005; Valarcher and 
Taylor, 2007; van Drunen Littel-van den Hurk etal., 2007). 
Both RSV, fusion and attachment, proteins are glycosylated and 
represent the targets of neutralising antibodies. The RSV F protein is potentially 
a good vaccine candidate due to its conserved and vital role in cell attachment. 
Passive immunisation with the monoclonal antibody specifically neutralising F 
protein has resulted in an effective protection against RSV. This licensed 
monoclonal antibody, named palivizumab (Synagis) is now used to provide 
passive protection for high risk infants from severe RSV (Ottolini et al., 2002). 
Motavizumab, variant of palivizumab, has been found to neutralise RSV by 
binding the RSV fusion protein F following the RSV attachment to the host cell 
but before the viral transcription (Huang et al., 2010). Palivizumab or 
motavizumab treatment is likely able to induce inhibition of cell-to-cell and virus-
to-cell fusion, by preventing the conformational changes in the F protein 
required for viral fusion. The effective use of palivizumab is limited due to the 
cost, therefore its use reserved for infants that are at high risk of bronchiolitis 
(Harkensee et al., 2006). Palivizumab, although effective, is costly and thus is 
not beneficial to the recipients especially during the periods outside RSV 
circulation. A cost effective means of producing RSV F neutralising antibodies 
was experimented in phages and plants. The efficacy of the plant derived 
palivizumab was found to be greater than the mammalian derived palivizumab 
(Zeitlin etal., 2013). 
The RSV genome codes structural and functional proteins that are 
immunogenic; and DNA based vaccines are developed based on these 
proteins. The process involves a DNA fragment coding part or whole protein of 
RSV being inserted into an appropriate expression plasmid vector under a 
constitutive promoter control. The initial work with this approach was successful 
in the expression in cells and in vivo murine models to eliminate the RSV 
infection, but the problem of RSV associated Th2 type immune response was 
persistent. To resolve this problem, Li et al. (200) attempted to manipulate the 
parameters of choice: the protein to be expressed, the expression vector, 
adjuvants, formulations and intracellular stability of the plasmid. Mice 
challenged with the RSV-G construct had balanced systemic and pulmonary 
Th1/Th2 cytokines and RSV neutralizing antibody responses (Li et a!., 2000). 
However, the wild type RSV F protein expressed from DNA plasmid was poorly 
expressed (Ternette et al., 2007) and has had low immunogenicity of F protein, 
the antagonistic activity of RSV for IFN and immunopathology (Martlnez-
Sobrido et al., 2006). Consequently, Wu et al. (2009) developed a DNA 
vaccination strategy against RSV using a mucosal adjuvant (Wu et al., 2009). 
The mice immunised with the DRF-412 vector contained less RSV RNA in lung 
tissue and induced a higher mixed Th1/Th2 cytokine immune response as well 
as better protection than those immunized with the DRF-412-P vector, which 
was confirmed by lung immunohistology studies (Wu et al., 2009). Likewise, 
Mycobacterium bovis Bacillus Calmette-Gue'rin (BCG) vaccine was modified to 
carry RSV N or M2 and was found to establish the Th1 type immunity in RSV 
challenged mice (Bueno et al., 2008). The recombinant vaccine also elicited the 
activation of RSV specific T cells producing IFN-y and IL-2, along with reduction 
in weight loss and lung viral protein load, thus establishing a Th1-polarized 
immune response (Bueno et al., 2008). This approach serves the purpose of 
naturally activating the immunostimulatory responses of the host while 
delivering the DNA vaccine. 
The bitter episode of FI-RSV vaccine has impeded the vaccine 
development and in fact has raised serious concern over the use of native RSV 
or its components. Recently, several applications of nanotechnology have 
appeared in the development of vaccines popularly known as Nanovaccines. 
DNA vaccine is prone to rapid degradation when introduced into an animal 
system; so to increase the retention and increase the efficacy of the DNA 
vaccines, they can be encapsulated into a polymer that will protect and facilitate 
controlled release. Various synthetic or natural polymers are now experimented 
for targeted delivery and controlled release of the carrier (Glenn et al., 2013; 
Smith et al., 2012). Chitosan is a polymer of great interest in respiratory disease 
treatment, because of its mucoadhesive property and biodegradability, which 
balances of longer retention and controlled release of carrier molecules 
encapsulated. Thus, chitosan nanoparticles are being developed against RSV 
(Glenn et al., 2013; Smith et al., 2012). 
In the case of RSV-naive infants and children, it remains to be seen 
whether vaccine candidates will be sufficiently immunogenic in infancy to 
provide effective protection against RSV disease. It seems unlikely that 
complete protection against infection can be achieved however; a substantial 
reduction in RSV replication should be effective in controlling severe disease. 
The recent successful development of live-attenuated paediatric vaccines 
against rotavirus, which faced many of the same obstacles, gives hope for 
success. 
1.6.2 Treatment 
The effect of removing cell surface HS chains, on viral infectivity has 
recently been examined. The in vitro studies have shown that pre-treating of the 
cells with heparinase I results in reduction of the HS iduronic acids units, while 
heparinase II led to lower N-sulfation and heparinase III removed the N-sulfation 
units (Guo et ai., 2008). These findings suggest that low molecular weight 
heparin (LMWH) can inhibit positively charged RSV infection through 
cooperative electrostatic association (Guo etal., 2008). 
There are very limited treatment options available for RSV. However, 
there are many drugs for the symptoms associated with RSV infection. The 
target genes and proteins vital for RSV infection are important for developing 
preventative and treatment measures. The mode of action and potency of a 
drug determines the approach of prophylactic or curative application. 
Considering RSV life cycle, theoretically, there are numerous modes to interfere 
with RSV infection, but not all may be viable research. Replication, transcription 
and fusion are a few target processes for drug development against RSV. A 
focus is therefore on development of potent drug that holds conformity in the 
human trials. 
Ribavirin or 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-
yl]-1H-1,2,4-triazole-3-carboxamide is a widely used broad spectrum synthetic 
anti-viral drug for both DNA and RNA virus treatment. Oral and nasal 
administration of ribavirin can be used as a treatment of severe lower 
respiratory tract infections caused by RSV and influenza virus (Bocchini et ai., 
2009). Ribavirin is phosphorylated in the cells and has been found to compete 
with adenosine-5'-triphosphate and guanosine-5'-triphosphate, for viral RNA-
dependent RNA polymerases in RNA viruses. The exact mechanism of anti-
viral activity of ribavirin against RNA and DNA viruses is still not clear. The 
usefulness of ribavirin against viruses is believed to be not only due to its anti-
viral activity but also due to its capability to modulate the immune system 
(Langhans et al., 2012). The derivatives of ribavirin such as viramidine, 
merimepodib, and other inhibitory molecules like mycophenolate and mizoribine 
have shown antiviral activity against the hepatitis C virus, and hence, there is 
scope for investigating them as potential anti-RSV drugs (Chapman et al., 2007; 
Gish, 2006). 
A number of small molecule anti-RSV compounds have been described 
over the last 15-20 years. Most of them have been discovered by screening of 
chemical libraries of natural products using classic virology assays, modified for 
high throughput testing. Recent advances in the development of anti-viral drugs 
have seen the rise of fusion inhibitors. The fusion inhibitors are usually synthetic 
compounds or molecules interrupting the fusion of virus with the host cell 
usually by binding the fusion proteins. The fusion inhibitors have been widely 
studied as anti-viral agents in several viruses including henipavirus, hendra 
virus, nipah virus, paramyxovirus, metapneumoviruses, HIV and RSV (Bossart 
et al., 2005; Deffrasnes et al., 2008; Porotto et al., 2007; Porotto et al., 2006; 
Porotto et al., 2010; Wang et al., 2003; Wild et al., 1993; Zhao et al., 2000). The 
first reports of the use of peptide(s) as fusion inhibitors, include the 
development of DP-178, a synthetic peptide based on the leucine zipper region 
of the HIV fusion glycoprotein gp41 (Wild et al., 1993) which achieved a 50% 
inhibition at 0.38 nM against HIV-1. Fusion inhibitors for the paramyxoviruses 
have also been developed based on the conserved region of the F protein. The 
F protein is widely known for its conserved nature among 
the Paramyxoviridae family. Lambert et al. (1996) developed the fusion 
inhibitors belonging to the conserved heptad repeat (MR) domains of F1 region 
of F protein which is analogous to the peptides DP-107 and DP-178 of HIV 
gp41 (Lambert et al., 1996). These fusion inhibitors were tested against RSV, 
human parainfluenza virus (PIV) 3 and measles virus, and showed antiviral 
activity specific to the species of origin. 
A series of benzimidazoles derivatives have been reported to interact 
with the F protein and, although dissimilar in structure, they all seem to bind to a 
hydrophobic pocket of the trimeric coiled-coil made by HRA (amino acids 153-
209) of the F1 chain (Zhao et a!., 2000). Binding to this pocket would interfere 
with the proper interaction of HRA with HRB (amino acids 482-520) and the 
formation of the six-helix bundle structure (6HB) that is required for completion 
of membrane fusion (Melikyan et al., 2000). Diverse array of other 
benzimidazoles (e.g., JNJ-2408068) and chemically unrelated compounds (e.g., 
VP14637) with subnanomolar activities have been described. Interestingly they 
also seem to target the hydrophobic pocket of the 6HB (Douglas et al., 2005; 
Lundin et al., 2010). Other RSV inhibitors have been described besides those 
targeting the F protein. For instance, NMSO3, a sulphated sialyl lipid, has been 
reported to inhibit virus binding, and mutants resistant to this compound had 
mutations in the G protein, identifying it as the presumptive target (Kimura etai, 
2004). Many negatively charged polymers, including heparin and dextran 
sulphate, also interfere with RSV binding, but their inhibitory concentrations are 
too high for application in the clinical setting. 
Sudo et al. (2005) discovered a benzazepine derivative (YM-53404) that 
worked relatively late in the replication cycle and that selected mutations in the 
L gene (Saito et al., 1997). Another benzodiazepine compound (RSV604) that 
worked late in the replication cycle was shown to select mutations in the N 
gene, pointing to this molecule as the drug target (Chapman et al., 2007). 
Interestingly, these mutations were located in the long p hairpin of the RSV N 
structure noted above that may mediate interaction between N protein in the 
ribonucleoprotein (RNP) and the polymerase complex (Tawar et al., 2009). 
There are several novel nonbenzimidazole based compounds, showing 
anti-RSV activity in vitro, but a more polar compound thiazole-imidazole 13 was 
selected due to compound potency, moderate permeability, and low metabolic 
rate in rats, and more detailed in vivo studies are further anticipated (Pryde et 
al., 2013). 
Besides chemical compounds, there are other ways to inhibit RSV 
infectivity. RNA interference (RNAi) which is a normal cellular event has 
become a powerful means of controlling gene regulation. The interference 
mediated by small interfering RNA (siRNA) was used against human 
immunodeficiency virus, poliovirus, hepatitis C and PIV in cell culture (Barik, 
2004; Lee et al., 2002; Zhang et al., 2010). The concept of inhibiting RSV 
infection using targeted antisense mechanism was applied by Jairath et al. 
(1997) by silencing the RSV-NS2 gene (Jairath etal., 1997). Following the RNAi 
approach, Bitko et al. (2005) designed siRNA against the P gene of RSV and 
PIV which protected mice against individual and mixed infections upon 
intranasal administration (Bitko et al., 2005). The effectiveness of siRNA action 
was observed with and without the use of transfection reagents. This approach 
was also effective when targeting the RSV-F gene (Bitko and Barik, 2001). 
Similar work on HEp-2 cell lines was replicated using four siRNA, designed to 
silence RSV F gene, which showed inhibitory action against RSV at various 
concentrations (Vig et a!., 2009). Silencing different RSV genes too had an 
inhibitory action on the RSV, a plasmid encoding siRNA which was complexed 
with chitosan targeting RSV-NS1 gene decreased RSV infection in BALB/c mice 
and Fischer 344 rats and also reduced the associated inflammation (Kumar et 
al., 2002; Zhang et al., 2005). Zhang et al. (2006) showed that siRNA 
nanoparticle targeting RSV NS1 gene resulted in increased IFN-/3and IFN-
inducible genes in A549 cells and in human DCs, and increased differentiation 
of CD4^T cells to Th1 cells (Zhang et al., 2005). In addition, mice treated with 
small interfering NS1 (siNS1) nanoparticles exhibited significant decrease in 
lung viral titres and inflammation. 
Alvarez et al. (2009) came up with a new RSV-NS1 gene specific siRNA 
(ALN-RSV01) having a broad spectrum of antiviral activity that targeted the 
nucleocapsid gene of RSV (Alvarez et al., 2009). In vivo BALB/c murine studies 
demonstrated that intranasal dosing of ALN-RSV01 resulted in a 2.5-3.0 log-unit 
reduction in RSV lung concentration. To scale up this molecule for RSV 
treatment in humans, the safety, tolerability, and pharmacokinetics were tested 
on healthy adults, demonstrating its safety and tolerance in human subjects 
(DeVincenzo et al., 2008). In the clinical trials of ALN-RSV01, healthy subjects 
were administered either, a placebo or ALN-RSV01 nasal spray for RSV. There 
was a 44% reduction in the RSV infection following ALN-RSV01 administration. 
Thus, this study in real terms has established a unique "proof-of-concept" for an 
RNAi therapeutic agent in RSV treatment (DeVincenzo et al., 2010). ALN-
RSV01 proved to be safe and was effective against RSV even in a complex 
clinical situation like lung transplants, which was a remarkable achievement 
(Zamora et al., 2011). ALN-RSV01 has recently completed phase II b clinical 
trials. 
Another approach of RNAi treatment to combat RSV is to decelerate the 
adverse effects of RSV mediated Th2 type immune response as the aggravated 
host immune response can be more harmful than RSV infection itself. 
Particularly in neonates, RSV bronchiolitis increases IL-4 receptor a levels, 
which results in increased Th2 response, so an antisense oligomer was 
synthesised for the local silencing of the IL-4 receptor a gene. Intranasal 
application of the antisense oligomers into a neonatal murine model reduced 
the Th2 type mediated pulmonary pathological signs of inflammation and lung 
dysfunction (Ripple et al., 2010). A combinatorial approach of the anti-sense 
oligomer against RSV and IL-4 receptor a would control RSV infection and the 
adverse effects of RSV mediated inflammation. 
Currently, there is no vaccine and effective treatment against RSV. 
Prevention of RSV infection at present is limited to only high risl< individuals with 
a limited efficacy. New preventive research like DNA vaccines, subunit vaccines 
and nano-vaccines has reached animal trials. In addition, RSV treatment 
approaches using antisense oligomers, fusion inhibitors, and benzimidazole 
drug have proceeded into clinical trials. The challenges associated with RSV 
management are categorically numerous. However, at the current pace of 
scientific research and development and with the implementation of scientific, 
commercial, and program recommendations to develop epidemiological 
strategies, it seems optimistic to have an effective diagnosis, prevention and 
treatment solution for RSV in near future. 
1.7 AIMS OF THIS THESIS 
RSV is one of the most important pathogens of childhood respiratory 
infections (IVIcNamara and Smyth, 2002). Since the failed FI-RSV vaccine trail, 
RSV disease had been characterised by an influx of eosinophils to the site of 
viral infection w/here eosinophils were believed to contribute to RSV 
pathogenesis. None the less, the role of eosinophils in RSV infection has been 
debated vigorously and in 2007, Phipps et al. (2007) demonstrated that 
eosinophils play a crucial role in clearance of RSV infection (Phipps et al., 
2007). In addition, RSV can re-infect the same individual several times 
throughout their life. Re-infection is characterised by an initial influx of NK cells 
followed by recruitment of helper CD4"*^  and CD8^ lymphocytes to the site of 
infection (Olson et al., 2008; Olson and Varga, 2007; Stevens et al., 2009). To 
complicate matters 004"^ and CDB^ T lymphocyte subsets contribute to clearing 
of the RSV infection, but that both also contribute to RSV disease pathogenesis 
(Graham et al., 1991). A number of viruses have demonstrated to have a great 
affinity for cell HSPGs, playing important roles in virus attachment and entry 
(Lee et al., 2006). HS has been shown to bind the RSV G protein on the cell 
surface of the HEp-2 cells (Krusat and Strecl<ert, 1997). In addition, HS mimetic, 
PI-88, has been shown to inhibit HSV infection of cells by blocking the binding 
of the viral attachment glycoproteins to the cell surface (Nyberg et al., 2004). 
It is important to note that there are several limitations to the previous 
literature findings as well as RSV-induced limitations due to its heterogenic 
nature which provides this virus with an ability to evade previously induced 
immunity (White et al., 2005) as adaptive immunity in response to RSV have 
been found to be limited, incomplete and short lived. As RSV infects mostly 
young children and elderty, it is important to note that a capacity to induce 
appropriate immune response is somewhat reduced at early and late stages of 
life (Adkins et al., 2004; Fulton et al., 2013; Levy, 2007). In addition, the role of 
eosinophils in RSV and viral infections in general is yet to be explored in depth. 
The depth of research into a positive role of eosinophil is still limited with only a 
handful of research groups focusing on the potential of these cells in viral 
clearance. Although there have been extensive studies of epidemiology, clinical 
manifestations, diagnostic techniques, animal models and the immunobiology of 
infection, there is not yet a convincing and safe vaccine available. For RSV the 
effective use of palivizumab treatment is limited due to the cost and thus only 
currently used in infants with high risk of bronchiolitis (Harkensee et a!., 2006). 
Therefore, inexpensive and more widely effective treatments are required 
urgently and as HS involvement in RSV infection is underexplored, it could 
potentially lead to the development of new, more effective and more affordable 
RSV therapeutics. 
Therefore, aims of this thesis are: 
Aim 1: To examine the In vitro effect of RSV on eosinophil morphology, release 
of eosinophil activation markers and eosinophil antiviral activity 
Aim 2: To evaluate eosinophil antiviral activity in four distinct mouse models 
following RSV infection and re-infection. 
Aim 3: To assess the efficacy of HS mimetics treatment on RSV infection in 
vitro and in vivo. 
Chapter 2. GENERAL METHODS 
2.1 HEAT INACTIVATION OF FETAL CALF SERUM 
In this procedure, fetal calf serum (FCS) (Sigma, Australia) is heated to 
56°C in a water bath to destroy heat-labile complement proteins prior to use in 
cell growth medium. 
Bhefly, heat inactivation procedure involves placing a 500 mL bottle of 
FCS from the -80°C freezer in the refrigerator to thaw overnight. The following 
day, completely thawed was placed in a 37°C water bath allowing serum to 
equilibrate at 37°C. The temperature was then raised to 56°C and the bottle of 
serum was incubated for 35 minutes with inversion every 10 minutes. Once 
bath reached 56°C, the serum was incubated for 30 minutes during which the 
bottle was again inverted every 10 minutes. The serum was allowed to cool at 
room temperature for 30 minutes. Heat inactivated (HI)-FCS was then aliquoted 
into 50 mL tubes and stored at -20°C. 
2.2 CELL CULTURE 
Immortal cell lines were used for in vitro experiments. HEp-2 (originally 
derived from an epidermoid carcinoma of the larynx) (ATCC CCL-23) and Vero 
E6 (originally isolated from kidney epithelial cells extracted from an African 
green monkey) (ATCC CRL-1586) cell lines were obtained from the American 
Type Culture Collection (ATCC, USA). Briefly, once cells were 80% confluent, 
culture medium was removed and discarded. The cell monolayer was washed 
twice with phosphate buffer solution (PBS) (ANU, Australia) to remove any 
serum residues. Cells were detached by covehng cell monolayer with 0.25% 
(w/v) Trypsin ((Merck, Australia) with 0.53 mM ethyenediaminetetraacetic acid 
(EDTA) in PBS (ANU, Australia)) and incubating for 5-15 minutes at 37°C. Cell 
suspension was diluted in complete growth medium (Dulbecco's Modified 
Eagle's Medium (Gibco, Australia) supplemented with 5% of HI-FCS (Sigma) 
(Dulbecco's modified eagle's medium (DMEM) with 5% HI-FCS) and usually 
one fifth of the cell suspension was transferred to new culture flask at required 
seeding density. 
2.3 THAWING OF CELLS FROM LIQUID NITROGEN 
STORAGE 
Cells were taken out from the liquid nitrogen storage and rapidly thawed 
in a water bath at 37°C. The cell suspension was transferred to a 10 mL sterile 
tube (Sarstedt, Australia) and media added to dilute the dimethyl sulphoxide 
(DMSO) (Univar, Asia Pacific Specialty Chemicals). Cells were then centrifuged 
at 670 X g (HD Scientific) for 5 minutes, supernatant was removed and fresh 
media added to resuspend the pellet appropriately. The cell suspension was 
then transferred to a T-25 tissue culture flask (Iwaki) and left to incubate at 37°C 
in a humidified atmosphere supplemented with 5% CO2. 
2.4 CRYOPRESERVATION OF CELLS 
Cells were frozen down using freezing medium made up of 95% of 
DMEM with 5% HI-FCS and 5% of DMSO (Univar). Cells were aliquoted into 
sterile cryovials (Iwaki) and stored at -80°C overnight. The following day cells 
were transferred to liquid nitrogen for long-term storage. 
2.5 CELL VIABILITY ASSAY 
Cell viability was tested using trypan blue dye (Invitrogen, Australia). The 
cytoplasm of dead cells is susceptible to trypan blue dye staining, due to cell 
membrane permeability, rendering all unstained cells as viable. The cell sample 
was mixed with 0.4% trypan blue (Invitrogen) solution at 1:1 ratio, the mix was 
then used to fill the haemocytometer chamber. Cells were counted under the 
microscope across four 1 x 1 mm squares of one chamber and the average 
number of cells was determined per square. The following formula was used to 
calculate number of cells per mL of cell suspension: 
. . , , cells Total number ofviable cells counted , ^ N 
Number of viable — — x 2 (dilution factor) x 10 ^ 
mL squares 
Equation 2.1. Calculation of a number of cells per mL of cell suspension 
2 .6 CYTOSPIN PREPARATION 
A cell suspension was prepared at 2 x I C cells/mL final concentration. 
Slides were mounted behind the filter cards (Thermo electron corporation, USA) 
and cuvette in the metal holder of the centrifuge. Approximately 200 |JL of cell 
suspension was loaded in the cuvette and spun at 800 x g (Shandon cytospin 
centrifuge, USA) for 5 minutes. The cuvette and paper were detached from the 
slide without damaging the fresh cytospin, which was then air-dried. Slides were 
stained using the May-Grunwald Giemsa staining procedure for differential 
leukocyte analysis (section 2.7). 
2.7 MAY-GRUNWALD AND GIEMSA STAINING 
Prepared cytospin and blood smear slides were fixed in 100% methanol 
(Scharlau, Spain) for 15 minutes. Slides were incubated in May-Grunwald 
staining solution for 5 minutes. May Grunwald staining solution was prepared by 
mixing equal parts of the May Grunwald stock solution (Australian Biostain, 
Australia) with buffered distilled water. Buffered distilled water was prepared as 
per instructions detailed in Appendix 1. Slides were then transferred into 
Giemsa staining solution for 10 minute Incubation. Giemsa stain was prepared 
by mixing 1 part of Giemsa stock solution (Australian Biostain, Australia) with 9 
parts of buffered distilled water. Subsequently, slides were then washed by 
transferring through three changes of buffered distilled water followed by a final, 
10 minute incubation in the last change to ensure cell differentiation. Slides 
were air-dried and analysed under a light microscope (Nikon) for different 
leukocyte populations present. 
2.8 R S V PROPAGATION 
Approximately 1x10^ Vero E6 cells were seeded in a T-150 flask (Iwaki) 
and left to incubate overnight at 37°C with 5% CO2. The following morning cell 
monolayer was checked for approximately 80% confluence. Once ready, the 
flask was rinsed with 10 mL of Hank's Balanced Salt Solution (HBSS) (ANU, 
Australia) followed by A2 RSV strain (provided by Dr. Ralph Tripp) inoculation at 
MOI of 0.5 prepared in serum free DMEM (Gibco). The cell monolayer was 
allowed to adsorb virus for 2 hours at 37°C with 5% CO2. After 2 hours, 8 mL of 
DMEM with 5% HI-FCS was added to the flask, and cells were incubated for 2-3 
days at 37°C with 5% CO2. The flask was checked daily for signs of syncytia 
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formation. The cells were deemed ready for harvest once there was 25-50% 
syncytium present with very little monolayer death. An optimal infection would 
result in syncytia evenly distributed across the entire flask. At the time of the 
harvest, approximately 80% of media was removed from the flask. The cell 
monolayer was scraped with a cell scraper (Thermo Fisher, Australia) and cell 
suspension collected in a pre-chilled 50 mL centrifuge tube. The cell suspension 
was sonicated 5 times for 5 seconds, at 25W in a biosafety cabinet. In between 
each sonication, the tube containing the cell suspension was chilled on ice for 2 
minutes. Cell debris was removed by centrifugation at 3000 rpm for 7 minutes at 
4°C. Supernatant was removed and aliquoted into sterile cryovials (Iwaki). Virus 
stock was stored -80°C until further processing. 
Ultraviolet-inactivated RSV (UV-RSV) was generated by exposing RSV 
to UV radiation (Laftech Bio-Cabinets, Top Safe Class II, Australia) for 40 
minutes. Immunostaining RSV viral titres assay (section 2.10) confirmed the 
absence of viable virus. 
2.9 PREPARATION OF 2 % METHYLCELLULOSE 
In a shott bottle, 75 mL of HBSS (ANU) was added and brought to the 
boil in the microwave. This was then placed on a heated stirring block and 10 g 
of methylcellulose (Sigma, Australia) was slowly added, allowing powder to 
dissolve before adding more. The mixture was autoclaved at 15 psi for 20 
minutes. While autoclaving, HBSS (ANU), HI-FCS (Sigma), DMEM (Gibco) and 
penicillin-streptomycin-neomycin (PSN) (Invitrogen, Australia) were pre-warmed 
in a 37°C water bath. When the autoclave run was finished, the mix was 
allowed cool down to 37°C whilst stirring. Once at 37°C, 40 mL HBSS (ANU), 
10 mL HI-FCS (Sigma) and 10 mL 50X PSN solution was added to the 
methylcellulose mixture. The preparation was finalised with addition of 400 mL 
of serum free DMEM (Gibco). The solution was allowed to mix for at least 30 
minutes at room temperature before being stored at 4°C until required. 
2 .10 IMMUNOSTAINING R S V PLAQUE ASSAY 
Approximately 2 x 10® Vero E6 cells (ATCC) per well were seeded in 24-
well plate (Iwaki) to obtain 80-90% confluence. Vero E6 cells (ATCC) were 
cultured in DMEM (Gibco) with 5% HI-FCS (Sigma) overnight at 37°C with 5% 
CO2. The following day, serial dilutions of RSV samples (10"^  to 10"®) were 
prepared in serum free DMEM (Gibco) and 200 pL of the corresponding sample 
was loaded in quadruplicates onto the 24-well plate. Inoculated cells were 
allowed to adsorb virus for 1 hour at 37°C with 5% CO2. After 1 hour, 1 mL of 
previously prepared, 2% methylcellulose was added to each well as an overlay 
and cells were left to incubate at 37°C with 5% CO2 for 6 days. On day 6, 
methylcellulose was removed and cell monolayer fixed with 60:40 ice-cold 
acetone (LabScan, Thailand): methanol (Scharlau) for 10 minutes. Plates were 
air dried and blocked with 5% skim milk powder (Diploma, Australia) diluted in 
PBS (AND) for 30 minutes at room temperature on a rocker. The block was 
removed and 200 pL of RSV monoclonal anti-F antibody 131-2A (Merck, 
Australia) was added per well, prepared at 1:1000 dilution in 5% skim milk 
blocking solution. Cells were incubated with primary antibody for 2 hours at 
37°C with 5% CO2. Cell monolayer was rinsed 3 times, 5 minutes each, with 
0.5% Tween20 (Sigma, Australia) in PBS (ANU). Cells were then incubated with 
200 pL/well of secondary antibody, goat anti-mouse IgG-alkaline phosphatase 
(Sigma, Australia) prepared at 1:1000 dilution in 5% skim milk blocking solution. 
Cells were incubated for 1 hour at 37°C with 5% CO2. Cell monolayer was 
rinsed 3 times, 5 minutes each with 0.5% Tween20 (Sigma) in PBS (ANU). Cell 
monolayer was stained for RSV plaques with Vector black alkaline phosphatase 
substrate (Vector Laboratories, Europe). Reaction was stopped with deionised 
water. Stained RSV plaques were counted under a light microscope. To 
calculate total number of plaque forming units (pfu) (or viral titres) per 1 mL of 
RSV sample the following formula was used: 
number of plaques in quadriplicates ^ „ , 
X dilution factor x 5 = plaques per mL 
4 
Equation 2.2. RSV plaques (or viral titres) per 1mL of RSV sample 
2.11 MICE STRAINS 
Male BALB/c mice aged 6 to 8 weeks were obtained from tlie pathogen 
free facilities at the University of Canberra (UC) animal facility and Australian 
National University (ANU) animal services. Animals were housed in approved 
containment facilities and treated in accordance with approved UC animal 
experimentation guidelines. BALB/c mouse strains used were wild type (WT) 
BALB/c, IL-5 Tg BALB/c, Rag 2 knockout (7 ) BALB/c and IL-5 Tg Rag 2 /" 
BALB/c. 
2.12 GENERAL ANIMAL HANDLING PROCEDURES 
2.12.1 Euthanasia 
At the conclusion of the experiment or if mice received a clinical score 
greater than 5, they were euthanised by CO2 asphyxiation procedure. Briefly, 
mice were placed into a tightly closed plastic container connected via a tube to 
CO2 which was slowly turned ON. Once animals would slow down/stopped 
moving, CO2 was turned OFF and container remained closed for another few 
minutes to ensure that the animal has been euthanised properly. Once no pedal 
reflexes were detected, the animal was dissected and samples collected. 
2.12.2 In vivo mouse monitoring procedures 
Mice were monitored daily for any change in body weight and symptoms 
of RSV disease. Clinical scores (Table 2.1) were assigned to each mouse daily 
and if at any point of the experiment mice scored 5 or higher, they were 
euthanised immediately as per protocol outlined previously (section 2.12.1). If 
mice received a clinical score of 3-5, they were provided wetted food on the 
cage floor. 
Table 2.1. Respiratory syncytial virus clinical scores for in vivo studies 
Numerical 
scores Physical symptoms displayed for infected mice 
1 Healthy (no obvious signs of illness) 
2 Barely ruffled fur and active 
3 Ruffled fur, less active than normal 
4 Ruffled fur, less active than normal and less than 20% weight loss 
5 Hunched posture 
6 20% weight loss of the starting weight-point of euthanasia 
7 Death 
2.12.3 Daily animal weighing procedure 
Mice were weighed daily and monitored for any signs of weight loss. A 
mouse was gently picked up by the tail and placed inside a plastic container 
sitting on an analytical balance. Weight was recorded and the mouse returned 
to its cage. 
2.12.4 Anaesthesia 
For intranasal inoculation mice were lightly anaesthetised with 
isofluorane (PharmaChem, Australia) using the open drop jar method of 
administration. Approximately 2-3 drops of isofluorane (PharmaChem) were 
applied to a cotton wool placed inside a transparent jar with a lid. To minimise 
mice coming into a direct contact with the anaesthetics and systemic 
absorption, cotton wool was covered by a mesh. Mice were placed over the 
mesh in the jar and removed as soon as consciousness was lost. Once no 
pedal reflexes were detected, we proceeded with intranasal inoculation. 
2.12.5 Intranasal inoculation 
Anaesthetised mice were restrained manually with the head tilted down 
at 35-40° angle. A volume of less than 50 pL of fluid (or RSV stock) was placed 
a drop at a time on the nostril of the mouse causing the mouse to aspirate the 
virus into the nose, throat and lungs while coughing reflex was negated by 
anaesthesia. 
2.12.6 Intraperitoneal inoculation 
The animal was restrained manually and tilted head down at 35-40° 
angle allowing the intestines to fall away from the injection site. A 27-gauge 
needle was inserted into the lower right quadrant of the abdomen, slightly off 
the midline, anterior to the bladder. Mice received 100 |JL Intraperitoneal 
injections of 10 mg/mL/kg HS mimetics previously prepared in sterile saline. 
2.13 IN VIVO SAMPLE COLLECTION 
2.13.1 Bronchoalveolar lavage fluid (BALF) collection 
Lungs were dissected free and the bronchus leading to the left lobe 
(apical, azygous, cardiac and diaphragmatic lobe) was temporarily tied up, while 
the right lobe was cannulated in order to perform BAL. The BALF was collected 
by gentle washing with 3 x 0.5 mL of sterile PBS and the sample placed on ice 
until further processing for differential leukocyte counts through cytospin 
preparation. 
2.13.2 Histological analysis 
The left anatomical lobe of the non-lavaged lung was fixed in 10% 
formalin (Sigma), embedded in paraffin and 3 mm sections stained with periodic 
acid-Schiff (PAS) or chromotrope (CR) stains (processed by A. Prins, John 
Curtin School of Medical Research, Australian National University). Slides were 
scored by an observer, blinded to the treatment groups for: parenchymal 
pneumonia (quantified on a 0 - 5 scale, 0 = none, 1.5 = minimal, 3 = medium 
and 5 = heavy); airways mucus occlusion (quantified on a 0 - 3 scale 0 = no 
occlusion, 1 = small areas of luminal accumulation of mucus, 2 = partial 
occlusion of at least one small airway and 3 = complete occlusion of at least 
one small airway); perivascular infiltrates (percentage of sites) (quantified on a 0 
- 3 scale, 0 = none, 1 = few (< 10%), 2 = many (10-50%) and 3 = majority (> 
50%)); peribronchiolar/bronchial infiltrates (percentage of sites) (quantified on a 
0 - 3 scale, 0 = none, 1 = few (< 25%), 2 = many (25-75%) and 3 = all (> 75%)); 
and quality of peribronchiolar/bronchial infiltrates (quantified on a 0 - 3 scale, 0 
= none, 1 = mild, 2 = moderate and 3 = severe). A combined histopathological 
score (HPS) (out of 17) was determined based on the sum of scores for these 
five observations. Histology slides were also evaluated for goblet cell count 
(average number of goblet cells counted over 10 high power fields per sample) 
and parenchymal eosinophil count (average number of eosinophil counted over 
10 high power fields per sample). 
2.13.3 Homogenising lung tissue 
Lungs were aseptically removed from mice and placed in a 2.0 mL 
microcentrifuge tube containing 1 mL of PBS (ANU) prepared with PSN 
(Invitrogen) (at 1X PSN final concentration) and one 5 mm steel ball (Procureit 
Australia). Tubes were snap frozen and stored at -80°C until further processing 
or were processed the same day. If frozen, the lung samples were partially 
thawed on ice. Samples were loaded into the two TissueLyser adapter blocks 
(pre-chilled at 4°C for at least 2 hours). Once blocks were balanced, samples 
were homogenised for 1 minute at a frequency of 30 Hz followed by 
centrifugation at 1700 x g (Eppendorf, Australia) for 1 minute at 4°C. In a 
biosafety cabinet, the supernatant of each sample was transferred into sterile 
1.5 mL tubes and stored at -80°C until processed using the immunostaining 
RSV plaque assay (Section 2.10). 
2.13.4 Blood smear 
A drop of blood was placed onto a slide and smeared, creating a thin 
layer of blood. Dried slides were fixed in 100% methanol (Scharlau) for 10 
minutes and processed with May-Grunwald and Giemsa staining (section 2.7). 
Leukocyte cell differentiation was performed under a light microscope (Nikon). 
2.13.5 Total leukocyte count 
Following heart puncture, 5 pL of blood was mixed with 95 pL of 
methylene blue (StemCell, Australia). Red blood cells were lysed using red cell 
lysis buffer (BD Pharmingen, Australia) for 5 minutes and total leukocytes were 
counted using haemocytometer. Following differential leukocyte analysis of 
blood smears, total leukocyte count was used to present a number of cells per 
mL of blood sample. 
Chapter 3. EFFECT OF RESPIRATORY SYNCYTIAL VIRUS 
INFECTION ON EOSINOPHIL BIOLOGY 
3.1 INTRODUCTION 
As mentioned in Chapter 1, viral bronchiolitis has been associated with 
eosinophilic inflammation as demonstrated by epidemiological studies linking 
severe RSV bronchiolitis with the development of asthma later on in life. In past, 
accumulation of eosinophils at the site of viral infection has been perceived in a 
negative light however, the specific role played by virus elicited eosinophils-
negative, positive or neutral-remains unclear. As a result, the role of eosinophils 
in RSV infection has been debated vigorously over the past few decades, with 
many researchers taking opposing stands on this issue. The aim of this study 
was to examine the in vitro effect of RSV on eosinophil morphology, release of 
eosinophil activation markers and eosinophil antiviral activity 
RSV is a major cause of viral bronchiolitis and hospitalisation in infants 
under six months of age (Openshaw et a/., 2003). In addition, early RSV 
infection is known to be associated with development of respiratory problems 
such as asthma and wheezing later in life (Openshaw, 2002). RSV disease has 
been characterised by pulmonary eosinophilia elicited in response to primary 
RSV infection; observed in both, human infants and mouse neonates 
(Rosenberg et al., 2009). As eosinophils are considered to be the main line of 
defence against parasites (Costa et al., 1997; Hitoshi et al., 1991) some 
researchers have focused their investigation on eosinophil antiviral ability. 
The first RSV vaccine thai with FI-RSV yielded disastrous results in 
young vaccine recipients, following natural RSV infection during the subsequent 
winter. The vaccine trial resulted in recipients developing enhanced pulmonary 
disease leading to hospitalisation and in some cases, death of a few vaccine 
recipients (Chin et ai, 1969; Fulginiti ef al., 1969; van Hagen et al., 1999). 
Studies with WT BALB/c mice have provided some insight into the mechanisms 
that may have contributed to FI-RSV enhanced pulmonary disease. These 
studies have found that WT BALB/c mice vaccinated with vectors expressing 
RSV G glycoprotein, purified G glycoprotein, or FI-RSV develop extensive 
enhanced pulmonary disease characterised by pulmonary eosinophilia, weight 
loss, exaggerated Th2-type cytokine responses and selective priming of CD4^ T 
cells (Graham et al., 2000; Hancock et al., 1996; Openshaw et al., 2001; Tripp 
et al., 2000; van Hagen et al., 1999; Varga et al., 2001). G glycoprotein was 
also shown to compete with the chemokine, fractalkine for binding to CX3CR1 
receptor, and to inhibit fractalkine mediated leukocyte chemotaxis (Tripp et a!., 
2001). These studies highlight that RSV G glycoprotein has immune modulatory 
activities associated with the CX3C motif. Consequently, based on the findings 
from these FI-RSV studies, eosinophils are believed to contribute to the 
pathology of RSV disease. 
However, very few research groups have focused on elucidating and 
understanding the potential that eosinophils may have in viral clearance. The 
first indication that eosinophils might have the means to function in promoting 
antiviral host defence came from a series of studies performed in the late 
1990s. In this work, it was determined that eosinophils had a potential to reduce 
RSV infectivity of target epithelial cells/n vitro (Domachowske et al., 1998a; 
Soukup and Becker, 2003) as well as inhibit RSV infection in tissue culture 
(Rosenberg et al., 2009). Interestingly, another study also revealed that RSV 
infected AdblGATA mice (eosinophil deficient) exhibited increased clinical 
illness similar to that observed in RSV infected WT BALB/c mice (Castilow, 
Legge, & Varga, 2008). Their findings also suggest that eosinophils are not 
required for increased weight loss, clinical illness and impaired lung capacity, 
the disease parameters most often associated with RSV vaccine enhanced 
disease (Castilow et al., 2008). Finally, Rosenberg and Domachowske (1999 
and 2001) were among the first groups to suggest that eosinophil recruitment 
and activation may lead to a positive host-defence (Domachowske and 
Rosenberg, 1999; Rosenberg and Domachowske, 2001). The possibility that 
eosinophils may be recruited in part to promote primary antiviral host defence is 
a very exciting concept (Rosenberg et al., 2009). 
Previous studies have also shown eosinophil activation in the presence 
of RSV infection (Domachowske et al., 1998a; Phipps et al., 2007). Eosinophil 
activation could result in piecemeal degranulation (PMD), a process known to 
lead to successful clearance of parasitic infections (Shamri et al., 2011) through 
a selective release of eosinophil granule content. Eosinophil granules contain 
four cytotoxic proteins: (1) MBP, which is located in the eosinophil granule core; 
(2) EPO, (3) ECP and (4) EDN found in the matrix of the eosinophil granule 
(Rosenberg et al., 2009). PMD leads to small vesicles budding from the 
secondary granules and subsequent transport of the granule protein subset to 
the cell surface, with a progressive and selective loss of secondary granule 
constituents (Dvorak et al., 1992; Dvorak et al., 1991). This process of 
eosinophil degranulation has been well characterised with the help of 
transmission electron microscopy (TEM) studies. TEM analysis revealed that 
MBP forms crystals characterised by a very regular pattern of electron-dense 
stripes, visualised as a dark line while the other three eosinophil proteins (ECP, 
EDN and EPO) are located in the surrounding matrix, and appear light grey in 
colour (Dvorak ef a/., 1993; Erjefalt etal., 1998; Erjefalt ef a/., 1999). 
RSV clearance may be assisted through a process of eosinophil 
recruitment and migration, involving both, cytoskeletal activation and 
reorganisation (Morales-Ruiz et al., 2000). Eosinophil migration is known to 
involve the formation of unique and highly dynamic adhesion structures called 
podosomes (sites of extravasation of the plasma membrane) (Siddiqui et al., 
2012). Podosomes are comprised of a core of short actin filaments and actin-
associated proteins, enabling eosinophil migration from the blood into a tissue 
(Linder et al., 2000). Migration is also enabled by activation of the microtubular 
network which can be visualised though fluorescence microscopy analysis 
(Remijsen et al., 2011). 
The activation of an immune response resulting in a positive resolution of 
RSV infection remains the most desired mechanism for the prevention and 
inhibition of RSV disease. This chapter aimed to examine the in vitro effect of 
RSV on eosinophil morphology, release of eosinophil activation markers and 
eosinophil antiviral activity. As previous studies have looked into RSV-induced 
eosinophil degranulation, in terms of ECP protein release only (Garofalo et al., 
1992; Olszewska-Pazdrak et al., 1998b; Saito et al., 1997), this chapter has 
focused on investigating early signs of eosinophil degranulation using MBP as 
the marker of eosinophil degranulation. In addition, extending on from the 
studies by Phipps et al. (2007) investigating eosinophil activation using EPO as 
the activation marker (Phipps et al., 2007), in this study, the effect of RSV on 
eosinophil chemotaxis, through the activation of the eosinophil cytoskeletal 
components, a-tubulin and F-actin was examined. Furthermore, the effect of 
RSV on eosinophil morphology with an in depth TEM analysis as well as the 
RSV kinetics in mouse eosinophils was also examined. 
3.2 METHODS 
3.2.1 Eosinophil fluorescence activated cell sort 
The leukocyte population was collected from IL-5 Tg BALB/c mice by 
peritoneal lavage. Mice were sacrificed by CO2 asphyxiation (section 2.12.1) 
and the peritoneal cavity exposed by an incision through the abdominal skin. 
The cavity was washed 3 times with 5 mL of sterile HBSS (ANU) using an 18-
gauge needle (Terumo, Australia). Lavage was collected and centrifuged at 240 
X g (Sigma 3-16 PK) for 5 minutes. The supernatant was discarded and the cell 
pellet resuspended in red blood cell lysing buffer (BD Pharmingen, Australia) for 
5 minutes. Cells were re-centrlfuged at 240 x g (Sigma 3-16 PK) for 5 minutes 
followed by removal of supernatant and resuspended in sterile HBSS (ANU), 
with a maximum density of 1 x 10^ cells/mL. All cell clumps and debris were 
removed prior to sorting, by filtration through a cell strainer (40 pm) (BD, 
Australia), then transferred into sterile 4 mL FACS tubes (BD Labware, Europe) 
and placed on ice prior to cell sorting. 
The fluorescence activated cell sorter (FACS) (BD Biosciences 
FACSVantage SE, USA) was used to sort mature eosinophils from the 
peritoneal cell mix, based on forward (FSC) and side scatter (SSC) parameters 
and polarised light as well as green (FL1) and red (FL2) fluorescence 
measurements. Polarised light is especially important in sorting eosinophils as 
measuring depolarised light scattering (dSSC) in combination with normal SCC, 
enables eosinophils to be sorted with high precision. Electronic gates were set 
in order to include eosinophils only, achieving approximately 97% cell purity. 
Eosinophils were sorted into DMEM (Gibco) with 30% HI-FCS (Sigma) and kept 
on ice prior to use. 
3.2.2 Eosinophil transmission electron microscopy 
(TEM) analysis 
Approximately 6 x 10® freshly sorted eosinophils (per sample) were 
treated with Vero E6 cell lysate (negative control) or RSV at multiplication of 
infection (MOI) of 1. RSV was allowed to adsorb for 2 hours, followed by 
change of RSV containing supernatant for fresh media. Samples were collected 
at 3, 6, 12, 18, 24 or 48 hours post incubation and fixed using 2% 
glutaraldehyde/O.IM Sodium cacodylate (Sigma, Australia) overnight at 4°C 
followed by further processing at the Microscopy and Cytometry Resource 
Facility (Ms C. Gillespie, The Microscopy and Cytometry Resource Facility, 
JCSMR, ANU) In accordance with detailed protocol described in Appendix 2. 
Briefly, following primary fixation with 2% glutaraldehyde in 0.1 M Sodium 
cacodylate (Sigma) for at least 2 hours, samples were secondary fixed with 1% 
Osmium textroxide (PriSciTech, Australia) for 1.5 hours followed by three 15 
minute washes with 0.1M Sodium cacodylate and one 15 minute wash with 
distilled water. Samples were then dehydrated in acetone (Univar) 
(concentrations included: 15 minutes in each 30, 50, 70, 90, 95% acetone and 
three 15 minute lots at 100% acetone), followed by embedment in Spurr's resin 
(PriSciTech, Australia). Sections of each sample were cut and stained with 2% 
uranyl acetate (PriSciTech, Australia) and Reynold's lead citrate (PriSciTech, 
Australia). Samples were analysed and photographed using a Hitachi H7000 
transmission electron microscope at 75kV. 
Secondary granules of each eosinophil in TEM sample were counted and 
classified into four categories (type I, intact; type II, loss of crystal core; type III, 
loss of matrix; and type IV, loss of crystal core and matrix). The extent of 
degranulation was quantified by calculating the percentage of degranulating 
cells using the following Equation 3.1: 
no. of activated granules (type II - IV) 
0/0 of degranulating cells total no. of granules 
Equation 3.1. Quantification of degranulating eosinophils 
3.2.3 Eosinophil degranulation assay 
The eosinophil degranulation assay was performed in 24-well tissue 
culture plates (Iwaki) as previously described by Clark (2004). Plates were 
coated with 2.5% w/v bovine serum albumin (BSA) (Fraction V) (Sigma, USA) 
diluted in PBS (ANU) (100 pL/weil) and incubated overnight at 37°C with 5% 
CO2. The next day, 250 pL of purified eosinophils (section 3.2.1) prepared in 
DMEM (Gibco) at 5 x 10® cells/mL concentration, was added to each well, 
followed by the same volume of stimulus (Vero E6 cell lysate (negative control), 
UV-RSV (additional negative control), 0.1 mM (final concentration) phorbol 
myristate acetate (PMA) (Sigma, Australia) or RSV at an MOI 1 (Sigma). The 
plates were incubated at 37°C with 5% CO2 for 4 hours, after which, they were 
spun down at 240 x g (Sigma 3-16 PK) for 5 minutes. The supernatants were 
collected into sterile eppendorf tubes and stored at -80°C, until assayed for 
MBP. 
3.2.3.1 Eosinophil major basic protein detection assay 
The samples collected for eosinophil degranulation were tested for MBP 
activity in the culture supernatant using a dot-blot assay as previously described 
by Hogan (1998). Briefly, polyvlnylidene difluoride (PVDF) (Millipore, USA) 
membrane was soaked in 100% methanol (Scharlau) for 1 minute, followed by 
Tris-buffed saline (TBS) (Sigma, Australia) for 5 minutes. The membrane was 
placed onto a dot blot manifold (Schleicher & Schuell, Germany) to ensure 
uniform distribution of protein for each sample, and 100 pL of the culture 
supernatant was added to the appropriate wells on the apparatus. After 
incubation for 1 hour, each well was washed 3 times with 200 pL of TBS. 
followed by removal from the apparatus and transfer into a blocking solution, 
containing 1% BSA (Fraction V) (Sigma) in TBST (TBS supplemented with 
0.1% Tween-20 (Sigma, Australia) overnight at 4°C. The membrane was then 
washed twice with TBST for 10 minutes followed by incubation with Rabbit anti-
murine MBP monoclonal antibody (50 pg/L) (Santa Cruz Biotechnology, 
Australia) at a dilution of 1:2500 in 1% BSA (Fraction V) (Sigma) in TBST for 2 
hours at room temperature. The membrane was washed three times with TBST 
for 15 minutes. Subsequently, the membrane was incubated with alkaline 
phosphatase-conjugated goat anti-rat antibody at a dilution of 1:1000 in 1% 
BSA in TBST (Sigma, Australia) for 1 hour at room temperature. Finally, the 
membrane was washed 3 times with TEST for 15 minutes each, followed by two 
10 minutes TBS washes. The process was finalised with a 5 minute 
development of the blot by addition of the Western blue-stabilised substrate 
(Promega, USA). The reaction was stopped by rinsing the membrane in distilled 
water for 10 minutes. The membrane was placed onto paper towel and covered 
with aluminium foil where it was left to dry. The dot-blot (image available in 
Appendix 3) was digitised by densitometry and image analysed using Multi 
Gauge Version 2.2 (Fujifilm, Japan). 
The following formulas were used to calculate percentage increase and 
decrease: 
(new number - original number) 
Percentage increase = 100 x 
Percentage decrease = 100 x 
original number 
(original number - new number) 
original number 
Equation 3.2. Percentage increase and decrease formula 
3.2.4 Eosinophil RSV kinetics 
Purified eosinophils (3x10® cells/well) were treated with RSV at an MOI 
1. The infection was set up in 24-well plates (Iwaki) and cells incubated at 37°C 
with 5% CO2 for 3, 6, 12, 24 or 48 hours. Following the incubation, cells and the 
supernatant were collected and assayed for viral titres using the 
immunostaining RSV plaque assay (section 2.10). 
3.2.5 Eosinopliil activation - EPO release assay 
To analyse eosinophil activation, 96-well plates (Iwaki) were prepared by 
coating each well with 60 pL of fibronectin (Sigma, Australia) solution (20 |jg/mL 
in PBS) overnight at 4°C. Wells were washed twice with PBS (ANU) and all 
non-coated sites were blocked with 0.1% (w/v) BSA (Fraction V) (Sigma) for 60 
minutes at 37°C with 5% CO2. Plates were then washed twice with PBS (ANU) 
and quickly air-dried. Purified eosinophils (5 x lO'* cells/well) were resuspended 
in Roswell Park Memorial Institute medium (RPMI)-1640 (Gibco, Australia) 
containing 4% HI-FCS (Sigma) and treated with Vero E6 cell lysate (negative 
control), UV-RSV (additional negative control), 0.1 mM (final concentration) 
PMA (Sigma) (positive control) or RSV at a MOI of 1. Samples were prepared in 
five replicates and incubated for 90 minutes at 37°C with 5% CO2. Following 
incubation, non-adhered cells were removed, and the remaining cells were 
washed twice with PBS (ANU) and lysed using 0.22% cetyl trimethylammonium 
bromide (CTAB) (Sigma, Australia) in 10 mM HEPES (pH 8) (Gibco, Australia). 
Cell lysates were serially diluted across an uncoated 96-well plate and 
100|iL/well of 0-phenylenediamine dihydrochloride substrate (40 mg substrate 
dissolved in 32 mL 1mM HEPES, pH 8) (Sigma, Australia) was added, followed 
by for 30 minute incubation in dark at room temperature. The reaction was 
stopped by adding 50 pL/well of 4M H2S04(Univar) and the product analysed at 
490 nm using a colorimetric plate reader (BioRad, USA). The number of 
adhered cells was calculated based on a standard curve generated by a known 
number of untreated eosinophils. Cells were lysed with 0.22% CTAB and 
processed in the same manner as the unknown samples. Readings from the 
negative control (eosinophils treated with Vero E6 cell lysate) were used as a 
baseline. 
3.2.6 Eosinophil activation with an agonist 
Eosinophil chemotaxis assay is based on the experimental set up by 
Olszewska et al. (1998) (Olszewska-Pazdrak et a!., 1998a). Approximately 2 x 
10® HEp-2 cells/well was seeded in a 24-well plate (Iwaki). Cells were incubated 
with Vero E6 cell lysate, UV-RSV or RSV at an MOI of 1 for 24 hours at 37°C 
with 5% CO2. RSV was allowed to adsorb for 2 hours, followed by change of 
RSV containing supernatant for fresh media. Following day, Costar transwell 
filters (Corning, USA) were coated with 50 ng/mL fibronectin for 2 hours at 37°C 
and rinsed twice with serum free RPMI-1640 (Gibco, USA). Freshly purified 
eosinophils were loaded in the top chamber of the transwell filter (5 x lO"* 
cells/well) and allowed to adhere for 20 minutes at room temperature. 
Supernatant (agonist) collected from Vero E6 cell lysate treated HEp-2 cells 
(negative control), UV-RSV treated HEp-2 cells (additional negative control), 0.1 
|JM PMA (Sigma) with 100 ng/mL eotaxin (Invitrogen, Australia) (positive 
control) or RSV infected HEp-2 cells (at an MOI 1) was placed in the bottom 
chamber of the transwell plate. Eosinophils were allowed to migrate for 10 
minutes towards the agonist at room temperature. Cells were fixed 4% 
paraformaldehyde (Sigma, Australia) for 10 minutes. Transwell filters were 
excised and placed in the bottom of a 24-well plate (Iwaki) for 
immunohistochemistry staining of the primary eosinophils for cytoskeletal 
components (section 3.2.6.1). 
3.2.6.1 Immunohistochemistry assay for cytoskeletal 
components in primary eosinophils 
Fixed cells were rinsed three times for 5 minutes with 0.1% Triton X-100 
(Sigma, Australia) pH 7.4 in PBS. Cells were permeabilised for 10 minutes with 
0.5% Triton X-100 (Sigma) pH 7.4 in PBS and rinsed again three times for 5 
minutes with 0.1% Triton X-100 (Sigma) pH 7.4 in PBS. Cells were then 
incubated for 2 hours at room temperature with blocking solution, 2% goat 
serum (Life technologies, Australia) in PBS (ANU) to eliminate any non-specific 
binding. This was followed by incubation with primary antibody, anti-F-actin or 
anti-a-tubulin at 1-10 pg/mL (Invitrogen, Australia) at 4°C overnight in a sealed 
plate or 1 hour at room temperature. Slides were rinsed five times for 5 minutes 
with 0.1% TritonX-100 (Sigma) in PBS (ANU) at room temperature. Secondary 
antibody, Texas red-phalloidin or boron-dipyrromethene (BODIPY)-FL 
(Invitrogen, Australia)) was prepared at 1:1000 in the blocking solution. Slides 
were incubated in the secondary antibody solution at 4°C overnight. Slides were 
rinsed five times for 5 minutes with 0.1% TritonX-100 (Sigma) in PBS (ANU) at 
room temperature. Slides were mounted using a small drop of 4',6-diamidino-2-
phenylindole (DAPI) antifade (Invitrogen, Australia). The filter (containing 
adhered eosinophils) from the bottom of the 24-well plate (Iwaki) was harvested 
and inverted onto a drop of DAPI antifade placed on a coverslip and sealed with 
nail polish. Slides were analysed for actin polymerisation and a-tubulin 
activation using a confocal microscope (Nikon Eclipse Ti). 
3.3 RESULTS 
3.3.1 RSV-induced changes to eosinophil 
morphology 
As eosinophils are found to play an important role in RSV infection, 
electron microscopy analysis of eosinophils was used to determine the extent of 
cellular activation following RSV treatment (Figure 3.1). Eosinophils showed 
signs of the granule protein release, mostly via a process of PMD (Figure 3.1). 
As seen in Figure 3.1 A, following 3 hour incubation untreated eosinophils 
(negative control) contained primarily type I granules with highly electron-dense 
crystals (core intact) and vesicles (matrix intact) (arrow and inset in A) with only 
20% of type II granule (thick arrows) present. As seen in Figure 3.1 B-D, the 
number of type II granules present in untreated eosinophils (negative control) 
increased over time (6-18 hours), from 30 to 50%, determined by a progressive 
increase in a number of electron-lucent crystals and accompanied by electron-
lucent vesicles. Moreover, at 24 hours post incubation untreated eosinophils 
displayed signs of type III granules (inset in E) (thin arrows), with the overall 
cellular structure still intact (Figure 3.1 E). 
In contrast, RSV-treated eosinophils incubated for 3 hours (Figure 3.1 F) 
contained a greater proportion of activated eosinophils undergoing PMD, with 
50% of type II granules present (indicative of loss of core content, thick arrows; 
inset in F). At 6 hours of incubation, RSV-treated eosinophils contained equal 
parts of type II and type III granules, approximately 50% each; while at 12 and 
18 hours post incubation, RSV-treated eosinophils contained close to 90% of 
granules that had lost their core, matrix or both granule constituents (Figure 3.1 
H and I). Following a 24 hour incubation period, the secondary granules of 
RSV-treated eosinophils were surrounded by small empty vesicles, type IV 
granules (arrow head), showing signs of apoptotic nucleus, cellular degradation 
(loss of membrane) and the release of the cellular contents into the surrounding 
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Figure 3.1. Respiratory syncytial virus (RSV) induced changes to 
eosinophil morphology (A-J) 
Electron photomicrographs (EM) of mouse eosinophils following 3, 6, 12, 18 and 24 hours 
treatment with Vero E6 cell lysate (untreated eosinophils; negative control) (A-E) or RSV at a 
multiplicity of infection of 1 (F-J). Following the incubation, cells were collected and processed for 
transmission electron microscopy. Eosinophil multilobed nucleus is labelled N on each EM image. 
Arrows indicate different signs of eosinophil degranulatlon (loss of core and/or matrix) and cellular 
integrity as described in the text. Samples were analysed and photographed using a Hitachi 
H7000 transmission electron microscope at 75kV. Data are representative of five replicate 
samples taken for each time point. 
3.3.2 Quantification of RSV-induced eosinophil 
activation 
in conjunction witti TEM analysis of eosinophils, RSV-induced eosinophil 
activation was quantified (Figure 3.2) by transforming data into the percentage 
of activated cells, determined by the number of type ll-IV granules present 
within eosinophils. Distinct differences in the degree of eosinophil activation 
were observed for untreated eosinophils (negative control) compared to RSV-
treated eosinophils. Following 3-18 hours post incubation, untreated eosinophils 
contained predominantly type I granules, with type II granules (partial loss of 
core) becoming more prominent over time, increasing from 20% at 3 hours post 
incubation to 55% by 18 hours post incubation. At 24 hours post incubation, 
untreated eosinophil granule content appeared to be made up of equal parts of 
type II and III (partial loss of matrix) granules, making approximately 90% of 
eosinophil granule content. 
In contrast, incubation of RSV treated eosinophils for 3 hours resulted in 
more than 50% of type II granules present, compared to untreated eosinophils 
(p < 0.0001). At 6, 12 and 18 hours post incubation, RSV treated eosinophils 
had 28, 38 and 36% respectively, greater proportion of type II and type III 
granules present compared to untreated eosinophil control at the corresponding 
incubation times (p < 0.005). Finally, at 24 hours post incubation, RSV treated 
eosinophils contained 100% type IV granules with a complete loss of eosinophil 
granule protein content (loss of core and matrix) and cellular integrity. 
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Figure 3.2. Quantification of respiratory syncytial virus (RSV) induced 
eosinophil activation 
Freshly isolated eosinophils from interleukin-5 transgenic BALB/c mice were incubated with Vero 
E6 cell lysate (untreated eosinophils; negative control) or RSV at a multiplicity of infection of 1 
and the percentage of degranulating cells was determined using transmission electron 
microscopy assay following 3, 6 ,12 ,18 and 24 hours incubation. The data is represented as the 
mean percentage of type ll-IV granules present in eosinophils (n = 10) ± standard deviation. 
Significant differences as determined by TWO-way ANOVA with Sidak's multiple comparison test 
(GraphPad Prism version X7), were seen in RSV treated samples compared to the corresponding 
untreated eosinophil samples ( " , p < 0.005 and p < 0.0001). 
3.3.3 RSV-induced eosinophil degranulation 
Eosinophil degranulation is indicative of eosinophil activation in the 
presence of an agonist. MBP was used as an eosinophil degranulation marker. 
Untreated eosinophils (treated with Vero E6 cell lysate; negative control) and 
UV-RSV treated eosinophils (additional negative control) displayed low levels of 
eosinophil degranulation (100 density/pixel^) (Figure 3.3). On the other hand, 
treatment with 0.1 pM (final concentration) PMA (positive control) induced a 
significant increase (p < 0.0001) in eosinophil degranulation with a reading of 
165 density/pixel^' corresponding to a 75% increase as compared to the 
negative control (Figure 3.3). However, RSV treatment of eosinophils induced 
degranulation with a reading of approximately 185 density/pixel^ suggesting an 
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Figure 3.3. Respiratory syncytial virus (RSV) induced eosinophil 
degranulation 
Freshly isolated eosinophils, from interleukin-5 transgenic BALB/c mice were incubated with Vero 
E6 cell lysate (untreated eosinophils; negative control - white bar), ultraviolet-inactivated RSV 
(UV-RSV) (additional negative control - light grey bar), 0.1 pM phorbol myristate acetate (PMA) 
(positive control - dark grey bar) or RSV (black bar) at multiplicity of infection of 1 for 4 hours. 
Samples were assessed for eosinophil degranulation using a major basic protein as a 
degranulation marker. Data is represented as the mean density/pixel^ (n = 5) ± standard 
deviation. Data was analysed using ONE-way ANOVA with Dunnet multiple comparison test 
(GraphPad Prism version X7) ( " " , p < 0.0001 compared to the negative control). 
3.3.4 Eosinophil RSV antiviral activity 
To investigate eosinophil antiviral activity, purified eosinophils isolated 
from IL-5 Tg BALB/c mice were treated with Vero E6 cell lysate (untreated 
eosinophils; negative control), UV-RSV (additional negative control) or RSV at 
an MO! of 1 for 0, 3, 6, 12, 18, 24 and 48 hours (Figure 3.4 A). Samples were 
collected and assayed for RSV litres. No viral titres were recovered from 
untreated (negative control) or UV-RSV (additional negative control) treated 
eosinophils. 
At 0 hours post incubation, RSV treated eosinophils received 
approximately 500 x 10^ pfu of RSV per sample. By 3 hours post incubation, the 
viral titre had decreased significantly (p < 0.0001) to 100 x 10^ pfu/mL. The viral 
titres continued to decrease over time, from 75 x 10^ pfu/mL at 6 hours post 
RSV treatment, down to 45 x 10^ pfu/mL at 12 hours. At 24 hours post RSV 
treatment a count of 25 x lO^pfu/mL was observed. At the experimental end 
point of 48 hours post RSV treatment, the viral titres had significantly decreased 
to 15 x 103 pfu/mL (Figure 3.4 A). 
Cell viability of purified eosinophils treated with Vero E6 cell lysate 
(untreated eosinophils; negative control), UV-RSV (additional negative control) 
or RSV at an MOI of 1 for 0, 3, 6, 12, 18, 24 and 48 hours was also assessed 
(Figure 3.4 B). Both, untreated (negative control) and UV-RSV (additional 
negative control) treated eosinophils induced a similar cell viability trend, with 
cell viability remaining above 85% for the first 6 hours of incubation for both 
treatment groups. However, by 12 hours post incubation, cell viability dropped 
to 38%, with a further decrease to 15% and 5% by 24 and 48 hours post 
incubation respectively for both, untreated and UV-RSV treated eosinophil 
groups. 
RSV treatment of eosinophils resulted in a significant reduction in cell 
viability over time, compared to the negative controls (p < 0.05). Within the first 
6 hours of incubation, RSV treated eosinophil cell viability decreased from 97% 
to 60% (p < 0.05). Only 20% of the RSV treated eosinophils were viable at 12 
hours post incubation (p < 0.0001) with continued decline to 10% and 0% by 24 
and 48 hours post incubation, respectively. 
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Figure 3.4. Eosinophils antiviral activity against respiratory syncytial virus 
(RSV; in vitro 
Freshly isolated eosinophils from interleukin-5 transgenic BALB/c mice were incubated with Vero 
E6 cell lysate (untreated eosinophils; negative control), ultraviolet-inactivated RSV (UV-RSV) or 
RSV at a multiplicity of infection of 1 for 0, 3, 6, 12, 24 and 48 hours at 37°C with 5% CO2. A) 
R S V replication kinetics in m o u s e eosinophi ls . Eosinophils and supernatant were collected 
and assayed for viral titres (plaque forming units (pfu)/mL). Initial RSV inoculum is represented by 
the grey bar. Samples are represented as a mean of RSV pfu/mL (n = 5) ± standard deviation. B) 
E o s i n o p h i l cel l viabil ity. Cell viability was measured using trypan blue exclusion assay. 
Samples are represented as a mean percentage cell viability (n = 5) ± standard deviation. Data 
was analysed using ONE-way ANOVA with Dunnet multiple comparison test (GraphPad Prism 
version X7). Asterisks denote significant decrease in RSV viral titres over time and cell viability 
compared to untreated eosinophils (*, p < 0.05 and p < 0.0001). 
3.3.5 Eosinophil migration 
3.3.5.1 Eosinophil activation - EPO release 
EPO was used as an eosinophil activation marker (Figure 3.5). Untreated 
eosinophils (treated with Vero E6 cell lysate; negative control) and UV-RSV 
treated eosinophils (additional negative control) induced low levels of eosinophil 
activation (0.5 optical density (OD)) (Figure 3.5). Eosinophil treatment with 0.1 
pM PMA (positive control) resulted in an increase in eosinophil activation with a 
reading of approximately 2 OD obtained (p < 0.001) (Figure 3.5) as well as 
300% increase in eosinophil activation compared to the negative control. 
However, RSV treatment of eosinophils induced eosinophil activation with a 
reading of approximately 3 OD indicating a 500% increase in eosinophil 
activation compared to the negative control (p < 0.001). 
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Figure 3.5. Respiratory syncyt ia l v i rus (RSV) induced eosinophi l activation 
Freshly isolated eosinophils, from interleukin-5 transgenic BALB/c mice were incubated with Vero 
E6 cell lysate (untreated eosinophils; negative control - white bar), ultraviolet-inactivated RSV 
(UV-RSV) (additional negative control - light grey bar), 0,1 | jM phorbol myristate acetate (PMA) 
(positive control - dark grey bar) or RSV (black bar) at a multiplicity of infection of 1 for 90 
minutes. Samples were assessed for eosinophil activation using an eosinophil peroxidase as an 
activation marker. Data is represented as the mean optical density (OD) (n = 5) ± standard 
deviation. Data was analysed using ONE-way ANOVA with Dunnet multiple comparison test 
(GraphPad Prism version X7) (* " , p < 0,001 compared to the negative control), 
3.3.5.2 Activation of alpha-tubulin 
Freshly sorted eosinophils, from IL-5 Tg BALB/c mice were allowed to 
migrate for 10 minutes towards Vero E6 cell lysate treated HEp-2 cells 
supernatant (untreated eosinophils; negative control) (Figure 3.6 A and B), UV-
RSV treated HEp-2 cells supernatant (additional negative control) (Figure 3.6 C 
and D), 0.1 |JM (final concentration) PMA with 100 ng/mL of eotaxin (positive 
control) (Figure 3.6 E and F) or supernatant collected following 24 hour RSV 
treatment of HEp-2 cells at an MOI of 1 (Figure 3.6 G and H). 
Untreated eosinophils migrating towards either Vero E6 cell lysate 
treated HEp-2 cells supernatant (negative control) or UV-RSV treated HEp-2 
cells supernatant (additional negative control) had punctate and non-
polymerised a-tubulin localised radially from the microtubules organising centre 
(MTOC) and around the peripheral cell membrane (Figure 3.6 B and C). The 
addition of an agonist induced rapid a-tubulin polymerisation and a formation of 
a distinct radial microtubular network, most prominent following eosinophil 
migration towards a mixture of 0.1 pM PMA with 100 ng/mL eotaxin (positive 
control) (Figure 3.6 F) This was also observed with eosinophils migrating 
towards RSV infected HEp-2 supernatant (Figure 3.6 H). The MTOC in 
migrating eosinophils remained localised at the centre of the elongated nucleus, 
anterior towards the leading pseudopodia (Figure 3.6 F and H). Controls of the 
BODIPY-labelled secondary antibody were also run to ensure the specificity of 
binding to the primary antibody only (data not shown). 

Figure 3.6. Respiratory syncytial virus (RSV) activation of eosinophil a-
tubulin 
Eosinophils migrating towards Vero E6 cell lysate treated HEp-2 cells supernatant (untreated 
eosinophils; negative control) (A and B), ultraviolet-inactivated (RSV) (UV-RSV) treated HEp-2 
cells supernatant (additional negative control) (C and D), 0.1 |JM phorbol myristate acetate (PMA) 
with 100 ng/mL of eotaxin (positive control) (E and F) or supernatant collected following 24 hour 
RSV treatment of HEp-2 cells at a multiplicity of infection of 1 (G and H) were stained with DAPI 
(A, C, E and G) and anti-a-tubulin and BODIPY-labelled secondary antibody (B, D, F and H) for 
detection of the microtubular network. Images were taken using the Nikon Eclipse Ti confocal 
microscope. Images are representative of two separate experiments with samples prepared in 
triplicates. 
3.3.5.3 Activation of F-actin 
Freshly sorted eosinophils, from IL-5 Tg BALB/c mice were allowed to 
migrate for 10 minutes towards Vero E6 cell lysate treated HEp-2 cell 
supernatant (untreated eosinophils; negative control) (Figure 3.7 A and B), UV-
RSV) treated HEp-2 cell supernatant (additional negative control) (Figure 3.7 C 
and D), 0.1 pM (final concentration) PMA with 100 ng/mL of eotaxin (positive 
control) (Figure 3.7 E and F) or supernatant collected following 24 hour RSV 
treatment of HEp-2 cells at a multiplicity of infection of 1 (Figure 3.7 G and H). 
Untreated eosinophils either migrating towards Vero E6 cell lysate 
treated HEp-2 cells supernatant (negative control) or towards UV-RSV treated 
HEp-2 cells supematant (additional negative control) had F-actin primarily 
localised and adjacent to the peripheral membrane (Figure 3.7 B and C). The 
addition of an agonist induced cell polarisation and accumulation of F-actin 
towards the leading pseudopod observed in eosinophils migrating towards a 
mix of 0.1 pM PMA with 100 ng/mL eotaxin (positive control) (Figure 3.7 F). 
Similar observations were made for eosinophil migration towards RSV infected 
HEp-2 supernatant (Figure 3,7 H). Thick arrows indicate leading edge 
formation, while thin arrows point towards direction of eosinophil migration 
(Figure 3.7 F and H). Controls of the Texas red anti-phalloidin-labelled 
secondary antibody were also run to ensure the specificity of binding to the 
primary antibody only (data not shown). 

Figure 3.7. Respiratory syncytial virus (RSV) activation of eosinophil F-
actin 
Eosinophils migrating towards Vero E6 cell lysate treated HEp-2 cells supernatant (untreated 
eosinophils; negative control) (A and B), ultraviolet-inactivated RSV (UV-RSV) treated HEp-2 
cells supernatant (additional negative control) (C and D), 0.1 |JM phorbol myristate acetate (PMA) 
with 100 ng/mL of eotaxin (positive control) (E and F) or supernatant collected following 24 hour 
RSV treatment of HEp-2 cells at a multiplicity of infection of 1 (G and H)were stained with DAPI 
(A, C, E and G) and anti-F-actin and Texas red anti- phalloidin for the detection of F-actin (B, D, F 
and H). Images were taken using the Nikon Eclipse Ti confocal microscope. Thick arrows depict 
leading edge formation, while thin arrows indicate direction of eosinophil migration. Images are 
representative of two separate experiments with samples prepared in triplicates. 
3.4 DISCUSSION 
Since the unsuccessful RSV vaccine trial in 1956 (Morris et al., 1956) 
numerous studies have tried to understand why the vaccine trial failed (Becker, 
2006; Olson et al., 2008; Wans et al., 1996). The consensus has been that 
eosinophilia, described by an Influx of eosinophils into the lung tissue, 
contributed to RSV disease pathology and therefore, became the hallmark of 
RSV disease (Rosenberg and Domachowske, 2001). Consequently, eosinophils 
were characterised as leukocytes contributing to RSV disease pathology and 
their presence during RSV infection or therapeutic interventions was deemed 
undesirable (Openshaw etal., 2003). 
Although some studies have concentrated on elucidating the role of 
eosinophils in viral infection (Adamko et al., 1999; Domachowske et al., 1998a; 
Phipps et al., 2007; Rosenberg and Domachowske, 2001), there are limitations 
to the knowledge and understanding that these studies offer. One of the major 
limitations of the previous electron microscopy analysis is that ssRNA was used 
to stimulate eosinophils (Phipps et al., 2007). As such, this provides a very 
limited view of RSV effect on eosinophil morphology. These findings could be 
expanded further by including a wider range of time points as well. It would 
enable a better understanding of RSV-induced changes to eosinophil 
morphology while characterising the eosinophil degranulation kinetics over time. 
In addition, previous eosinophil degranulation studies have only focussed on 
levels of ECP in tissue culture and nasopharyngeal secretions from human 
infants (Olszewska-Pazdrak et al., 1998b; Saito et al., 1997). However, these 
studies have failed to note that, as ECP is located in the matrix of the eosinophil 
granule its release is preceded by the release of MBP from the core. In addition, 
there is a difference in opinion whether RSV can infect eosinophils (Dyer et al., 
2009; Kimpen, 2001a) and therefore promote antiviral host defence. This 
controversy is under explored and requires further investigation. Finally, 
previous studies have only examined eosinophil activation using EPO, as the 
activation marker however expanding on these findings would enable us to 
generate a bigger picture of RSV-induced activation by also examining 
eosinophil cytoskeleton involvement in subsequent processes such as 
migration. 
In vitro results from the electron microscopy analysis revealed a 
significant (p < 0.005) RSV-induced effect on eosinophil morphology over time 
(Figure 3.1 and Figure 3.2). TEM results indicate RSV-induced eosinophil 
activation as demonstrated by the release of eosinophil granule content into the 
external cell environment. The release was mainly characterised by partial and 
complete loss of eosinophil granule core contents following the RSV treatment 
of eosinophil for 6, 12 and 18 hours (Figure 3.1 G, H and I). RSV-induced 
changes to eosinophil morphology became even more evident following 24 
hours post RSV incubation of eosinophils. At this time, eosinophil granules were 
completely devoid of core and matrix content and apoptotic nuclei became the 
hallmark of RSV treatment (Figure 3.1 J). These findings for the first time 
demonstrate clearly RSV-induced changes to eosinophil morphology over time 
as a result of RSV treatment of eosinophils. Previous findings by Phipps et al. 
(2007) support described TEM findings in this chapter, as they have also 
showed that a ten minute treatment of eosinophils with ssRNA results in a loss 
of the eosinophil crystal core content as demonstrated by TEM analysis (Phipps 
et al., 2007). The study conducted by Clark et al. (2004) also revealed similar 
changes to eosinophil morphology observed in an allergic asthma model using 
TEM (Clark et a!., 2004). Together, these novel findings demonstrate how RSV 
treatment of eosinophils has detrimental effect on eosinophil morphology and 
integrity over time, resulting in granule content and subsequent cytotoxic protein 
release via process of PMD and concluding in a loss of cellular structure and 
cell apoptosis. It is important to note that the use of eosinophil survival factor 
was not required in the expehment examining RSV-induced changes to 
eosinophil morphology as appropriate eosinophil controls (untreated 
eosinophils) were used at each time point. Trypan blue viability test was the 
only test performed assessing the cell health status. Although this may be 
perceived as a limitation of this study, it is consistent with other research groups 
who have not used eosinophil survival factors in experiments similar to the one 
described in this study (Phipps et al., 2007; Rosenberg and Domachowske, 
2001). 
The current studies suggest for the first time that presence of MBP may 
not be a by-product of cellular degenerative processes but rather result directly 
in response to RSV-mediated eosinophil activation. Earlier studies examining 
RSV-induced eosinophil degranulation, found high levels of ECP present in the 
lung epithelial tissue culture (Olszewska-Pazdrak et al., 1998b) and 
nasopharyngeal secretions of human infants (Saito et al., 1997). However, the 
importance of eosinophil degranulation in response to respiratory viral infection 
has yet to be fully elucidated, with studies yet to examine early signs of 
eosinophil degranulation. The degranulation study in this chapter examined 
early signs of eosinophil degranulation using MBP as the degranulation marker. 
MBP is located in the core of eosinophil granule and is the first granular protein 
to be released following eosinophil activation. Results showed a significant 
increase (p < 0.0001) in eosinophil degranulation following RSV treatment of 
eosinophils (Figure 3.3). It is important to highlight the potential of RSV-
mediated eosinophil activation as these results indicate that eosinophils have 
the potential to generate a targeted response to RSV infection. 
Together, these findings are suggestive of eosinophil ability to play a role 
in antiviral activity. These observations were supported further by the in vitro 
study showing a significant decline (p < 0.0001) in RSV titres over time, 
following 3, 6, 12, 18 and 24 hours RSV treatment of eosinophils compared to 
the initial RSV inoculum (time 0 hours) (Figure 3.4 A). These results are in 
agreement with previous studies demonstrating eosinophil antiviral activity 
following RSV infection of the epithelial cells ;n v/fro (Domachowske et al., 
1998b; Soukup and Becker, 2003). In addition, the current antiviral study 
implies RSV inability to infect murine eosinophils and to establish active 
replication within, as indicated by a reduction in viral titres recovered. Similarity, 
TEM analysis of RSV treated eosinophils also revealed no RSV viral particles 
present inside the eosinophils following RSV treatment, suggesting that RSV 
may be unable to infect murine eosinophils. Taking into account previous 
studies, which showed that RSV could infect human eosinophils and that PVM 
can infect mouse eosinophils (Dyer et al., 2009; Kimpen et al., 1996), these 
results may be a result of incompatibility between RSV as a human respiratory 
pathogen and the mouse purified eosinophils used in the in vitro studies. 
Despite similar morphology, human and mouse eosinophils differ from one 
another, and cannot be presumed to function identically in all circumstances 
(Lee etal., 2012a). The mechanism that offers protection of mouse eosinophils 
against RSV infection may offer important insights into preventing human 
infection as well. It is therefore important to explore this mechanism further. 
The current studies found that eosinophils were significantly less viable 
following the RSV treatment (p < 0.05), supporting the concurrent findings that 
dennonstrated RSV-induced eosinophil activation and subsequent degranulation 
followed by the loss of cellular structure and cell apoptosis. However, these 
results contradict previous studies with PVM which showed that virus infection 
has no effect on the cell viability of eosinophils in cell culture (Dyer et al., 2012). 
The difference in findings between PVM versus RSV treatment and eosinophil 
viability could only be due to the interaction between the human pathogen, RSV 
and murine eosinophils as the experimental set up was similar to PVM infection 
of murine eosinophils. Nevertheless, these findings are the first to show that 
RSV has detrimental effect on cell viability resulting in, accelerated cell 
apoptosis. Finally, RSV treatment of eosinophils leads to eosinophil activation, 
cell migration and degranulation; with RSV treated eosinophils showing 
significantly greater number of activated cells present compared to the negative 
control (p < 0.001) (Figure 3.5) as demonstrated by EPO release. These 
findings are in agreement with previous finding by Phipps et al. (2007) who also 
showed an increase in EPO as a result of ssRNA activation of eosinophils 
(Phipps et al., 2007). Furthermore, Olszewska-Pazdrak at al. (1998) study 
found that RSV infection results in the secretion of the proinflammatory C-C 
chemokines RANTES, MCP-1 and MIP-1a from epithelial cells of the human 
lower respiratory tract. They also showed the chemokines produced by RSV-
infected epithelial cells have biological activity relevant to the pathogenesis of 
allergic inflammation, as they exhibit chemotaxis for blood eosinophils 
(Olszewska-Pazdrak et al., 1998a). In our study, we have expanded on 
Olszewska-Pazdrak et al. (1998) findings by examining which cytoskeletal 
components are activated as a result of eosinophil chemotaxis towards 
chemokine containing supernatant, collected from RSV infected HEp-2 cells. 
Eosinophil migration study revealed that eosinophil migration towards RSV 
infected HEp-2 cell supernatant resulted in activation of the microtubular 
network (Figure 3.6) and high polymerisation of F-actin (Figure 3.7). F-actin 
polymerisation led to formation of leading edge pseudopod as well as star-like 
microtubular formation of a-tubulin, indicative of a cell in its migration state. 
Migration study, in addition to eosinophil activation findings, is the first study to 
demonstrate RSV-induced effect on eosinophil cytoskeletal components, 
indicating that eosinophil migration may be a result of targeted response as 
oppose to nonspecific response, which may be crucial in ensuring an effective 
viral clearance. 
In summary, the chapter 3 findings suggest that eosinophils have a 
potential to play a positive role in viral clearance, demonstrated by, what 
appears to be RSV inability to infect murine eosinophils. As previously stated, 
the protection that murine eosinophils enjoy in response to RSV infection is 
worth further exploration. This study also demonstrated RSV-induced changes 
to eosinophil morphology, eosinophil degranulation, activation and migration as 
well as activation of eosinophil cytoskeletal components. Together, these 
findings indicate that eosinophil activation following RSV treatment may be a 
result of targeted response as oppose to nonspecific immune response. 
Although pulmonary eosinophilia is a hallmark response to FI-RSV (Percopo et 
al., 2009), there is no clear indication that eosinophils actually contribute to the 
negative sequel of RSV disease. In addition, while severe primary RSV infection 
is associated with pulmonary eosinophilia and progression to asthma, the 
mechanism by which these two features are linked has not been elucidated 
clearly (Rosenberg et al., 2009). Among the possibilities that have yet to be 
explored, eosinophil function may be less dependent on the number of recruited 
cells and related more closely to the quality and extent of the immune cell 
milieu. These are all issues that are worthy of further consideration. In 
conclusion, it is important to elucidate the role of eosinophils in viral infection, 
both antiviral and pathogenic, as they may be involved in immune 
compensation with assistance from other innate/adaptive immune cells. 
Chapter 4. THE ROLE OF INNATE AND ADAPTIVE 
IMMUNITY IN RESPIRATORY SYNCYTIAL 
VIRUS INFECTION AND RE-INFECTION 
4.1 INTRODUCTION 
Expanding on the in vitro results from Chapter 3, the role of eosinophils 
in RSV infection was examined in the in vivo model. Previous studies examining 
human and murine models revealed that inefficient immune system regulation 
escalates respiratory disease pathology following RSV infection, and can also 
lead to less optimal viral clearance (Culley et a!., 2002; Tasker et ai., 2008; 
Welliver et ai., 2008). Therefore, in order to clear pathogens from the host, the 
immune system must induce balanced release of whatever is required to 
effectively activate and clear the pathogen. Consequently, immune system must 
induce self-regulated responses to prevent unbalanced immunity and 
successive collateral damage of the host tissue. 
As innate immunity is the first line of defence (Goldsby et al., 2003), 
initially its response involves a release of effector molecules and phagocytic 
cells to the site of infection. However, as innate immunity lacks immunological 
memory (IVIcNamara and Smyth, 2002), it induces the same sequence of 
immune cell responses over and over again. Furthermore, RSV infection has 
been associated with skewing of the immune system away from an antiviral Th1 
response towards a Th2 response, which is believed to be undesirable immune 
response leading to disease pathology instead of effective viral clearance 
(Welliver et al., 2008). Nevertheless, important cells of the innate immunity 
involved in response to RSV are DCs, macrophages, neutrophils, eosinophils 
and NK cells as well as the lung epithelial cells. 
DCs, as the primary APCs, are the first to encounter RSV, subsequently 
inducing activation of the naive virus-specific T cells (Braciale, 2005). 
Macrophages play an important role in controlling the immune response to viral 
infection (Kimpen, 2001b) with murine studies showing that macrophages 
provide an immediate response of pro-inflammatory cytokines following RSV 
infection (Pribul et al., 2008). Furthermore, macrophages are a major producer 
of type I IFN (Kumagai et al., 2007) and appear to be important in both, 
restricting the virus and clearing cellular debris later in infection. Without 
clearance, cellular debris can lead to further damage and inflammation (Reed et 
al., 2008). Neutrophils are the predominant airway leukocytes in RSV 
bronchiolitis and they are activated in the presence of infection (Lukens et al., 
2010). 
Eosinophils have been shown to play a specialised role in the innate host 
defence against RSV as the potential exists to mediate direct killing via the 
release of cytotoxic proteins and the eosinophil RNases (Dyer et al., 2009). As 
mentioned in Chapter 3, several studies have found that eosinophils have the 
means to promote antiviral host defence in vitro (Domachowske et al., 1998a; 
Soukup and Becker, 2003). Also, Phipps et al. (2007) study revealed 
accelerated clearance of RSV from the lungs of IL-5 Tg BALB/c mice (Phipps et 
al., 2007) demonstrating eosinophil antiviral role in vivo as well. Furthermore, 
NK cells are recruited locally during the initial phases of virus infection (Hussell 
and Openshaw, 1998) and accumulate in the lung during the first few days of 
RSV infection, producing T cell recruiting cytokines and chemokines, such 
as IL-8, MIP-1a and RANTES (Fauriat et al., 2010; Hussel et al., 1997a; 
Hussell and Openshaw, 1998). In addition, NK cells are responsible for the 
early production of IFN-y and contributing to inhibition of lung eosinophilia 
(Hussel et al., 1997a; Hussell and Openshaw, 1998). The main function of NK 
cells is to recognise and destroy virus-infected cells on the basis of alterations 
that occur on the surface proteins of the normal cell (Message and Johnston, 
2001). Apart from being effector cells, NK cells have a regulatory role during an 
immune response by affecting DCs, macrophages, and mast cells (Moretta et 
al., 2005). Recently, the notion that NK cells are truly innate cells has been 
called into question because specific subsets of mouse liver NK cells have been 
described to have the adaptive immunity property of lasting memory against 
specific viral antigens (Gillard et al., 2011; Vivier et al., 2011). In addition, 
recently discovered ILC2 cells, play a very important role in the innate immunity. 
In adult mice, ILC2 cells are a rare population that expands in response to IL-25 
or IL-33 or during helminthic infection (Neill et al., 2010). They represent a chief 
source of IL-13, a pleiotropic cytokine that mediates a variety of effects, 
including suppression of cytokine production by monocytes (Minty et al., 1993), 
mucus production by goblet cells and the recruitment of eosinophils by epithelial 
cells (Cohn et al., 1999; Grunig et al., 1998; Pope et al., 2001). ILC2 cells can 
also produce IL-5, which has been linked to eosinophil recruitment, as well as 
IL-9 (Wilhelm et al., 2011), which is prominent during helminthic infections 
(Faulkner et al., 1997; Richard et al., 2000) and has been linked to atopic 
disease (Shimbara et al., 2000). ILC2 cells have been shown to be involved in 
the immunity against helminths as well as in the allergic conditions such as 
asthma and chronic sinusitis (Chang et al., 2011; IVIjosberg et al., 2011; Mora et 
al., 2010; Neill et al., 2010) but are also probably important for maintaining 
tissue homeostasis (Monticelli etal., 2011). Finally, epithelial cells provide a link 
to the initial innate immune response assisting in an adaptive immune system 
activation following RSV infection (Lotz and Peebles, 2012). 
As RSV has been found to re-infect the same individual several times 
throughout its life, understanding the adaptive immune response to RSV re-
infection is imperative to providing long lasting protection against RSV. RSV re-
infection is characterised by an initial influx of NK cells follow/ed by recruitment 
of helper CD4''and cytotoxic CDS'" lymphocytes to the site of infection (Olson et 
al., 2008; Olson and Varga, 2007; Stevens et al., 2009). A mouse study found 
that the CD4''and CD8''T lymphocyte subsets contribute individually to clearing 
of the RSV infection however, both can also contribute to disease pathogenesis, 
especially CD8^ T cells (Graham et al., 1991). Although RSV-specific CD8*T 
cells can provide protection against infection, the effect is short lived (Connors 
etal., 1991; Kulkarni etal., 1995). Nevertheless, there are also a number of risk 
factors that have been found to lead to severe RSV disease early in life, 
including prematurity, low titres of maternal antibodies, lack of previous RSV 
infection (Berkovich, 1964; Cunningham et al., 1991), underlying 
cardiopulmonary disease (Groothuis et al., 1988; MacDonald et al., 1982), 
immunosuppression (especially T cell deficiencies) (Falsey, 2007; Falsey et al., 
2005) (Whimbey and Ghosh, 2000) as well as immunodeficiency disorders 
(Fishaut etal., 1980; Mcintosh etal., 1984). RSV re-infection may also be aided 
by features that help RSV evade host defences. Several factors that allow RSV 
to evade host defence include the secreted form of the G protein (Bukreyev et 
al., 2008), the glycoprotein sheath of the G protein, and the presence of two 
antigenic subgroups (Waris, 1991). Other factors of the immune evasion include 
the tropism of the virus for the superficial layer of the respiratory epithelium and 
its relatively non-invasive nature (Lotz and Peebles, 2012). This may delay and 
reduce the exposure of viral antigen to the host immune system. In addition, the 
lumen of the respiratory tract is poorly accessed by serum antibodies, therefore 
reducing their ability to restrict viral replication. In addition, recent murine 
studies indicate that CD8'' cytotoxic T lymphocytes are functionally down-
regulated in the lung, which may be a host mechanism to reduce tissue damage 
however this also would result in reduced immune protection (DiNapoli et al., 
2008; Vallbracht et al., 2006). Thus, both, host and viral factors are believed to 
contribute to reduced efficacy of RSV immune control. 
Previous research into RSV-induced innate and adaptive immunity has 
highlighted that RSV infection skews the immune system towards an 
undesirable Th2 response (Welliver etal., 2008). Also, until recently eosinophils 
were believed to contribute to RSV disease pathology (Haynes et al., 2003) and 
that RSV infection does not induce a long memory response (Connors et al., 
1991; Kulkarni et al., 1995). With recent findings by Phipps et al. (2007) 
demonstrating the positive role of the eosinophil in RSV clearance in vivo, it is 
important to expand on this finding further. 
The aim of this chapter was to evaluate eosinophil antiviral activity in four 
distinct mouse models following RSV infection and re-infection. These BALB/c 
mice were WT, IL-5 Tg and/or Rag 27" animals. As such, the history of these 
genetic modifications is important to be discussed, including the development of 
the humanised models and their application. 
Decades ago, IL-5 transgenic mice were produced in a way so the 
transcription of the IL-5 gene is under the influence of the dominant control 
region (DCR) of the gene encoding human CD2 (a T cell surface antigen) (Lang 
et al., 1988). The use of the CD2 DCR ensures constitutive expression by T 
cells (Gleich and Adolphson, 1986; Lang et al., 1988; Sanderson et al., 1988). It 
seems remarkable that these animals with such high levels of potentially 
damaging leukocytes remain normal; suggesting that eosinophils require other 
factors for degranulation and subsequent tissue damage. As eosinophils play a 
role in allergic disease, these animals provide a model for testing modifiers of 
eosinophil production (Dent et al., 1990). Furthermore, Rag 27" mice were 
designed through the deletion of Rag 2 recombination activating gene, resulting 
in the arrest of rearrangement of the B (immunoglobulin production) and the T 
cell receptors; and the absence of the T and B cell differentiation. These mice 
have high levels of NK-cell activity but do not show Ig leakiness and they are 
less sensitive to radiation compared to SCID mice. The main applications of 
Rag 21- mice are in the investigation of lymphocyte gene function in 
differentiation, HIV and other immune deficiency diseases, the immune 
system's role in tumourgenesis and metastasis, and autoimmune and infectious 
diseases (Shinkai et al., 1992; Shultz et al., 2007). Loss of Rag 2 function in 
vivo results in total inability to initiate V(D)J rearrangement with Rag 2 function 
and V(D)J recombinase activity found to be only required by no other cells than 
lymphocytes (Shinkai et a!., 1992). As IL-5 Tg Rag 2-1- BALB/c was a new 
mouse model, recently developed by our group, it was novel to examine: if each 
of these genetic mutations continue to function as intended or if they would 
inhibit each other's function in some way. 
Therefore, the hypothesis that eosinophils may have the capacity to 
provide immune compensation in the absence of the mature T (CD4^ and 
CD8'') and B cells following RSV re-infection was assessed; as well as 
eosinophil RSV antiviral potential to inhibit RSV infection across all four BALB/c 
strains, especially the eosinophil enriched ones. Furthermore, as CDS'" cells 
have been shown to contribute to disease pathology, CD4'' cell role in viral 
clearance and lung pathology was examined. 
4.2 METHODS 
4.2.1 Mice strains 
Male BALB/c mice aged 6 to 8 weeks were obtained from the pathogen 
free facility at the University of Canberra (UC) Animal facility. Animals were 
housed in approved containment facilities and treated in accordance with UC 
animal experimentation guidelines. BALB/c mouse strains (section 2.12) used 
were WT, IL-5 Tg, Rag 27" and IL-5 Tg Rag 27" BALB/c. Genotype and 
phenotype differences are outlined in the Table 4.1 below. 
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4.2.2 RSV infection of mouse strains 
On day 0, mice were lightly anesthetised with isofluorane (PharmaChem) 
(section 2.12.4) and infected with RSV by intranasal inoculation (50 pL of 1 x 
10^ pfu/mL = 5 X lO^pfu/mouse). On day 5, mice were euthanised by CO2 
asphyxiation (section 2.12.1) and samples collected for further processing 
(sections 2.13). 
4.2.3 RSV infection of BALB/c mutants followed by 
RSV re-infection 
On days 0 and 12 mice were lightly anesthetised with isofluorane 
(PharmaChem) (section 2.12.4) and infected with RSV by intranasal inoculation 
(50 pL of 1 X 10^ pfu/mL = 2 x 10® pfu/mouse). On day 17, mice were 
euthanised by CO2 asphyxiation (section 2.12.1) and samples collected for 
further processing (sections 2.13). 
4.2.4 Adoptive transfer of 604"^ cells 
CD4'' T cells were harvested from spleens of WT BALB/c mice, and 
transferred into IL-5 Tg Rag 27" BALB/c mice as described previously 
(Plotnicky-Gilquin et al., 2002). Briefly, spleens of WT BALB/c mice were 
removed, mashed and filtered through a cell strainer (BD, Australia). Red blood 
cells were removed using lysing buffer (BD Pharmingen). CD4^ cells were 
purified from the resulting lymphocyte population using MagCellect Mouse 
Naive CD4^T cell isolation kit (R&D Systems, USA) according to the 
manufacturer's protocol. IL-5 Tg Rag 27" BALB/c mice received 3 x 10® 
CD4'' cells/ mouse via tail-vein injection 4 days prior to the first RSV inoculation 
(Figure 4.1). 
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Figure 4.1. Experimental timeline of CD4^ T cell adoptive transfer followed 
by respiratory syncytial virus (RSV) re-infection of interleukin-5 transgenic 
Rag 2 knockout (IL-5 Tg Rag 2 /•) BALB/c 
Purified CD4^T cell were adoptively transferred into IL-5 Tg Rag 2f mice intravenously 4 days 
prior to RSV primary infection on day 0 (intranasal inoculation w/ith 5 x 10^ plaque forming units 
(pfu)/mouse). Mice were re-infected with RSV (5 x 10^ pfu/mouse) on day 12 and samples 
collected on day 17. 
4.2.5 Statistical analysis 
Data are presented as mean ± standard deviation. A ONE-way or TWO-
way ANOVA was used to determine statistical significance. Data were analysed 
using GraphPad Prism version X7. A p value of less than 0.05 was considered 
statistically significant. 
4 . 3 RESULTS 
4.3.1 Primary RSV infection in BALB/c mice 
Primary RSV infection was set up in four different BALB/c mouse strains 
with their genotype and phenotype make up contributing to the variations in the 
innate immune response. The outcome of primary RSV infection in vivo was 
assessed by examination of lung viral titres, BAL and blood leukocyte 
population infiltrates as well as lung histopathology. 
4.3.1.1 Viral titres in BALB/c mice following primary RSV 
infection 
No viral titres were recovered from the lung samples of Vero E6 cell 
lysate (negative control) or UV-RSV (additional negative control) inoculated WT, 
IL-5 Tg, Rag 27" and IL-5 Tg Rag 27" BALB/c mice, following immunostaining 
RSV plaque assay (data not shown). Highest viral titres were recovered from 
the lung of RSV inoculated WT and Rag 2 /" BALB/c mice. RSV inoculated IL-5 
Tg and IL-5 Tg Rag 2 /" BALB/c had the lowest viral loads recovered (Figure 
4.2). In addition, RSV infection of IL-5 Tg and IL-5 Tg Rag 2"/" BALB/c mice 
yielded 90% and 75% less viral titres, respectively, compared to RSV infected 
WT and Rag 2"/" BALB/c mice (p < 0.0001). There was no statistically significant 
difference in viral titres recovered between RSV infected IL-5 Tg BALB/c and to 
IL-5 Tg Rag 2 /" BALB/c mice. 
WT IL-5 Tg Rag 27 • IL-5 Tg Rag 27 
Figure 4.2. Eosinophil overproduction leads to accelerated viral clearance 
in the lung of the BALB/c mice 
Wild type (WT), interleukin-5 transgenic (IL-5 Tg), Rag 2 knockout (Rag 2 / ) and IL-5 Tg Rag 21-
BALB/c mice were infected with Vero E6 cell lysate, ultraviolet-inactivated respiratory syncytial 
virus (UV-RSV) or RSV at 5 x 10^ plaque forming units (pfu)/mouse on day 0, by intranasal 
inoculation. Lungs were harvested 5 days after infection and viral titres enumerated using a RSV 
immunohistochemistry viral titre assay. Titres are represented as pfu/gram of lung tissue. Data is 
representative of mean (n = 5) ± standard deviation. Data was analysed using a ONE-way 
ANOVA with Tukey's multiple comparison test (GraphPad Prism version X7) with *, p < 0.0001 for 
IL-5 Tg mice compared to WT and Rag 2f ; also for IL-5 Tg Rag 2/- compared to WT and Rag 2-
/•mice. 
4.3.1.2 Bronchoalveolar lavage fluid (BALF) leukocyte 
population in BALB/c mice following primary RSV 
infection 
BAL leukocyte cell analysis revealed no significant difference in 
macrophage (Figure 4.3 A), lymphocyte (Figure 4.3 B), eosinophil (Figure 4.3 
C) and neutrophil (Figure 4.3 D) numbers between all Vero E6 cell lysate 
(negative control) and corresponding UV-RSV inoculated mice. There was also 
no significant difference in macrophage (Figure 4.3 A) or lymphocyte (Figure 4.3 
B) numbers following RSV infection of WT, IL-5 Tg, Rag 27" and IL-5 Tg Rag 27" 
BALB/c mice compared to their corresponding negative controls. 
Although RSV infection of WT, Rag 27" and IL-5 Tg Rag 27" BALB/c mice 
revealed no significant change in eosinophil numbers (Figure 4.3 C) compared 
to their corresponding negative controls, RSV infection of IL-5 Tg did induce a 
significant decrease in the number of eosinophils compared to the IL-5 Tg 
negative control (p < 0.0001). There was no statistical difference in the number 
of eosinophils recovered from BAL between IL-5 Tg and IL-5 Tg Rag 27" mice 
infected with RSV. However, there was a significant decrease in the number of 
eosinophil infiltrates following RSV infection of IL-5 Tg and IL-5 Tg Rag 27" mice 
compared to Rag 2"/" mice (p < 0.005) (Figure 4.3 C). 
Neutrophil numbers (Figure 4.3 D) decreased slightly following RSV 
infection of WT BALB/c mice compared to WT negative control while a slight 
increase in numbers was observed following RSV infection of IL-5 Tg and IL-5 
Tg Rag 27" BALB/c mice compared to their corresponding negative control. 
Neutrophil numbers were significantly higher (p < 0.001) following RSV 
infections of Rag 2 /" BALB/c mice compared to the negative control. In addition, 
neutrophil numbers were significantly higher for RSV infected Rag 2 /" BALB/c 
mice compared to RSV inoculated IL-5 Tg and IL-5 Tg Rag 2"/" BALB/c mice (p 
< 0.005). 
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Figure 4.3. Leukocyte population in bronchoalveolar lavage fluid (BALF) 
following primary respiratory syncytial virus (RSV) infection in vivo 
Wild type (WT), interleukin-5 transgenic (IL-5 Tg), Rag 2 knockout (Rag 2-/-) and IL-5 Tg Rag 2-/-
BALB/c mice were inoculated with Vero E6 cell lysate (negative control), ultraviolet-inactivated 
RSV (UV-RSV) RSV (5 x 10^ pfu/mouse) on day 0 and samples collected on day 5 post RSV 
infection. Leukocyte population was determined by the number of macrophages (A), lymphocytes 
(B), eosinophils (C) and neutrophils (D) present in BALF (number of cells x IC/mL). Data is 
representative of mean (n = 5) ± standard deviation. Data was analysed using a ONE-way 
ANOVA with Tukey's multiple comparison test (GraphPad Prism version X7) (*, p < 0.005 
compared to corresponding negative control, #, p < 0.05 compared to the RSV infected WT 
BALB/c). 
4.3.1.3 Peripheral blood leukocyte population in BALB/c mice 
following primary RSV infection 
Leukocyte analysis revealed no significant change in monocyte (Figure 
4.4 A), lymphocyte (Figure 4.4 B), eosinophil (Figure 4.4 C) and neutrophil 
(Figure 4.4 D) numbers between Vero E6 cell lysate (negative control) and UV-
RSV inoculated mice for all strains. Also, no change in monocyte numbers 
(Figure 4.4 A) was observed following RSV infection of WT, Rag 27" and IL-5 Tg 
Rag 2i- BALB/c mice compared to their corresponding negative controls. In 
contrast, monocyte numbers decreased significantly following RSV infection of 
IL-5 Tg BALB/c mice compared to the corresponding negative control (p < 
0.001). Similar trend was also observed for the number of lymphocytes and 
eosinophils present in blood for all mice strains (Figure 4.4 B and C). No 
change in lymphocyte and eosinophil numbers was observed following RSV 
infection of WT, Rag 27" and IL-5 Tg Rag 27" BALB/c mice compared to the 
corresponding negative controls; while significant decrease was observed in 
RSV infected IL-5 Tg BALB/c compared to IL-5 Tg negative control (p < 0.005). 
Neutrophil numbers (Figure 4.4 D) remained unchanged following RSV infection 
of WT, IL-5 Tg, IL-5 Tg Rag 27" and Rag 27" BALB/c mice compared to their 
corresponding negative controls. The number of neutrophils from IL-5 Tg Rag 2 
/- BALB/c mice was significantly higher compared to RSV infected Rag 27" 
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Figure 4.4. Leukocyte population in blood following primary respiratory 
syncytial virus (RSV) infection in vivo 
Wild type (WT), interleukin-5 transgenic (IL-5 Tg), Rag 2 knocl<out (Rag 21) and IL-5 Tg Rag 21-
BALB/c mice were inoculated with Vero E6 cell lysate (negative control), ultraviolet-inactivated 
RSV (UV-RSV) RSV (5 x 10^ pfu/mouse) on day 0 and samples collected on day 5 post RSV 
infection. Leukocyte population was determined by the number of macrophages (A), lymphocytes 
(B), eosinophils (C) and neutrophils (D) present in blood (number of cells x lO'i/mL). Data is 
representative of mean (n = 5) ± standard deviation. Data was analysed using a ONE-way 
ANOVA with Tukey's multiple comparison test (GraphPad Prism version X7) (*, p < 0.005, p < 
0.001 and p < 0.0001 compared to corresponding negative control). 
4.3.1.4 Lung histopathology in BALB/c strain mice following 
primary RSV infection 
Following a Vero E6 cell lysate (negative control), UV-RSV (additional 
negative control) or RSV inoculation of BALB/c mice strains, lungs were 
assessed for ain/vays mucus occlusion, degree of parenchymal pneumonia, 
peribronchial infiltrates, quality of peribronchial infiltrates, perivascular infiltrates, 
histopathological score, number of goblet cells and eosinophil tissue Infiltrates. 
4.3.1.4.1 Descriptive analysis 
Lung pathology of, Vero E6 cell lysate (negative control) and UV-RSV 
(additional negative control) inoculated WT, IL-5 Tg, Rag 27" and IL-5 Tg Rag 2" 
/" BALB/c mice, show clear alveoli (Figure 4.5 squares) and minimal 
inflammatory infiltrates present around bronchioles (thin arrows) as well as 
blood vessels (thick arrows) indicating the absence of viral infection. An 
inflammatory response was observed on day 5 post RSV infection in all BALB/c 
mice. The extent of inflammation was different for each BALB/c strain. WT 
BALB/c mice showed signs of moderate parenchymal pneumonia, presence of 
goblet cells (circle), moderate airway occlusion and leukocyte infiltration around 
bronchioles and blood vessels. RSV infection of IL-5 Tg BALB/c mice resulted 
in mild signs of parenchymal pneumonia and leukocyte infiltrates around 
bronchioles and blood vessels while RSV infection of Rag 27" and IL-5 Tg Rag 
27" BALB/c resulted in the same pathological signs as WT BALB/c however with 
increased goblet cells present (Figure 4.5). 
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Figure 4.5. Hypereosinophilic (IL-5 Tg) BALB/c mice alleviate pathological 
signs of primary respiratory syncytial virus (RSV) infection 
Wild type (WT), IL-5 Tg, Rag 2 knockout ( f ) and IL-5 Rag 2-/-BALB/c were infected intranasally 
with Vera E6 cell lysate (negative control), ultraviolet-inactivated RSV (UV-RSV) or RSV (5 x 10^ 
plaque forming units/mouse). A) WT negative control (i and ii), WT UV-RSV (ill and iv) and WT 
RSV (V and vi). B) IL-5 Tg negative control (i and ii), IL-5 Tg UV-RSV (ill and iv) and IL-5 Tg RSV 
(v and vi). C) Rag 2-/-negative control (i and ii). Rag 27-UV-RSV (ill and iv) and Rag 2-/-RSV (v 
and vi). D) IL-5 Tg Rag 2/-negative control (i and ii), IL-5 Tg Rag 2/-UV-RSV (ill and iv) and IL-5 
Tg Rag 2-/- RSV (v and vi). Lungs were collected on day 5 and processed for histology using 
periodic acid Schiff (PAS) stain. Arrows, squares and circles indicate the different signs of 
inflannmation in mice as described in the text. Magnification (i, ill and v) was 100X and (ii, iv and 
vi) 400X including the eyepiece. Images are representative of each group (n = 5). 
4.3.1.4.2 Numerical (score) analysis 
Vero E6 cell lysate (negative control) compared to UV-RSV (additional 
negative control) inoculated groups for all BALB/c strains showed no statistical 
differences across all pathological scores. RSV infection of WT, IL-5 Tg, Rag 
27" and IL-5 Tg Rag 27" BALB/c, has resulted In a significant increase in airway 
mucus occlusion (Figure 4.6 A), parenchymal pneumonia (except for IL-5Tg 
Rag 27 ) (Figure 4.6 B), peribronchial infiltrates (Figure 4.6 C) and quality of 
peribronchial infiltrates (Figure 4.6 D) compared to the corresponding Vero E6 
cell lysate and UV-RSV inoculated BALB/c strains (p < 0.05). Perivascular 
infiltration analysis revealed statistically significant increase in leukocyte 
infiltration around blood vessels for RSV infection of WT BALB/c mice only (p < 
0.05) (Figure 4.6 E). Combined HPS analysis revealed a significant Increase in 
HPS for all RSV infected BALB/c strains with HPS ranging between 9-11 out of 
17 compared to the corresponding Vero E6 cell lysate and UV-RSV controls 
with HPS ranging between 1-5 out of 17 (p < 0.0001) (Figure 4.6 F). 
Additionally, RSV infection of WT and IL-5 Tg BALB/c mice compared to 
their Vero E6 cell lysate and UV-RSV groups, has resulted in no significant 
increase in goblet cell numbers; while RSV infection of Rag 2 /" and IL-5 Tg Rag 
2-1- induced a significant increase in the number of goblet cells recovered 
compared to Vero E6 cell lysate and UV-RSV controls (Figure 4.6 G). Primary 
RSV infection of IL-5 Tg and IL-5 Tg Rag 2 /" mice induced an increase in the 
number of eosinophils present in the lung tissue (p < 0.005) compared to 
negative controls, while no significant change was observed for RSV infected 
WT and Rag 2/" mice compared to their negative controls (Figure 4.6 H). 
A) 
C 




I I L_ 
i 
WT IL-6TG RTO27 IL-6TORAG27 
C) 3 I 














I I I 
D ) 




i O- 1 
Q I I 
WT IL-6TG RAG2/ IL-6TGR»G2; 
• VERO E 6 CELL LYSATE [:=] U V - R S V H R S V 



















WT IL-STfl RagZ/ IL-6TgRag2/ 
AA i 






















IL-6 Tg Rag2 / IL-5 Tg Raa2 / 
J J f l 
« « 
nnl nn i 
I I I I 
WT IL-5Tg Rag2/' IL-6TgRag2r 
CD Vero E6 cell lysate !=• UV-RSV m RSV 
Figure 4.6. Histopathological score (HPS) assessment of mouse lungs 
following 
Wild type (WT), IL-5 Tg, Rag 2 knockout ( f ) and IL-5 Rag 2-/-BALB/C were infected intranasally 
witti Vero E6 cell lysate (negative control), ultraviolet-inactivated respiratory syncytial virus (UV-
RSV) or RSV (5 x 10^ plaque forming units /mL final concentration) on day 0 and lungs tissue 
collected and processed for histopathology. Lungs w/ere analysed for: A) Airways mucus 
occlusion, B) Parenchymal pneumonia, C) Peribronchial infiltrates, D) Quality of peribronchial 
infiltrates, E) Perivascular infiltrates, F) Combined HPS, G) Goblet cell count and H) Eosinophil 
count in the lung tissue. Data is representative of mean (n = 5) ± standard deviation. Data was 
analysed using ONE-way ANOVA with Tukey's multiple comparison test (GraphPad Prism 
version X7) (*, p < 0.05, p < 0.005, p < 0.001 and p < 0.0001 compared to 
corresponding negative control). 
4.3.2 RSV re-infection of BALB/c mice 
Following primary RSV infection, four BALB/c mouse strains we re-
infected with RSV; and the effect of their genotype and phenotype on adaptive 
immunity was assessed by examining the lung viral titres, BAL and blood 
leukocyte population infiltrates, as well as lung histopathology. Adoptive transfer 
of T lymphocytes into IL-5 Tg Rag 27" mice was performed to assess 
aspects of innate and/or adaptive immunity involved in RSV re-infection. 
4.3.2.1 Viral titres in BALB/c strain mice following RSV re-
infection in vivo 
No viral titres were recovered from the lung samples of Vero E6 lysate 
(negative control) and UV-RSV (additional negative control) inoculated WT, IL-5 
Tg, Rag 27" and IL-5 Tg Rag 27" BALB/c mice, following RSV 
immunohistochemistry viral titres assay (data not shown). 
RSV re-infection of WT and IL-5 Tg BALB/c mice resulted in a significant 
reduction of viral titres compared to titres recovered following RSV re-infection 
of the Rag 27" and IL-5 Tg Rag 2 /' mice (p < 0.0001) (Figure 4.7). RSV re-
infection of WT and IL-5 Tg mice resulted in 70 and 83% lower viral titres, 
respectively, compared to Rag 27" mice and IL-5 Tg Rag 27" (p < 0.0001). IL-5 
Tg Rag 27" and Rag 2 /" resulted in a similar number of viral titres recovered 
wi th no s ign i f i can t d i f f e r e n c e o b s e r v e d b e t w e e n the t w o B A L B / c s t ra ins 
f o l l ow ing R S V re- in fec t ion . 
C D 4 ^ adop t i ve t r ans fe r in to R S V re- in fec ted IL-5 T g R a g 27" m i c e 
resu l ted in a 7 5 % reduc t i on in v i ra l t i t re c o m p a r e d to IL-5 T g Rag 27" a n d R a g 
27" B A L B / c R S V re - in fec ted cont ro ls . CD4- ' adop t i ve t rans fe r into IL-5 T g R a g 2" 
/" r e d u c e d v i ra l t i t res to t h e s a m e leve ls o b s e r v e d fo l l ow ing R S V re- in fec t ion of 
t h e W T a n d IL-5 T g B A L B / c m ice . 
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F i g u r e 4 .7 . C D 4 * c e l l s a d o p t i v e a c c e l e r a t e s v i r a l c l e a r a n c e f o l l o w i n g 
r e s p i r a t o r y s y n c y t i a l v i r u s ( R S V ) r e - i n f e c t i o n in vivo 
Wild type (WT), interleul<in-5 transgenic (IL-5 Tg), Rag 2 knockout (Rag 2f) and IL-5 Tg Rag 2i-
BALB/c mice were infected intranasally with Vera E6 cell lysate (negative contral), ultraviolet-
inactivated RSV (UV-RSV) or RSV (5 x 10^ plaque forming units (pfu)/mouse) on day 0 and re-
infected with Vera E6 cell lysate (negative control), ultraviolet-inactivated RSV (UV-RSV) or RSV 
(5 X 105 pfu/mouse) on day 12. CD4-cells (3 x 10^/ mouse) were isolated from WT mice spleen 
and adoptively transferred intravenously into IL-5 Tg Rag 2f mice 4 days prior to day 0 
inoculation. Lungs were harvested 17 days post infection, and viral titres enumerated using a 
RSV immunohistochemistry viral titre assay. Titres are represented as pfu/gram of lung tissue. 
Data is representative of mean (n = 5) ± standard deviation. Data was analysed using a ONE-
way ANOVA with Tukey's multiple comparison test (GraphPad Prism version X7) (*, p < 0.0001 
compared to Rag 27-and IL-5 Tg Rag 2"/-; #, p < 0.0001, compared to Rag 2 /-and IL-5 Tg Rag 
27-; +, p < 0.0001, compared to IL-5 Tg Rag 2f with CD4-^ cells adoptive transfer). 
4.3.2.2 Analysis of BALF leukocyte population in BALB/c 
strain mice following RSV re-infection in vivo 
Following re-infection with RSV there was no significant difference in 
macrophage (Figure 4.8 A), lymphocyte (Figure 4.8 B), eosinophil (Figure 4.8 
C) and neutrophil (Figure 4.8 D) numbers between the corresponding Vero E6 
cell lysate (negative control) and UV-RSV (additional negative control) 
inoculated BALB/c mice. 
BAL leukocyte cell analysis revealed no change in macrophage numbers 
(Figure 4.8 A) following RSV re-infection of IL-5 Tg, Rag 27" and IL-5 Tg Rag 27" 
BALB/c mice compared to their corresponding negative control; while 
macrophage numbers decreased following RSV re-infection of WT BALB/c mice 
compared to its negative control (p < 0.001). In addition, RSV re-infection of WT 
BALB/c mice resulted in lower macrophage numbers compared to each RSV re-
infected IL-5 Tg, Rag 27" and IL-5 Tg Rag 27" BALB/c mice (p < 0.0001). 
RSV re-infection also resulted in an increase in lymphocyte numbers for 
WT and IL-5 Tg BALB/c mice (p < 0.001) compared to the corresponding 
negative controls while numbers remained unchanged for Rag 27" and IL-5 Tg 
Rag 27" BALB/c mice compared to their negative controls (Figure 4.8 B). RSV 
re-infection of WT and IL-5 Tg BALB/c mice induced an increase in lymphocyte 
numbers compared to all other RSV re-infected BALB/c strains (p < 0.0001). 
RSV re-infection of IL-5 Tg BALB/c mice resulted in a decrease in 
eosinophil numbers compared to its negative control (p < 0.001) while 
eosinophil numbers remained unchanged following RSV re-infection of WT, Rag 
2"/" and IL-5 Tg Rag 2"/" BALB/c mice compared to the corresponding negative 
controls (Figure 4.8 C). RSV re-infection of WT BALB/c mice resulted in 
significantly lower number of eosinophils compared to RSV re-infected IL-5 Tg 
and Rag 2"/" BALB/c mice (p < 0.0001). Neutrophil numbers (Figure 4.8 D) 
remained unchanged for all RSV re-infected BALB/c mice strains compared to 
their corresponding negative controls. 
CD4+ adoptive transfer into IL-5 Tg Rag 2 /" BALB/c mice followed by 
RSV re-infection resulted in no change in macrophage numbers, significant 
increase in lymphocyte and neutrophil numbers as well as a decrease in 
eosinophil numbers compared to its negative control (p < 0.05). CD4'' adoptive 
transfer into IL-5 Tg Rag 2 /" BALB/c mice followed by RSV re-infection has 
resulted in a significant increase in lymphocyte numbers compared to RSV re-
infected Rag 27" and IL-5 Tg Rag 27- BALB/c mice. In addition, CD4'' adoptive 
transfer into IL-5 Tg Rag 27" BALB/c mice followed by RSV re-infection has 
induced significant increase in eosinophil numbers compared to RSV re-
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Figure 4.8. Leukocyte population in bronchoalveolar lavage fluid (BALF) 
following respiratory syncytial virus (RSV) re-infection in vivo 
Wild type (WT) , interleukin-5 transgenic (IL-5 Tg), Rag 2 knockout (Rag 2f). IL-5 Tg Rag 2 f a n d 
IL-5 Tg Rag 2 f B A L B / c with CD4-^ nnice were infected by intranasal inoculation with RSV (5 x 10^ 
plaque forming units (pfu)/mouse) on day 0 and re-infected with RSV (5 x 10® ptu/mouse) on day 
12. CD4* cells (3 x 10^ cells/mouse) were isolated from WT mice spleen and adoptively 
transferred intravenously into IL-5 Tg Rag 2 /-mice 4 days prior to day 0 inoculation. On day 17, 
BALF was collected and analysed for the number of macrophages (A), lymphocytes (B), 
eosinophils (C) and neutrophils (D) present in BALF. Data is representative of mean (n = 5) ± 
standard deviation. Data was analysed using a ONE-way ANOVA with Tukey's multiple 
comparison test (GraphPad Prism version X7) (*, p < 0.05, p < 0.001 and * " * , p < 0.0001 
compared to Vero E6 cell lysate inoculated group for each corresponding mouse strain). 
4.3.2.3 Peripheral blood leukocyte population following RSV 
re-infection 
Blood leukocyte cell analysis revealed no significant difference between 
corresponding Vero E6 cell lysate (negative control) and UV-RSV (additional 
negative control) inoculated BALB/c strains for monocyte (Figure 4.9 A), 
lymphocyte (Figure 4.9 B), eosinophil (Figure 4.9 C) or neutrophil (Figure 4.9 D) 
numbers. 
Differential cell analysis of blood revealed no change overall In monocyte 
numbers (Figure 4.9 A) following re-infection of WT, Rag 27" and IL-5 Tg Rag 
27" BALB/c mice compared to their negative controls. In contrast, the number of 
monocytes decreased following RSV re-infection of IL-5 Tg BALB/c mice 
compared to the corresponding negative control. 
No change in lymphocyte numbers was observed for RSV re-infection of 
all BALB/c mice (except for IL-Tg BALB/c) (Figure 4.9 B) compared to the 
corresponding negative controls. RSV re-infection of IL-5 Tg BALB/c resulted in 
significant increase in lymphocyte numbers compared to negative control (p < 
0.0001). Additionally, RSV re-infection of IL-5 Tg BALB/c resulted in significantly 
greater eosinophil numbers compared to RSV re-infected WT, IL-5 Tg, Rag 27" 
and IL-5 Tg Rag 2 /" BALB/c mice (p < 0.0001). 
No difference in eosinophil numbers was observed for any BALB/c 
strains re-infected with RSV (Figure 4.9 C) compared to their corresponding 
negative controls. However, re-infection of the IL-5 Tg BALB/c group with Vero 
E6 cell lysate, UV-RSV and RSV has resulted in significantly higher eosinophil 
numbers present in blood compared to all other BALB/s groups (p < 0.0001) re-
infected with Vero E6 cell lysate, UV-RSV and RSV. No change in neutrophil 
numbers was observed for RSV re-infection of any BALB/c strains (Figure 4.9 
C) compared to the corresponding negative controls. 
CD4+ adoptive transfer into IL-5 Tg Rag 27" BALB/c mice followed by 
RSV re-infection resulted in no change in monocyte, lymphocyte, eosinophil and 
neutrophil numbers compared to the corresponding negative controls. 004"^ 
adoptive transfer into IL-5 Tg Rag 27" BALB/c mice followed by RSV re-infection 
has resulted in a significant increase in monocyte numbers compared to RSV 
re-infected WT BALB/c, while monocyte numbers decreased compared to RSV 
re-infected IL-5 Tg BALB/c mice. In addition, adoptive transfer into IL-5 Tg 
Rag 27" BALB/c mice followed by RSV re-infection has induced significant 
decrease in lymphocyte numbers compared to RSV re-infected IL-5 Tg BALB/c 
mice (p < 0.0001) as well as significant increase in eosinophil numbers 
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Figure 4.9. Leukocyte population in blood following respiratory syncytial 
virus (RSV) re-infection in vivo 
Wild type ( W T ) , interleukin-5 transgenic (IL-5 Tg), Rag 2 l<nockout (Rag 2 f ) , IL-5 Tg Rag 21-
and IL-5 Tg Rag 27-BALB/c with CD4-^ mice were infected by intranasal inoculation with RSV (5 x 
105 plaque forming units (pfu)/mouse) on day 0 and were re-infected with RSV (5 x 10^ 
pfu/mouse) on day 12. CD4-" cells (3x10® cells/mouse) were isolated from WT mice spleen and 
adoptively transferred intravenously into IL-5 Tg Rag 2 /-mice 4 days prior to day 0 inoculation. 
On day 17, BALF was collected and analysed for the number of macrophages (A), lymphocytes 
(B), eosinophils (C) and neutrophils (D) present in blood. Data is representative of mean (n = 5) ± 
standard deviation. Data was analysed using a ONE-way ANOVA with Tukey's multiple 
comparison test (GraphPad Prism version X7) ( " * * , p < 0.0001 compared to negative inoculated 
group for corresponding mouse strain). 
4.3.2.4 Lung histopathology of BALB/c strain mice following 
RSV re-infection 
Following a Vera E6 cell lysate (negative control), UV-RSV (additional 
negative control) or RSV inoculation of BALB/c mice strains, lungs were 
assessed for airways mucus occlusion, degree of parenchymal pneumonia, 
peribronchial infiltrates, quality of peribronchial infiltrates, perivascular infiltrates, 
histopathological score, number of goblet cells and eosinophil tissue infiltrates. 
4.3.2.4.1 Descriptive analysis 
Lung pathology for Vero E6 cell lysate (negative control) and UV-RSV 
(additional negative control) inoculated WT, IL-5 Tg, Rag 27" and IL-5 Tg Rag 
27" BALB/c mice demonstrates absence of viral infection as per clear alveoli 
(squares) and no/minimal inflammatory infiltrates present around bronchioles 
(thin arrows) or vessels (thick arrows) (Figure 4.10). RSV re-Infection resulted in 
extensive inflammatory response characterised by macrophages, lymphocytes 
and eosinophils infiltrates. On day 17, RSV re-infection of WT and IL-5 Tg 
BALB/c mice induced mild to moderate parenchymal pneumonia and airway 
occlusion while macrophage and lymphocyte infiltration around bronchioles and 
blood vessels was moderate to severe. RSV re-infection of Rag 2 /- and IL-5 Tg 
Rag 2"/" BALB/c mice resulted in moderate parenchymal pneumonia, airway 
occlusion with several goblet cells present as well as cellular infiltrates around 
bronchioles and blood vessels, dominated predominantly by eosinophils and 
macrophages. Pathology of lung collected from IL-5 Tg Rag 2 /" with adoptive 
transfer of cells, shows very high levels of leukocyte infiltrates (mainly 
eosinophils and macrophages) in addition to severe parenchymal pneumonia 
and moderate airway occlusion. 
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Figure 4.10. Importance of a functional adaptive immunity on BALB/c mice 
pathology following respiratory syncytial virus (RSV) re-infection 
Wild type (WT), interleukin-5 transgenic (IL-5 Tg), Rag 2 knockout (Rag 2 f ) , IL-5 Rag 2 f a n d 
were IL-5 Rag 2 /- BALB/c with adoptive transfer of CD4* cells were infected intranasally with Vero 
E6 cell lysate (negative control), ultraviolet-inactivated RSV (UV-RSV) or RSV (5 x 10^ plaque 
forming units/nnouse). A) WT negative control (i and ii), WT UV-RSV (ill and iv) and WT RSV (v 
and vi). B) IL-5 Tg negative control (i and ii), IL-5 Tg UV-RSV (iii and iv) and IL-5 Tg RSV (v and 
vi). C) Rag 2/-negative control (i and ii). Rag 2/-UV-RSV (iii and iv) and Rag 2-/-RSV (v and vi). 
D) IL-5 Tg Rag 2-/-negative control (i and ii), IL-5 Tg Rag 2/-UV-RSV (iii and iv), IL-5 Tg Rag 27-
RSV (v and vi). E) IL-5 Rag 2-/-with CD4-cells negative control (i and ii), IL-5 Rag 2/-with 
CD4" cells UV-RSV (iii and iv) and IL-5 Rag 27-with CD4^ cells RSV (v and vi). Lungs were 
collected on day 17 and processed for histology using periodic acid Schiff (PAS) stain. Arrows, 
squares and circles indicate the different signs of inflamnnation in mice as described in the text. 
Magnification (i, iii and v) was 100X and (ii, iv and vi) 400X including the eyepiece. Images are 
representative of each group (n = 5). 
4.3.2.4.2 Numerical (score) analysis 
Negative control compared to UV-RSV inoculated groups for all BALB/c 
strains showed no statistical differences across all histopathological analyses. 
However, RSV re-infection of WT, IL-5 Tg, Rag 27" and IL-5 Tg Rag 27" resulted 
in a significant increase in ainway mucus occlusion for all BALB/c strains (p < 
0.005) except for WT BALB/c where no change was observed (Figure 4.11 A). 
Increase in parenchymal pneumonia was observed for all BALB/c strains with p 
< 0.05 (Figure 4.11 B). Peribronchial infiltrates and quality of those infiltrates 
mirrored the same trend across all RSV re-infected BALB/c strains, with an 
increase observed in peribronchial infiltrates compared to their negative controls 
(p < 0.005); except for RSV re-infected Rag 27" BALB/c where no change was 
observed compared to its negative control (Figure 4.11 C and D). No change in 
perivascular infiltrates was observed for all RSV re-infected BALB/s strains 
(Figure 4.11 E). Combined HPS analysis revealed significant increase in HPS 
for all RSV infected and re-infected BALB/c mice with HPS ranging between 7-
16 out of 17 compared to the corresponding negative and UV-RSV controls with 
HPS ranging between 1-7 out of 17 (p < 0.05) (Figure 4.11 F). Increase in a 
number of goblet cell was observed for IL-5 Tg, Rag 27" and IL-5 Tg Rag 27" 
BALB/c only (p < 0.005) (Figure 4.11 G). 
RSV re-infection of IL-5 Tg Rag 27" mice and IL-5 Tg Rag 27" mice with 
CD4^ adoptive transfer induced an increase in a number of eosinophils present 
in the lung tissue (p < 0.001) compared to their negative controls while no 
significant change was observed for RSV re-infected WT, IL-5 Tg and Rag 27" 
mice (Figure 4.11 H). The number of eosinophils was also significantly higher in 
IL-5 Tg Rag 2 /" mice following CD4''adoptive transfer (p < 0.0001). 
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Figure 4.11. Histopathological score (HPS) assessment of mice lungs 
following respiratory syncytial virus (RSV) re-infection in vivo 
Wild type (WT), interleukin-5 transgenic (IL-5 Tg), Rag 2 knocl<out (Rag 2-/-), IL-5 Rag 2 / - a n d 
were IL-5 Rag 2-1- BALB/c with adoptive transfer of CD4-" cells were infected intranasally with Vero 
E6 cell lysate (negative control), ultraviolet-inactivated RSV (UV-RSV) or RSV (5 x 10^ plaque 
forming units/mouse) on days 0 and 12. 004-" cells (3 x 10® cells/mouse) were isolated from WT 
mice spleen and adoptively transferred intravenously into IL-5 Tg Rag 27-mice 4 days prior to day 
0 inoculation. Lung tissue was collected and processed for histopathology. Lungs were analysed 
for: A) Airways mucus occlusion, B) Parenchymal pneumonia, C) Peribronchial infiltrates, D) 
Quality of peribronchial infiltrates, E) Perivascular infiltrates, F) Combined HPS, G) Goblet cell 
count and H) Eosinophil count in the lung tissue. Data is representative of mean (n = 5) ± 
standard deviation. Data was analysed using ONE-way ANOVA with Tukey's multiple comparison 
test (GraphPad Prism version X7) (*, p < 0.05, **, p < 0.005, p < 0.001 and p < 0.0001 
compared to Vero E6 cell lysate inoculated group for the corresponding mouse strain; ####, p < 
0.0001 compared to RSV re-infected IL-5 Tg Rag 2-/-BALB/c). 
4.4 DISCUSSION 
To understand the pleiotropic effects of RSV infection on the immune 
response, it is important to acknowledge that infections with different strains of 
RSV, that exhibit significant genetic variability, result in altered virulence and 
subsequent disease pathogenesis (Lotz and Peebles, 2012). The mechanisms 
by which RSV causes disease and is capable of repeated infection in humans 
remain to be determined. As many promising vaccine/therapeutic candidates in 
the animal model were found to be unsuccessful in human trials, it is important 
to continue on building our knowledge and understanding on how RSV interacts 
with humans to cause disease, evade innate immune response and inhibit the 
development of long-term protective immunity. More research is urgently 
needed to bridge this gap. 
Previous studies suggest that RSV infection and re-infection result in 
skewed immunity towards an undesirable Th2 response (Welliver et al., 2008) 
resulting in eosinophilia (Haynes et al., 2003) and a short-term memory 
response (Connors et al., 1991; Kulkarni et al., 1995). In addition to in vitro 
findings (Domachowske et al., 1998a; Soukup and Becker, 2003), murine study 
has shown that eosinophils play a positive role in RSV clearance in vivo (Phipps 
et al., 2007). Consequently, the aim of this chapter was to evaluate eosinophil 
antiviral activity in four distinct mouse models following RSV infection and re-
infection. The hypothesis that eosinophils may have the immune capacity to 
compensate for the absence of the mature T (CD4'' and CDS'") and B cells 
following RSV re-infection was assessed; as well as the potential of the 
eosinophil to inhibit RSV infection across all four BALB/c strains. Furthermore, 
as CDS"^  cells have been shown to contribute to disease pathology, the role of 
CD4'' cells in viral clearance and lung pathology was also examined. A greater 
understanding of the role of the innate and adaptive immunity in RSV infection 
and re-infection could assist in the development of a successful RSV vaccine 
and/or therapeutic. 
As previously mentioned innate immunity is the first line of defence in 
RSV infection (Goldsby et a!., 2003). Expanding on the study by Phipps et al. 
(2007), the antiviral role of the eosinophil in RSV infection was examined using 
a murine RSV model. The infection study results revealed a significant 
reduction (p < 0.0001) in viral titres following RSV infection of IL-5 Tg and IL-5 
Tg Rag 27" BALB/c compared to RSV infected WT and Rag 2"/" BALB/c mice 
(Figure 4.2). Furthermore, it is important to note that WT and Rag 27" BALB/c 
mice had the same viral load present suggesting that adaptive immunity does 
not contribute to viral clearance in RSV primary infection. Together, these 
results are in agreement with findings by Phipps et al. (2007) who found that 
following ssRNA treatment of IL-5 Tg BALB/c, a significant reduction in viral 
infection was observed (Phipps et al., 2007), demonstrating eosinophil driven 
viral inhibition in IL-5 Tg mice. In addition, eosinophil involvement in antiviral 
activity against RSV could also be responsible for observed reduction (p < 
0.001) in eosinophil numbers present in the BALF and blood of IL-5 Tg BALB/c 
subsequent to RSV infection. Through a process of degranulation, eosinophils 
could become apoptotic, accounting for the reduction in eosinophil numbers 
observed. It is interesting that although, RSV inoculation of IL-5 Tg Rag 27" 
BALB/c Induced 70% reduction in viral load compared to the RSV inoculated 
WT BALB/c; RSV inoculation of IL-5 Tg BALB/c induced 90% compared to the 
RSV inoculated WT BALB/c (Figure 4.2). This 20% difference in viral inhibition 
could be a result of the Rag 2 deletion in IL-5 Tg Rag 2 /" BALB/c and therefore 
a result of humanised model limitation. As t h e transcription of the IL-5 gene is 
under the influence of the DCR of the gene encoding CD2, expressed at the cell 
surface of T cells (Gleich and Adolphson, 1986; Lang ef a/., 1988; Sanderson et 
al., 1988), it is possible that Rag 2 deletion has an effect on eosinophil 
recruitment numbers or even the rate at which eosinophils are recruited. This is 
noted as the number of eosinophils present in BALF (Figure 4.3) and blood 
(Figure 4.4) following a primary infection of IL-5 Tg Rag 2 /" BALB/c did not 
reflect the same eosinophil response following a primary infection of IL-5 Tg 
BALB/c. In contrast, RSV infected IL-5 Tg Rag 2 /" BALB/c had significantly (p < 
0.0001) higher number of eosinophils present in the lung tissue (Figure 4.6 H) 
compared to RSV infected IL-5 Tg BALB/c. These results suggest that Rag 2 
deletion may affect the rate of eosinophil recruitment, resulting what appears to 
be a slightly delayed response in comparison to IL-5 Tg BALB/c. 
Furthermore, these findings are supported by previous studies which 
show that eosinophils do not play a negative role in viral infections 
(Domachowske et al., 1998a; Phipps et al., 2007; Rosenberg et al., 2009; 
Soukup and Becker, 2003) and do not contribute to viral pathology (Castilow et 
al., 2008). In contrast, no eosinophil infiltration observed following RSV infection 
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of the WT and Rag 2"/" BALB/c can be correlated to the absence in viral load 
reduction Figure 4.2). RSV primary infection of WT and Rag 27" BALB/c also 
reveals that eosinophil immune response is dependant not only on the 
transcription of the IL-5 but also the presence of mature T cells to enable 
eosinophil recruitment. Taken together with the study by Phipps et al. (2007), 
these results demonstrate the importance of a prompt and effective eosinophil 
recruitment. Interestingly, in uninfected IL-5 Tg BALB/c mice, eosinophils 
normally contribute to over 30% of the leukocyte population In blood and BALF 
while in WT and Rag 27" BALB/c, eosinophils constitute for only about 1-3% of 
leukocyte population in blood and BALF. If eosinophils are the key to viral 
clearance, then the prophylactic treatment with immune modulatory 
therapeutics may facilitate eosinophil induced viral clearance necessary to clear 
RSV infection in WT and Rag 2 /- BALB/c mice. However, it is important to 
highlight that the key to eosinophil beneficial role most likely lies in the close 
regulation of the eosinophil recruitment. 
RSV infection in the first two years of life is believed to lead to long-term 
deficiencies In protective immunity to RSV (Welliver, 2003). As such, the 
hypothesis that the eosinophil may be involved in the immune compensation in 
the absence of the mature T (CD4^ and CD8^) and B cells was investigated. 
Furthermore, as CDS"^  cells have been shown to contribute to disease 
pathology, the role of CD4'' cells in viral clearance and disease pathology was 
also examined. RSV re-infection of IL-5 Tg BALB/c and WT BALB/c mice 
(Figure 4.7), has resulted in the highest reduction (p < 0.0001) of viral load 
compared to the RSV re-infected Rag 2"/" and IL-5 Tg Rag 2 /" BALB/c. BALB/c 
strains containing Rag 2 deletion exhibited the highest viral load present 
following RSV re-infection. These results demonstrate importance of the mature 
T and B cells in secondary viral infections. Furthermore, these results are also 
indicative of blurred line existing between innate and adaptive immunity 
especially in terms of their involvement in primary and secondary infections. 
This is especially important when examining the effect of RSV re-infection on 
the Rag 2 /" BALB/c strains. Therefore, as Rag 2 /" BALB/c have NK and ILC2 
cells present despite the lack of mature T and B cells, it is important to reflect on 
how these cells could be involved in the immune response following RSV re-
infection. Recently, the notion that NK cells are truly innate cells has been 
called into question because specific subsets of mouse liver NK cells have been 
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described to have the adaptive immunity property of lasting memory against 
specific viral antigens (Gillard et al., 2011; Vivier et al., 2011). Furthermore, 
ILC2 cells, present in Rag 27" mice, are responsive to IL-25 and IL-33 during 
helminthic infection. However, their population numbers decrease soon after 
induction and these mice are unable to expel the worm burden effectively (Neill 
et al., 2010). This suggests that T cells play a role in ILC2 cells maintenance, 
and in addition, boost the type 2 immune response by producing more type 2 
cytokines. Respiratory infections with rhinovirus or respiratory syncytial virus are 
known to promote type 2 responses, and exacerbate allergic asthma. Chang et 
al. (2011) demonstrated that influenza virus-induced asthma is not mediated by 
adaptive immunity, but by IL-33-dependent ILC2 cells (Chang et al., 2011). 
Together, these findings highlight the importance of chapter 4 findings. 
Although, Rag 27" BABL/c strains do not express the mature T and B cells, 
results revealed some lymphocytes present in BALF and blood of IL-5 Tg Rag 
27" BABL/c. These lymphoid cells could be NK cells and/or even ILC2 cells as 
these are known to be present in Rag 2"/" mice. 
Previous depletion studies have demonstrated an importance of adaptive 
immunity in viral infection with studies revealing an increase in morbidity in 
CD8'' and NK cell depleted mice following RSV infection (Bender et al., 1992; 
Graham and Braciale, 1997; Topham and Doherty, 1998) while more recently, 
Lee et al. (2005) showed that mice lacking B cells succumbed to influenza 
H1N1 infection despite the infiltration of a larger number of CDS'" cells (Lee et 
al., 2005). These findings are in agreement with chapter 4 results, which 
indicate that intact adaptive immunity is very important for RSV inhibition. 
Despite its previously described inadequate response, each subsequent RSV 
infection results in an increase in protective immunity (Henderson et al., 1979) 
and reduction in disease severity. 
Although RSV-specific CD8^ T cells have been shown to provide 
protection against infection, their effect is short-lived (Connors et al., 1991; 
Kulkarni et al., 1995). However, depletion of CD4^ cells has been shown to 
result in delayed viral clearance and survival of infected mice following RSV re-
infection (Allan et al., 1990; Mozdzanowska et al., 2000). Also, H1N1 infection 
of mice lacking CD4^ cells resulted in mice recovering from infection in a similar 
fashion to the WT mice (Lee et al., 2005). Therefore, the role of CD4^ T cells 
and their effect on viral clearance and disease pathology was examined in more 
detail. T lymphocytes adoptive transfer into IL-5 Rag 27" BALB/c followed 
by RSV re-infection, resulted in over 80% viral titres reduction (p < 0.0001) 
(Figure 4.7) and an increase in eosinophil tissue infiltrates compared to RSV re-
infected IL-5 Rag 27" BALB/c (p < 0.0001) (Figure 4.11). These results mimic 
the trend of the immune response observed in BALF and blood following RSV 
re-infection of IL-5 Tg BALB/c mice. However, the main difference is in the HPS 
results, where CD4'' T lymphocytes adoptive transfer into IL-5 Tg Rag 27" 
BALB/c induced the highest HPS scores across the board. These results 
confirm the importance of CD4'' T cells in viral inhibition which is supported by 
previous study showing that the CD4^ and CD8^ T lymphocyte contribute 
individually to clearing of the RSV infection (Graham et at., 1991). The lack of 
eosinophil numbers present in BALF (Figure 4.8) and blood (Figure 4.9) 
following RSV re-infection of IL-5 Tg Rag 27" BALB/c, demonstrates the 
importance of T cells role in a T cell-driven prompt eosinophil response to a viral 
infection. This result is similar to those following primary RSV infection of IL-5 
Tg Rag 27" BALB/c in terms of eosinophil recruitment to BALF and blood. As 
such, primary and secondary RSV infection of IL-5 Tg Rag 2 /- BALB/c reveal 
significant increase (p < 0.0001) in eosinophil tissue infiltrates, suggesting that a 
delay in eosinophil immune response may be a result of T cell deficiency 
present in Rag 2/" mice. However, this issue appears to be overcome at a much 
slower rate potentially through the signalling the innate cells such as ILC2 cells. 
Furthermore, an increase (p < 0.0001) in eosinophil tissue infiltration (Figure 
4.11 H) was also observed following the RSV re-infection of IL-5 Rag 27" 
BALB/c with CD4'' T cells adoptive transfer, supporting the hypothesis that T 
cells are very important in eosinophil recruitment process. Also, these findings 
demonstrate for the first time that accelerated viral clearance in IL-5 Tg BALB/c 
is dependent on a presence of at least one component of adaptive immunity (in 
this case CD4^ T lymphocytes), hence indicating that eosinophil antiviral activity 
may be dependent on a degree of T cell response. Furthermore, 004"^ T 
lymphocytes adoptive transfer into IL-5 Rag 27" BALB/c has also resulted in an 
increase (p < 0.0001) in HPS scores compared to RSV re-infected IL-5 Tg Rag 
27" BALB/c (Figure 4.11). These findings suggest that although CD4^ T cells 
have been shown to play an important role in viral clearance following RSV re-
infection, they also contribute to RSV disease pathology. These findings are in 
agreement with a previous study by Graham et al. (1991) which showed that 
both, CD4-' and CD8'' lymphocytes contribute to RSV disease pathology 
(Graham et al., 1991). However, recent study by Lee et al. (2012) also found 
that vaccine-elicited effector anti-RSV CDS"^  T cells protected mice against RSV 
infection and pathogenesis (Lee etal., 2012b). Based on the findings of chapter 
4 study and previous studies by other research groups, it appears that more 
work is required to elucidate the role of T lymphocytes in RSV infection and 
disease pathology. 
In summary, eosinophils have been shown to play a very positive role in 
viral clearance following RSV infection and re-infection. However, their antiviral 
activity appears to be modulated by the number of cells recruited to lungs in 
response to viral infection. This has been especially evident with Rag 27" mice, 
which are lacking the T and B cells, as eosinophil recruitment has been shown 
to depend on IL-5 production; tightly regulated by the CD2 expressed on the T 
cell surface. This regulation appears to extend to eosinophil numbers present in 
BALF and blood. However, in the case of Rag 27" mice, this issue appears 
somewhat overcome through the eosinophil regulation via most likely ILC2 cells 
IL-5 production. Recent study by Roediger et al. (2013) has shown that both NK 
and ILC2 cell express CD2, required for eosinophil recruitment (Roediger et al., 
2013). Furthermore, several studies have shown that RSV infection alters 
functionality of T lymphocytes (Fulton et al., 2008; Gray et al., 2005) resulting in 
inadequate immune response and low T lymphocyte numbers. Although this 
phenomenon has been observed in multiple viral models, the underlying 
mechanisms are still unknown. The impaired function of T lymphocytes in the 
lung during virus infection has been proposed to be the consequence of virus-
induced changes in the lung environment (Gray et al., 2005) as well as virus-
induced immune evasion tactics (Lotz and Peebles, 2012; Moreau et al., 2003). 
Future RSV immunisation strategies should strive to achieve a balanced 
immune response. In addition, to induce a more desirable immune response, a 
focus on blocking RSVs evasion tactics is recommended which could be 
achieved using therapeutics targeting virus itself or by immune modulation. This 
information would be invaluable in facilitating the design of safe and effective 
vaccines against what remains a major human pathogen. 
Chapter 5. HEPARAN SULFATE TREATMENT OF 
RESPIRATORY SYNCYTIAL VIRUS INFECTION 
5.1 INTRODUCTION 
In Chapters 3 and 4, innate and adaptive immunity were examined in 
response to RSV infection {in vitro and in vivo) and re-infection {in vivo). The 
knowledge gained from the previous two chapters could be utilised In the 
development of much needed RSV therapeutics. In Chapter 1, it was shown 
that HS mimetics have a potential to become a therapeutic agent against RSV 
infection and that further in vitro and in vivo investigation is warranted. 
As HSPGs consist of a core protein bearing GAG chains, they are 
composed of unbranched HS chains, structurally related to heparin (Bishop et 
al., 2007). Heparin is a GAG, exclusively synthesised by mast cells and it has a 
crucial role as a depot for various mediators and for the morphology of the 
granules (Forsberg et al., 1999; Humphries et al., 1999). In contrast, HS is 
expressed on the cell surface and ECM of a wide range of cells of vertebrate 
and invertebrate tissues (lozzo and San Antonio, 2001; Kjellen and Lindahl, 
1991). However, both heparin and heparan sulfate play a very important role in 
host immune defence. In 1964, heparin was found to be the first GAG to affect 
virus replication and was shown to limit the growth of HSV (Nahmias and 
Kibrick, 1964). Other viruses have also been found to interact with GAGs, 
including dengue virus (Lee et al., 2006), Sindbis virus (Byrnes and Griffin, 
1998; Klimstra et al., 1998), foot and mouth disease virus (O'Donnell et al., 
2008), human immunodeficiency virus type 1 (De Francesco et al., 2011) and 
vaccinia virus (Ho et al., 2005). At the molecular level, the negatively charged 
sulfated or carboxyl groups of HSPGs or heparin (Hallak et al., 2000b) interact 
with a cluster of positively charged basic amino acids present within the linear 
HBD of RSV G protein (Feldman et al., 1999). Interestingly, a similar putative 
HBD was also identified in RSV F protein (Feldman et al., 2000), suggesting 
that the HSPG-HBD interaction is a common theme for RSV proteins that 
mediate infection, making it a preferred target for the development of antiviral 
compounds against RSV. It is not clear, however, what type of GAGs and GAG 
components are involved, whether the important GAGs are on the virus 
(Bourgeois et al., 1998) or the cell (Krusat and Streckert, 1997), and the 
magnitude of their contribution to the infection (Hallak et al., 2000a). It is 
apparent that they have an important role as demonstrated by previous studies 
which have shown an 80% reduction in RSV infection using GAG deficient cell 
lines (Hallak ef al., 2000a). 
Based on the findings of previous studies, the importance and efficacy of 
HS mimetics treatment on RSV infection was assessed. Viral attachment, cell 
surface interaction and inhibition of viral replication were tested in vitro in the 
presence of 53 HS mimetic compounds at concentrations of 5, 20 and 100 
|jg/mL. Following in vitro studies, six HS mimetics were tested in vivo for their 
efficacy against RSV infection and as a potential candidate for prophylactic 
treatment of RSV infection. 
5.2 METHODS 
5.2.1 HS mimetics 
HS mimetics (Table 5.1) were generously supplied by Dr. C. Freeman 
(John Curtin School of Medical Research (JCSMR), Australian National 
University (AND)). All HS compounds, in their powder form, were stored in a 
desiccated jar at 4°C. Compounds were diluted in sterile saline solution and 
aliquots kept frozen at -20°C until required. 
Table 5.1. List of heparan sulfate mimetics 
Group 1-Heparins and modified heparins (~12kDa) 
201 Mucosal heparin (12.5kDa) 
204 Mucosal heparin glycol split (go) periodate treated/NaBH4 reduced 
205 Mucosal heparin go (pNAc) (part deNS/NAc) 
207 Mucosal heparin go de2S (periodate then lyophilise in 0.1 M NaOH) 
230 Desulfated mucosal heparin 
384 Mucosal heparin gc Nac 
448 
MH-NAc ie deNS, then re acetylate ; loss of 1 anionic charge 
perdisaccharide 
465 Mucosal heparin-gc butyl 
466 Mucosal heparin-gc hexyl 
481 MH-gc-NH 
483 MH-NH ie deNS ie GlcNH+ ; loss of 2 anionic charges per disaccharide 
G r o u p 2 - L o w m o l e c u l a r w e i g h t hepar ins (LMWH) {5kDa and 3kDa) 
and e n o x a p a r i n w i t h / w i t h o u t g l y c o l sp l i t (gc) 
217 Mucosal heparin 5kDa LMWH (Sigma) 
218 Mucosal heparin 5kDa gc split 
219 Mucosal heparin 5kDa gc split part deNS/NAc 
228 Decarboxylated mucosal heparin 
331 Mucosal heparin Sigma 3kDa 
332 Mucosal heparin Sigma 3kDa gc 
333 Mucosal heparin Sigma 3kDa de2S 
394 Enoxaparin 3kDa 
408 Enoxaparin-gc 
416 Mucosal heparinSkDa gc-CHO + Benzhydrazide 
418 Mucosal heparin3kDa gc-CHO + Anthranilic acid (NH2-Q-COOH) 
419 Mucosal heparinSkDa gc-CHO + ANTS (1,3,6 triSOs-aminonaphthaline) 
424 Mucosal heparin with glycol split 3kDa 
G r o u p 3 -Fuco idans and mod i f i ed f u c o i d a n 
259 Fucoidan (Sigma) 
497 Fucoidan Marinova 
498 Fucoidan 30min ascorbate/peroxide 
499 Fucoidan 60min ascorbate/peroxide 
500 Fucoidan 90min ascorbate/peroxide 
501 Fucoidan 120min ascorbate/peroxide 
502 Fucoidan ISOmin ascorbate/peroxide 
G r o u p 4-Car rageenans 
266 lota-carrageenan 
267 Lambda-carrageenan 3S/disacc 
494 lota-carragenan Fe/Ascorbate 
495 Lambda-carragenan Fe II 
496 Lambda-carragenan Fe/ascorbate 
Group 5-Other HS compounds 
81 Cellobiose sulfate 
106 Maltotetraose H -itol (reduced) 
109 Lactose-CO-NH-CH2-C6H4-CH2-NH-CO-lactose (meta linked xylyl) 
111 Lact-C0-NH-(CH2)n-NH-C0-lact n = 12 
229 Pentosan polysulfate 5kDa Sigma 
238 Chondroitin 4-sulfate 
241 Dermatan sulfate 
242 Chondroitin 6-sulfate 
254 Dextran Sulfate 5kDa 
486 Suledexide 5kDa 
510 Polyvinyl sulfate Na+ (Sigma) charcoal treated 
511 A Polyvinyl sulfate Na+ (Sigma) polymerised A 
511 B Polyvinyl sulfate Na+ (Sigma) polymerised B 
512 D Polyvinyl sulfate Na+ (Sigma) polymerised D 
512 E Polyvinyl sulfate Na+ (Sigma) polymerised E 
PI-88 A mixture of highly sulfated, monophosphorylated mannose oligosaccharides 
Suramin A polyanionic compound- contains eight benzene rings, four amide groups, one urea and six sulfonate groups 
Table 5.1 legend: 
The following legend is provided to explain abbreviations used in the 
table above. Abbreviations listed refer to chemical and/or structural 
modifications present in the corresponding HS mimetic compounds. 
• gc = periodate treated (glycol split); opens ring; makes it more flexible; no 
anticoagulant activity 
• de2S = 2 sulfate (S) groups removed; low/no anticoagulant activity 
• gs/de2S = glycol split; then 2 sulfate (S) groups removed; it makes it less 
likely to bind to other proteins 
• pNAc = part deNS, replace with NAc; even less sulfation and binding to 
other proteins 
• CR = decarboxylated (not an anti-coagulant, reduces binding to many 
compounds)-COOH » - C H 2 O H 
5.2.2 Mouse strain 
Male WT BALB/c mice aged 6 to 8 weeks were obtained from the 
pathogen free animal facility at the University of Canberra (UC). Animals were 
housed in approved containment facilities and treated in accordance with UC 
animal experimentation guidelines. 
5.2.3 HS cytotoxicity assay 
HS mimetic compounds were evaluated for cell cytotoxicity in vitro. The 
AlamarBlue assay (Invitrogen, Australia) was used to assess cell health and 
viability following incubation with HS mimetics. The assay was set up in a 96-
well plate. Vero E6 cells were prepared in Opti-MEM (Gibco, Australia) with 5% 
PCS (Sigma) and plated at 6000 cells/well. All samples were prepared in 
quadruplicates. Cells in the 96-well plate were allowed to Incubate and adhere 
for 4 hours at 37°C and 5% CO2. Following the 4 hour incubation, 100 pL of 
each HS mimetic at 100 (jg/mL (final concentration) was added to appropriate 
set of quadruplicates. Plate was incubated for 24 hours at 37°C and 5% CO2, 
following which, 10X AlamarBlue reagent (Invitrogen) was added to each well at 
IX final concentration and the plate incubated for 4 hours at 37°C and 5% CO2. 
Samples was analysed using a spectrophotometer (SPECTROstar Omega, 
BMG Labtech) at dual wavelength of 570 and 600 nm. Vero E6 cells (ATCC) 
were used as a standard for the cell proliferation assay. Standards were serially 
diluted 1 in 2 with concentrations ranging from 12000 to 94 cells per well. 
Standards were included in the assay to enable determination of cell 
concentration of unknown samples (Vero E6 cells incubated with HS mimetics). 
5.2.4 HS mimetics treatment of RSV infection in vitro 
The effect of HS mimetics on RSV infection was tested in vitro. All 
compounds were tested at 100 pg/mL, while a selected number of compounds 
were tested at 20 and 5 pg/mL concentration. All samples were processed for 
immunostaining RSV plaque assay (section 2.10). Compounds were tested 
under four different conditions and variations were as follows: Condition A-
incubating Vero E6 cell lysate (negative control), UV-RSV (additional negative 
control) or RSV (200 pfu) with HS mimetics for 10 minutes at 37''C and 5% CO2; 
Condition B- incubating Vero E6 monolayer with HS mimetics for 10 minutes at 
37°C and 5% CO2; Condition C- incubating Vero E6 cell lysate (negative 
contro l ) , U V - R S V (add i t iona l negat ive contro l ) or R S V (200 pfu) w i th the cel l 
m o n o l a y e r fo r 10 m inu tes (a l lowing v i rus to adhere ) at 37 °C and 5 % C O 2 ; and 
C o n d i t i o n D- i ncubat ing V e r o E6 cel l lysate (negat ive control) , U V - R S V 
(add i t iona l negat ive cont ro l ) o r R S V (200 pfu) w i th the cell mono laye r for 1 hour 
(a l lowing v i rus to adhe re ) at 3 7 ° C and 5 % C O 2 . T h e exper imen ta l des ign Is 
deta i led in F igure 5.1. 
Condition A 
RSV (200 pfu/well) 
and HS compound 
I 
Incubate for 10 
minutes at 37 °C 
and 5% CO2 
Add the mixture to 
the cell (Vero E6) 
monolayer 
Incubate for 1 
hour at 37 °Cand 
5% CO2 
Condition B Condition C 
Add HS compound 
to the cell (Vero 
E6) monolayer 
Add RSV (200 pfu/ 
well) to cell (Vero 
E6) monolayer 
i 
Incubate for 10 
minutes at 37 °C 
and 5% CO2 
Incubate for 10 
minutes at 37 °C 
and 5% CO2 
* i 
Add RSV (200 pfu/ 
well) to cell 
monolayer 
Add HS compound 
to cell monolayer 
Incubate for 1 
hour at 37 °Cand 
5% CO2 
Incubate for 1 
hour at 37 °Cand 
5% CO2 
Condition D 
Add RSV (200 pfu/ 
well) to cell (Vero 
E6) monolayer 
Incubate for 1 
hour at 37 °Cand 
5% CO2 
X 
Add HS compound 
to cell monolayer 
I 
Add 1 mL of methylcellulose 
i 
Incubate for 6 days at 
37 °C and 5% CO2 
i 
Process as per 
immunostaining RSV plaque 
assay (refer to section 2.10) 
Figure 5.1. H e p a r a n sul fate (HS) mimet ics in vitro exper imenta l des ign 
HS treatment of respiratory syncytial virus (RSV) (200 plaque forming (pfu)/well) infection under 
four conditions: Condition A- incubating RSV with HS for 10 minutes at 37°C and 5% CO2; 
Condition B- incubating Vero E6 monolayer with HS mimetics for 10 minutes at 37°C and 5% 
CO2; Condition C- incubating RSV (allowing virus to adhere) with the cell monolayer for 10 
minutes at 37°C and 5% CO2; and Condition D- incubating RSV (allowing virus to adhere) with 
the cell monolayer for 1 hour at 37°C and 5% CO2. Viral litres were determined by 
immunostaining RSV plaque assay. 
5.2.5 HS mimetics treatment of RSV infection in vivo 
Following in vitro studies, the best performing HS compounds were 
selected for in vivo studies. The selected HS mimetics were: HS 228 (carboxyl 
reduced mucosal heparin), HS 259 (fucoidan-sulfated polysaccharide), HS 267 
(lambda carrageenan (200kDa)) and HS 424 (mucosal heparin with glycol split 
(3kDa)). HS 230 (desulfated heparin) and HS 254 (dextran sulfate (5kDa)) were 
included as HS negative and positive controls, respectively. Treatment groups 
are listed in the Table 5.2 below. 
Table 5.2. In vivo treatment groups 
Treatment Inoculum 
Saline (negative control) Vero E6 cell lysate 
Saline (additional control) UV-RSV 
HS 230 (negative HS control) Vero E6 cell lysate 
HS 254 (positive HS control) Vero E6 cell lysate 
HS 228 Vero E6 cell lysate 
HS 259 Vero E6 cell lysate 
HS 267 Vero E6 cell lysate 
HS424 Vero E6 cell lysate 
Saline (positive control) RSV at 200 pfu/well 
HS 230 RSV at 200 pfu/well 
HS 254 RSV at 200 pfu/well 
HS 228 RSV at 200 pfu/well 
HS 259 RSV at 200 pfu/well 
HS 267 RSV at 200 pfu/well 
HS 424 RSV at 200 pfu/well 
Selected HS mimetics were tested for the RSV inhibition under following 
two conditions: HS mimetics treatment of RSV infection and prophylactic HS 
treatment of RSV infection. 
The effect of HS mimetics on RSV infection, in vitro and in vivo was 
assessed by calculating the percent inhibition of viral infection. This was done 
using the formula below: 
Inhibition = 100 x (Original Number - New Number) / Original Number 
Equation 3.1. Formula for the percent Inhibition of RSV infection 
5 . 2 . 5 . 1 HS mimetics treatment of RSVinfection 
On day 0 WT BALB/c mice were lightly anesthetised with isofluorane 
(PharmaChem) (section 2.12.4) and intranasally inoculated with either Vero E6 
cell lysate, UV-RSV or RSV (50 (jL of 1 x 10^ pfu/mL = 5 x 10® pfu/mouse). On 
days 1-4, mice were treated with selected HS mimetics at 10 mg/mL/kg (100 |JL 
intraperitoneal injections) (Figure 5.2). On day 5 mice were euthanised by CO2 
asphyxiation (section 2.12.1) and samples collected (sections 2.13). 
Intraperitoneal Injection of 100 nL of heparan 
sulfate mimetics at 10 mg/mL/kg concentration 
days 0 
t t 
intranasal inoculation w i th 
2 X 10® plaque forming units/mouse 
Sample 
collection 
Figure 5.2. Heparan sulfate (HS) mimetic treatment of respiratory syncytial 
virus (RSV) infection experimental timeline 
On day 0, wild type BALB/c mice were inoculated with RSV and receiving daily HS mimetics 
treatment at 10 mg/mL/kg on days 1-4. On day 5, mice were sacrificed and samples collected. 
5.2.5.2 Prophylactic HS treatment of RSV infection 
WT BALB/c mice received daily HS mimetics treatment at 10 mg/mL/kg 
(100 |JL intraperitoneal injections), starting 48 hours prior to intranasal 
inoculation and continuing until 4 days after the inoculation. On day 0 WT 
BALB/c mice were intranasally inoculated with either Vero E6 cell lysate, UV-
RSV or RSV (50 pL of 1 x 10^ pfu/mL= 5 x 10^ pfu/mouse) (Figure 5.3). On day 
5 mice were euthanised by CO2 asphyxiation (section 2.12.1) and samples 
collected (sections 2.13). 
r 
Intraperitoneal injection of 100 (iL of heparan 
sulfate mimetics at 10 mg/mL/kg concentration 
A . ^ 
A 




1 hour post heparan sulfate 
administration; intranasal inoculation wi th 
2 X 10^ plaque forming units/mouse 
Sample 
collection 
Figure 5.3. Prophylactic heparan sulfate (HS) treatment of respiratory 
syncytial virus (RSV) infection experimental timeline 
WT BALB/c mice received daily HS mimetics treatment at 10 mg/mL/kg (100mL intraperitoneal 
injections), starting 48 hours prior to intranasal inoculation and continuing until 4 days after. On 
day 0, WT BALB/c mice were intranasally inoculated with either Vero E6 cell lysate, ultraviolet-
inactivated RSV (UV-RSV) or RSV infected with RSV (5 x 10^ plaque forming units/mouse) by 
intranasal inoculation. On day 5, mice were sacrificed and samples collected. 
5.2.6 Statistical analysis 
Data are p resented as m e a n + s tandard deviat ion. A O N E - w a y or T W O -
w/ay A N O V A w a s used to de te rm ine stat ist ical s igni f icance. Data w e r e ana lysed 
us ing G r a p h P a d Pr ism vers ion X7. A p va lue of less than 0.05 was cons idered 
stat ist ical ly s igni f icant. 
5.3 RESULTS 
5.3.1 HS cytotoxicity study 
HS mimetics were tested at 100 |jg/mL for cellular cytotoxicity using Vero 
E6 cells. It was found that HS mimetics are not toxic (Appendix 4). 
5.3.2 HS mimetics treatment of RSV infection in vitro 
Vero E6 cell lysate (negative control - data not shown) and UV-RSV 
(additional negative control-data not shown) inoculated samples that received 
either saline or tested HS mimetics were assessed for viral titres using RSV 
immunohistochemistry plaque following all four testing conditions and no viral 
titres were recovered. In addition, in vitro results of only 27 out of 53 tested HS 
mimetics are represented in this result chapter. These compounds were 
selected based on their antiviral activity, chemical and structural variations; 
representing an average HS mimetics performance, at three different 
concentrations and under four different conditions, for the group that they are 
representing. Graphs of other compounds can be found in Appendix 5. 
5.3.2.1 HS induced RS V inhibition in vitro 
5.3.2.1.1 Condition A 
HS 230 (negative HS control) showed no reduction of RSV infection 
while HS 254 (positive HS control) induced 90 and 50% inhibition of RSV 
infection (p < 0.001) at 100 and 5|jg/mL, respectively. Overall, group 1 HS 
mimetics, the heparins and modified heparins (~12kDa), induced a 60-80% 
reduction in RSV plaques (Figure 5.4 A). HS 201 was found to inhibit RSV 30% 
better (p < 0.001) at 100 ^g/mL concentration compared to 5 (jg/mL. HS 204, 
HS 205 and HS 207 did not inhibit RSV at any of the three tested HS 
concentrations. 
Group 2 (low molecular weight heparins (5kDa and 3kDa) and 
enoxaparin with/without glycol split) HS mimetics showed more dose dependant 
RSV inhibition (Figure 5.4 B). HS 218 and HS 219 induced 80% RSV inhibition 
at 5 and 100 pg/mL concentrations resulting in almost 20% greater (p < 0.005) 
inhibition compared to 20 pQ/mL dose. HS 331 and HS 332 RSV inhibition 
increased from 60-90% following an increase in HS mimetics concentration 
from 5 to 100 ^ig/mL. In contrast, HS 416 and HS 424 RSV inhibition was 
improved from 65-85% (p < 0.005) by reducing HS mimetics concentration from 
100 to 5 |jg/mL. HS 217 and HS 333 achieved 80% and 40% RSV inhibition, 
respectively, and were unaffected by change in HS mimetic concentration. 
HS 259, belonging to group 3 (fucoidans and modified fucoidans) HS 
mimetics, showed almost 100% RSV inhibition at 5, 20 and 100 |jg/mL 
concentrations (Figure 5.4 C). All Group 4 (carrageenans) HS mimetics were 
found to induce 100% RSV inhibition in at least one of the concentrations 
examined. HS 266 induced 100% RSV inhibition (p < 0.0001) at 100 and 20 
pg/mL while only 60% inhibition at 5 p/mL (p < 0,0001). HS 267 inhibited RSV 
100% (p < 0.0001) irrespective of the HS mimetics concentration (Figure 5.4 D). 
Several group 5 (other) HS mimetics were found to perform better at 
lower concentrations (Figure 5.4 E). HS 111, HS 238, HS 241, HS 242, PI-88 
and suramin showed a significant RSV inhibition (60-80%) (p < 0.005) at 5 
and/or 20 pg/mL while RSV inhibition was reduced to 0% at 100 pg/mL 
concentration. HS 81, HS 106 and HS 109 induced 60%, 90% and 70% RSV 
inhibition (p < 0.005) respectively, irrespective of the HS mimetic concentration. 
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Figure 5.4. Heparan sulfate (HS) in vitro (Condition A) treatment of 
respiratory syncytial virus (RSV) infection 
The assay was carried out in 24-well flat bottom plate. Group 1 (heparins and modified heparins (-
12kDa)) (A), Group 2 (low molecular weight heparins (LMWH) (5kDa and 3kDa) and enoxaparin 
with/without glycol split) (B), Group 3 (fucoidans and modified fucoidan) (C), Group 4 
(carrageenans) (D) and Group 5 (other) (E) HS mimetics were tested at 100, 20 or 5 | jg/ml-
Briefly, 100 fjl/well of HS mimetics was incubated with RSV (200 plaque forming units/well) for 10 
minutes at 37°C and 5% CO2. Following the incubation, HS with RSV mixture was added to Vero 
E6 cell monolayer and allowed to incubate for 1 hour at 37°C and 5% CO2. Plate was processed 
by immunostaining RSV plaque assay (section 2.10). Data are represented as a mean of RSV 
plaques recovered (n = 4) ± standard deviation. HS compounds 230 (negative) and 254 (positive) 
were used as HS mimetic controls. For each graph, the controls HS 230, HS 254 and RSV results 
are presented in boxed area for comparison. Data were analysed using a ONE-way ANOVA with 
Tukey's multiple comparison test (GraphPad Prism) (**, p < 0.005, p < 0.001 and ** " , p < 
0.0001). 
5.3.2.1.2 Condition B 
The hypothesis that HS mimetics may bind to the negatively charged 
sulfate and carboxyl groups of the glycosaminoglycan chains of HS on the cell 
surface of Vero E6 cells was tested. HS 230 (negative HS control) did not 
induce RSV inhibition while HS 254 (positive HS control) exhibited 
approximately 75% inhibition at all three tested HS concentrations. Treatment 
with group 1 HS mimetics (heparins and modified heparins (~12kDa)) (Figure 
5.5 A) resulted in a 30-80% reduction in RSV plaques recovered. HS 201 was 
found to be almost 40% more effective against RSV at the 20 and 100 |jg/mL 
concentrations than at 5 pg/mL (p < 0.0001). HS 204, 205 and 207 achieved 65, 
30% and 45% inhibition, respectively, and were unaffected by HS 
concentrations (Figure 5.5 B). 
The Group 2 (low molecular weight heparins (5kDa and 3kDa) and 
enoxaparin with/without glycol split) HS mimetics 217, HS 218 and HS 228 
induced approximately 80% RSV inhibition and their efficacy was found to be 
unaffected by change in HS concentration (Figure 5.5 C). HS 219, HS 331 and 
HS 332 induced 75-80% RSV inhibition at 5 and 20 pg/mL compared to only 35-
45% inhibition at 100 pg/mL (p < 0.05). HS 416 and HS 424 showed the 
opposite trend with an increase in RSV inhibition from 65-90% as the 
concentration increased from 5-100 pg/mL. HS 333 induce the lowest level of 
RSV inhibition, only 30%, at all three tested HS concentrations. 
Group 3 (fucoidans and modified fucoidans) HS 259 showed an average 
of 90% RSV inhibition at 5, 20 and 100 pg/mL concentrations (Figure 5.5 C). In 
contrast. Group 4 (carrageenans) HS mimetics RSV inhibition decreased with 
reduction in HS mimetic concentrations. HS 266 induced 100%, 90% and 60% 
RSV inhibition at 100, 20 and 5 pg/m, respectively (p < 0.0001). HS 267 
induced 100% RSV inhibition at 10 and 20 pg/mL while only 70% at 5 pg/mL 
(Figure 5.5 D). 
Most of the group 5 (other) HS mimetics performed best at 5 and/or 20 
pg/mL concentration (Figure 5.5 E). HS 81, HS 111, HS 238, HS 241, HS 242, 
PI-88 and suramin showed a significant increase (65-90%) in RSV inhibition at 
5 and/or 20 pg/mL compared to only 0-20% at 100 pg/mL (p < 0.05). HS 106 
and HS 109 induced close to 85% and 65% RSV inhibition respectively, 
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Figure 5.5. Heparan sulfate (HS) in vitro (Condition B) treatment of 
respiratory syncytial virus (RSV) infection 
The assay was carried out in 24-well flat bottom plate. Group 1 (heparins and modified heparins 
(~12kDa)) (A), Group 2 (low molecular weight heparins (LMWH) (5kDa and 3kDa) and 
enoxaparin with/without glycol split) (B), Group 3 (fucoidans and modified fucoidan) (C), Group 4 
(carrageenans) (D) and Group 5 (other) (E) HS mimetics were tested at 100, 20 or 5 pg/mL and 
100 |jl/well of HS mimetics was incubated with Vero E6 cell monolayer for 10 minutes at 37°C 
and 5% CO2. Following the incubation, RSV (200 plaque forming units/well) was added to Vero 
E6 cell monolayer with HS mimetics and allowed to incubate for 1 hour at 37°C and 5% CO2. 
Plate was processed by immunostaining RSV plaque assay (section 2.10.). Data are represented 
as a mean of RSV plaques recovered (n = 4) ± standard deviation. HS 230 (negative) and 254 
(positive) were used as HS mimetic controls. For each graph, the controls HS 230, HS 254 and 
RSV results are presented in boxed area for comparison. Data were analysed using ONE-way 
ANOVA with Tukey's multiple comparison test (GraphPad Prism) (*, p < 0.05, p < 0.005, p 
<0.001 and " * * , p < 0.0001). 
5.3.2.1.3 Condition C 
The ability of the HS mimetics to compete with RSV for the cell surface 
HS binding site, following the RSV incubation with Vero E6 cells for 10 minutes 
at 37°C and 5% CO2, was assessed under condition C. HS 230 (negative HS 
control) did not inhibit RSV infection while HS 254 (positive HS control) 
treatment inhibited RSV by 80% and 60% at 100 and 5 |jg/mL, respectively (p < 
0.05). Group 1 HS mimetics (heparins and modified heparins (~12kDa)) 
induced an increase in RSV Inhibition from 50% to 80% by increasing HS 
concentration from 5-100 pg/mL (p < 0.05) (Figure 5.6 A). HS 204, HS 205 and 
HS 207 performed the best at 5 pg/mL concentration achieving 70%, 85% and 
80% RSV inhibition, respectively (p < 0.05). 
The group 2 (low molecular weight heparins (5kDa and 3kDa) and 
enoxaparin with/without glycol split) HS mimetics exhibited a more pronounced 
dose dependant effect on RSV inhibition (Figure 5.6 B). HS 217 performed the 
best at 5 and 100 (jg/mL inducing over 80% RSV inhibition compared to only 
60% at 20 pg/mL (100 pg/mL versus (vs.) 20 pg/mL, p < 0.05). HS 218 and HS 
219 showed similar inhibition trends achieving 80%, 50% and 55% at 100, 20 
and 5 pg/mL, respectively (100 pg/mL vs. 20 pg/mL, p < 0.05). HS 228 
performed best at 5 and 100 pg/mL inducing over 80% RSV inhibition compared 
to only 45% at 20 pg/mL (100 pg/mL vs. 20 pg/mL; 100 pg/mL vs. 5 pg/mL, p < 
0.0001). HS 331, HS 332 and HS 424 inhibited RSV at 80%, 70% and 80% 
respectively at all three tested HS concentrations. HS 333 and HS 416 inhibited 
RSV by 70% at 20 pg/mL. 
The group 3 (fucoidans and modified fucoidans) HS 259 inhibited RSV 
by 90% at 5, 20 and 100 pg/mL concentrations (Figure 5.6 C). The Group 4 
(carrageenans) HS mimetic, 266, inhibited RSV by 80% at 5 and 20 pg/mL in 
contrast to only 65% at the higher dose of 100 pg/mL (p < 0.001). HS 267 
induced 90% RSV inhibition at 5 and 100 pg/mL while only 70% at 20 pg/mL (p 
<0.0001) (Figure 5.6 D). 
The group 5 (other) HS mimetics HS 81, HS 238, HS 241 and HS 242 
induced approximately 70% inhibition of RSV irrespective of the HS mimetic 
concentration. HS 106, HS 111, PI-88 and suramin performed best at 5 and 100 
pg/mL inhibiting RSV by 75-90% compared to 20-45% at 20 pg/mL (p < 0.05) 
(Figure 5.6 E). 
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Figure 5.6. Heparan sulfate (HS) in vitro (Condition C) treatment of 
respiratory syncytial virus (RSV) infection 
The assay was carried out in 24-well flat bottom plate. RSV (200 plaque forming units/well) was 
added to Vero E6 cell monolayer and allowed to incubate for 10 minutes at 37°C and 5% CO2. 
Following ttie incubation, 100 |jl/well of Group 1 (heparins and modified heparins (~12kDa)) (A), 
Group 2 (low molecular weight heparins (LMWH) (5kDa and 3kDa) and enoxaparin with/without 
glycol split) (B), Group 3 (fucoidans and modified fucoidan) (C), Group 4 (carrageenans) (D) and 
Group 5 (other) (E) HS mimetics were added at 100, 20 or 5 pg/mL to Vero E6 cell monolayer 
treated with RSV and incubated for 1 hour at 37°C and 5% CO2. Plate was processed by 
immunostaining RSV plaque assay (section 2.10.). Data are represented as a mean of RSV 
plaques recovered (n = 4) ± standard deviation. HS 230 (negative) and 254 (positive) were used 
as HS mimetic controls. For each graph, the controls HS 230, HS 254 and RSV results are 
presented in boxed area for comparison. Data were analysed using ONE-way ANOVA with 
Tukey's multiple comparison test (GraphPad Prism) (*, p < 0.05, **, p < 0.005, p < 0.001 and 
" " , p < 0.0001). 
5.3.2.1.4 Condition D 
The HS mimetics were also assessed for their ability to compete with 
RSV for the cell surface HS binding site following RSV incubation with Vero E6 
cells for 1 hour at 37°C and 5% CO2 and HS for potentially inhibiting the cell-to-
cell spread of RSV under condition D. This condition represents the most 
clinically relevant in vitro experimental set up. 
HS 230 (negative HS control) showed no viral inhibition while HS 254 
(positive HS control) inhibited RSV by 80% at 100 pg/mL (p < 0.005). The group 
1 HS mimetics (heparins and modified heparins (~12kDa)) induced 40-65% 
reduction in RSV plaques at 100 pg/mL while less than 10% at 5 and 20 MQ/mL 
(Figure 5.7 A). 
The group 2 (low molecular weight heparins (5kDa and 3kDa) and 
enoxaparin with/without glycol split) HS mimetics induced dose dependant RSV 
inhibition with HS 217, HS 218, HS 219 and HS 228 inhibiting RSV by 60-65% 
at 100 pg/mL while at 5 and 20 pg/mL these HS mimetics had minimal effect on 
RSV inhibition (Figure 5.7B). HS 331 induced 40% RSV inhibition at all three 
HS mimetics concentrations while treatment with HS 332 resulted in 40 and 
50% RSV inhibition at 20 and 5 pg/mL, respectively. HS 333, HS 416 and HS 
424 RSV inhibition improved with an increase in HS concentrations, resulting in 
20-80% inhibition (p < 0.0001). 
The group 3 (fucoidans and modified fucoidans) HS mimetic HS 259 
inhibited RSV by 30% at all three concentration, 100, 20 and 5 pg/mL (Figure 
5.7 C). Group 4 (carrageenans) HS mimetic, HS 266, inhibited RSV by 20% at 5 
and 20 pg/mL and by 40% at the higher dose of 100 pg/mL (Figure 5.7D). HS 
267 induced 55% and 40% RSV inhibition at 5 and 20 pg/mL and 60% at 100 
pg/mL. 
Group 5 (other) HS mimetics HS 81, HS 106, HS 109, HS 238, HS 241 
and HS 242 induced approximately 35-40% inhibition of RSV and was 
unaffected by the HS mimetic concentration. HS 111, PI-88 and suramin 
performed best at 20 and 100 pg/mL inhibiting RSV by 35% compared to less 
than 10% at 5 pg/mL (p < 0.0001) (Figure 5.7E). 
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Figure 5.7. Heparan sulfate (HS) in vitro (Condition D) treatment of 
respiratory syncytial virus (RSV) infection 
The assay was carried out in 24-well flat bottom plate. RSV (200 plaque forming units/well) as 
added to Vero E6 cell monolayer and allowed to incubate for 1 hour at 37°C and 5% CO2. 
Following the incubation, 100 pl/well of Group 1 (heparins and modified heparins (~12kDa)) (A), 
Group 2 (low molecular weight heparins (LMWH) (5kDa and 3kDa) and enoxaparin with/without 
glycol split) (B), Group 3 (fucoidans and modified fucoidan) (C), Group 4 (carrageenans) (D) and 
Group 5 (other) (E) HS mimetics were added at 100, 20 or 5 pg/mL to Vero E6 cell monolayer 
treated with RSV. Plate was processed as per Immunostaining RSV plaque assay (Section 2.7.). 
Data are represented as a mean of RSV plaques recovered (n = 4) ± standard deviation. HS 230 
(negative) and HS 254 (positive) were used as HS mimetic control. For each graph, the controls 
HS 230, HS 254 and RSV results are presented in boxed area for comparison. Data were 
analysed using ONE-way ANOVA with Tukey's multiple comparison test (GraphPad Prism) ( " , p 
<0.005 and " " p < 0.0001). 
5.3.3 HS mimetlcs treatment of RSV infection in vivo 
Following in vitro HS screening, the four best performing compounds 
across all four conditions A, B, C and D, in addition to the positive and negative 
HS controls, were tested for their antiviral ability in vivo. The selected 
compounds were: HS 228 (carboxyl reduced mucosal heparin), HS 259 
(fucoidan - sulfated polysaccharide), HS 267 (lambda carrageenan (200kDa) 
and HS 424 (mucosal heparin with glycol split (3kDa) with the negative HS 
control, HS 230 (desulfated heparin) and the positive HS control, HS 254 
(dextran sulfate (5kDa). It is important to note that preliminary in vivo results 
(data not shown) revealed that HS mimetic treatment could not be delivered 
intranasally to the RSV-inoculated mice. Intranasal HS mimetic treatment 
evoked an excessive immune response in the mucosal surfaces of the nose, 
throat and lungs of RSV-inoculated mice, resulting in death within the 24-48 
hours of the HS mimetic treatment. Consequently, through another pilot study, 
an i.p. delivery of HS mimetlcs to RSV-inoculated mice for both, post and 
prophylactic treatment of RSV-infection, resulted in an effective immune 
response and successful recovery from the RSV infection. As a result, HS 
treatment was delivered via i.p. route to all RSV-inoculated mice involved in the 
in vivo studies discussed in this chapter. It is important to note that i.p. delivery 
route was also used by several studies treating HSV and dengue infections, and 
proteinuria with HS mimetlcs (Lee et al., 2006; Levidiotis et al., 2004; Nyberg et 
al., 2004). 
5.3.3.1 Weight and RSV clinical scores 
There were no significant changes in weights of mice for Vero E6 cell 
lysate (negative control), UV-RSV (additional negative control) or RSV 
inoculated conditions (data not shown). RSV inoculated mice showed signs of 
RSV infection as described in the section 2.12.2, RSV clinical scores reaching a 
maximum score of 4. There was no statistically significant difference in the 
clinical scores recorded for Vero E6 cell lysate, UV-RSV or RSV inoculated HS 
treated groups (data not shown). 
5.3.3.2 Viral titres 
RSV immunohistochemistry plaque assay analysis of Vero E6 cell lysate 
(negative control - data not shown) and UV-RSV (additional negative control-
data not shown) inoculated groups following a treatment with saline, revealed 
no viral titres present (data not shown). Treatment of RSV inoculated groups 
with HS 230 (negative HS control) and 254 (positive HS control) did not have 
any effect of RSV infection compared to treatment of RSV inoculated group with 
saline (positive control). Only compounds HS 228 (carboxyl reduced mucosal 
heparin) and HS 259 (fucoidan) induced a statistically significant reduction (p < 
0.05) in RSV titres compared to the positive control (Figure 5.8). HS 228 and 
HS 259 RSV inhibition was also significant (p < 0.05) compared to the treatment 
of RSV inoculated groups with HS 230 (negative HS control) and HS 254 
(positive HS control) (Figure 5.8). HS 267 and HS 424 appeared to inhibited 
RSV infection marginally however the reduction was not statistically significant. 
800 
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Figure 5.8. Post respiratory syncytial virus (RSV) infection treatment with 
heparan sulfate (HS) mimetics induced viral titres reduction in vivo 
On day 0, wild type BALB/c mice were infected by intranasal inoculation with RSV (dark grey bar) 
( 5 x 1 0 ® plaque forming units (pfu)/mouse). On days 1-4, mice received daily HS mimetics (228, 
230, 254, 259, 267 and 424) treatment at 10 mg/mL/kg concentration by intraperitoneal injections 
(100 pL). On day 5, mice were euthanised and samples collected. Titres are represented as 
pfu/gram of lung tissue. Data are represented as mean (n = 5) ± standard deviation. HS 230 
(negative) (white bar) and 254 (positive) (light grey bar) were used as HS mimetic controls. Data 
were analysed using a ONE-way ANOVA with Tukey's multiple comparison test (GraphPad 
Prism) (* p < 0.05 compared to saline treatment of RSV inoculated group). 
5.3.3.3 Leukocyte population in a BALF 
Analysis of the leukocyte population present in BALF revealed a 
significantly lower (7.5 x I C macrophages/mL of BALF) number of 
macrophages present, following the Vero E6 cell lysate (negative control) or 
UV-RSV (additional negative control) inoculation of saline treated groups 
compared to treatment of RSV inoculated group with saline (positive control) 
(21 X 10'' macrophages/mL of BALF) (p < 0.0001) (Figure 5.9 A). Treatment of 
Vero E6 cell lysate inoculated groups with HS 230 (negative HS control) or HS 
254 (positive HS control) resulted in a significant reduction (p < 0.0001) of 
macrophages present in BALF compared to the negative control. Reduction in 
macrophages numbers present in BALF was also observed following treatment 
of Vero E6 cell lysate inoculated groups with HS 259 or HS 267 (p < 0.0001) 
compared to the negative control. In contrast, treatment of Vero E6 cell lysate 
inoculated group with HS 424 resulted in a significant increase in macrophages 
present in BALF (p < 0.0001) compared to the negative control. Moreover, 
treatment of Vero E6 cell lysate inoculated group with HS 424 also induced an 
increase in a number of macrophages (p < 0.0001) compared to Vero E6 cell 
lysate inoculated groups treated with HS 230, HS 254, HS 228, HS 259 or HS 
267. Interestingly, treatment of RSV inoculated groups with any of the six HS 
mimetics resulted in a reduction (2.5-7.5 x 10" macrophages/mL of BALF) (p < 
0.0001) in macrophage numbers present in BALF compared to the positive 
control (21 x 10" macrophages/mL of BALF). However, treatment of RSV 
inoculated group with HS 230 (negative HS control) and HS 254 (positive HS 
control) induced an increase in a number of macrophages (p < 0.0001) 
compared to the corresponding HS treated Vero E6 cell lysate inoculated 
groups. In contrast, treatment of RSV inoculated groups with HS 228, HS 267 or 
HS 424 resulted in a decrease (p < 0.0001) in a number of macrophages 
compared to the corresponding HS treatment of Vero E6 cell lysate inoculated 
groups. 
Lymphocyte BALF analysis revealed a significantly lower (0.25-0.5 x 10" 
lymphocytes/mL of BALF) number of lymphocytes present in the BALF following 
Vero E6 cell lysate (negative control) or UV-RSV (additional negative control) 
inoculation of saline treated groups compared to the positive control (1.5 x 10" 
lymphocytes/mL of BALF) (p < 0.0001) (Figure 5.9 B). Treatment of Vero E6 cell 
lysate inoculated groups with HS 230 (negative HS control) or HS 254 (positive 
HS control) resulted in no change in lymphocyte numbers compared to the 
negative control. In addition, treatment of Vero E6 cell lysate inoculated groups 
with HS 228, HS 259, HS 267 or HS 424 also induced no change to lymphocyte 
numbers compared to the negative control. Similarly, treatment with HS 230 
(negative HS control), HS 254 (positive HS control) or HS 228 of RSV 
inoculated group has resulted in no change in lymphocyte numbers compared 
to the lymphocyte numbers from the positive control group. However, treatment 
with HS 259, HS 267 and HS 424 following RSV inoculation resulted in a 
reduction (p < 0.0001) in lymphocytes present in BALF compared to the 
lymphocyte numbers recovered from the positive control. In addition, treatment 
of RSV inoculated groups with HS 230 (negative HS control) or HS 254 
(positive HS control) resulted in an increase (p < 0.05) in the number of 
lymphocytes compared to Vero E6 cell lysate inoculated groups treated with the 
corresponding HS mimetic. Treatment of RSV inoculated groups with HS 228 
induced an increase (p < 0.05) in the number of lymphocytes compared to Vero 
E6 cell lysate inoculated groups treated with HS 228. Finally, treatment of RSV 
inoculated groups with HS 259, HS 267 or HS 424 resulted in no change in 
lymphocyte numbers compared to Vero E6 cell lysate inoculated groups treated 
with the corresponding HS mimetic. 
No significant difference in eosinophil numbers was observed between 
saline treatments of Vero E6 cell lysate (negative control) or UV-RSV (additional 
negative control) inoculated groups (Figure 5.9 C). In addition, treatment of 
Vero E6 or UV-RSV inoculated group with HS mimetics (applies for all six 
tested HS mimetics) showed no significant difference in eosinophil numbers 
between groups. RSV inoculation of the saline treated group (positive control) 
induced a significant trafficking of eosinophils into BALF (p < 0.0001) compared 
to the negative control. Treatment of RSV inoculated groups with HS 230 
(negative HS control) and HS 254 (positive HS control) resulted in no change in 
eosinophil numbers compared to the positive control (Figure 5.9 C). In contrast, 
treatment of the RSV inoculated groups with HS 228, HS 259 or HS 424 has 
resulted in lower (p < 0.0001) eosinophil numbers compared to the eosinophil 
numbers present in BALF of the positive control. Treatment of the RSV 
inoculated group with HS 230 (negative HS control) resulted in a significant 
increase (p < 0.0001) in a number of eosinophils in BALF compared to the 
group treated with HS 230 following Vero E6 cell lysate inoculation. However, 
eosinophil increase following treatment of the RSV inoculated groups with HS 
254 (positive HS control), HS 228, HS 259 or HS 424 was not statistically 
significant compared to Vero E6 cell lysate inoculated groups treated with 
corresponding HS mimetics. In the RSV inoculated group treated with HS 267, 
a significant increase (p < 0.0001) in a number of eosinophils in BALF was 
observed compared to the group treated with HS 267 following Vero E6 cell 
lysate inoculation. 
Finally, no significant difference in neutrophil numbers was observed 
between saline treatments of, Vero E6 cell lysate (negative control) or UV-RSV 
(additional negative control) inoculated groups (Figure 5.9 D). In addition, 
treatment of Vero E6 or UV-RSV inoculated group with HS mimetics (applies for 
all six tested HS mimetics) showed no significant difference in neutrophil 
numbers between groups. RSV inoculation of the saline treated group (positive 
control) resulted in no change in neutrophil numbers present in BALF compared 
to the negative control. Treatment of Vero E6 cell lysate inoculated groups with 
HS 230 (negative HS control), HS 254 (positive HS control), HS 228, HS 259, 
HS 267 or HS 424 resulted in no change in neutrophil numbers compared to 
negative control (Figure 5.9 D). In addition, treatment of RSV inoculated groups 
with HS 230 (negative HS control), HS 254 (positive HS control), HS 228, HS 
259, HS 267 or HS 424 resulted in no change in neutrophil numbers compared 
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Figure 5.9. Differential leukocyte count in bronchoalveolar lavage fluid 
(BALF) following HS treatment of respiratory syncytial virus (RSV) 
infection in vivo 
Wild type BALB/c mice were infected with Vera E6 cell lysate (white bar), ultraviolet-Inactivated 
RSV (UV-RSV) (grey bar) or RSV (black bar) (5 x 10^ plaque forming units (pfu)/mouse) on day 
0, On days 1-4, mice received daily treatment of saline or HS mimetics (228, 230, 254, 259, 267 
and 424) at 10 mg/mL/kg concentration by intraperitoneal injections (100 pL). On day 5, mice 
were sacrificed and BALF was collected. BALF was assessed for differential leukocyte counts 
using cytospin preparations. Following May-Grunwald and Giemsa staining of the BALF 
cytospins, leukocyte differential counts were performed using a light Nikon microscope and 
macrophage (A), lymphocyte (B), eosinophil (C) and neutrophil (D) counts were determined. Data 
are represented as mean (n = 5) + standard deviation. HS compounds 230 (negative) and 254 
(positive) were used as HS mimetic controls. Data were analysed using TWO-way ANOVA with 
Tukey's multiple comparison test (GraphPad Prism) ( " " , p < 0.0001 compared to Vero E6 cell 
lysate inoculated and saline treated group (negative control); ##, p < 0.005 and ####, p < 0.0001 
compared to RSV inoculated, saline treated group; +, p < 0.05 and ++++, p < 0.0001 compared to 
corresponding Vero E6 cell lysate Inoculated HS treated group). 
5.3.3.4 Differential analysis of leukocyte population in blood 
Analysis of the leukocyte population present in blood revealed no change 
in the number of monocyte Infiltrates following Vero E6 cell lysate (negative 
control) or UV-RSV (additional negative control) inoculation of saline treated 
groups compared to treatment of RSV inoculated groups with saline (positive 
control) (Figure 5.10 A). Treatment of Vero E6 cell lysate inoculated groups with 
HS 230 (negative HS control) or HS 254 (positive HS control) induced no 
change in monocyte infiltrates in blood compared to the negative control. 
Additionally, no change in monocyte numbers was observed following HS 
treatment of Vero E6 cell lysate inoculated groups compared to the negative 
control. Reduction in monocyte numbers present in blood (1 x 10" 
monocytes/mL) was observed following treatment of RSV inoculated groups 
with HS 424 (p < 0.0001) when compared to Vero E6 cell lysate inoculated 
groups treated with HS 424 (5x10® monocytes/mL). 
Lymphocyte blood analysis revealed a significantly higher (23 x 10® 
lymphocytes/mL) number of lymphocytes following Vero E6 cell lysate (negative 
control) or UV-RSV (additional negative control) inoculation of saline treated 
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groups compared to the positive control (10x10® lymphocytes/mL) (p < 0.0001) 
(Figure 5.10 B). Treatment of Vero E6 cell lysate inoculated groups with HS 230 
(negative HS control) or HS 254 (positive HS control) resulted in an increase (p 
< 0.0001) in lymphocyte numbers compared to the negative control. Moreover, 
Vero E6 cell lysate inoculated groups treated with HS 228, HS 259, HS 267 or 
HS 424 also showed an increase (p < 0.0001) in lymphocyte numbers 
compared to the negative control. Treatment with HS 230 (negative HS control), 
HS 254 (positive HS control), HS 228, HS 259, HS 267 or HS 424 following 
RSV inoculation resulted in an increase (p < 0.0001) in lymphocytes present in 
blood compared to the lymphocyte numbers present in the positive control. 
However, treatment of RSV inoculated groups with HS 230 (negative HS 
control) or HS 254 (positive HS control) resulted in a reduction (p < 0.0001) in 
the number of lymphocytes compared to treatment with corresponding HS 
mimetics in Vero E6 cell lysate inoculated groups. In addition, HS 228 and HS 
424 treatment of RSV inoculated groups induced a reduction (p < 0.0001) in the 
number of lymphocytes compared to the Vero E6 cell lysate inoculated groups 
treated with corresponding HS mimetics. Treatment of RSV inoculated groups 
with HS 259 resulted in no change in lymphocyte numbers compared to Vero 
E6 cell lysate inoculated groups treated with HS 259. However, treatment of 
RSV inoculated groups with HS 267 resulted in an increase (p < 0.005) in 
lymphocyte numbers compared to Vero E6 cell lysate inoculated groups treated 
with HS 267. 
No significant difference in eosinophil numbers was observed between 
Vero E6 (negative control) and UV-RSV (additional negative control) inoculated 
groups treated with either, saline or HS mimetics. RSV inoculation of saline 
treated groups also resulted in no change in eosinophil trafficking compared to 
the negative control. Similarly, treatment of the RSV inoculated groups with HS 
230 (negative HS control) or HS 254 (positive HS control) resulted in no change 
in the number of eosinophils compared to the positive control. Treatment of 
RSV inoculated groups with HS 228 or HS 424 also resulted in no change in a 
number of eosinophils. In contrast, treatment of the RSV inoculated groups with 
HS 259 or HS 267 induced an increase (p < 0.0001) in eosinophil numbers 
compared to the positive control (Figure 5.10 C). Treatment of the RSV 
inoculated groups with HS 230 (negative HS control) or HS 254 (positive HS 
control) resulted in no change in the number of eosinophils present in blood 
compared to Vero E6 cell lysate groups treated with HS 230 or HS 254. In 
addition, treatment of RSV inoculated groups with HS 228 or HS 424 induced 
no change to the number of eosinophils present in blood compared to treatment 
of Vero E6 cell lysate inoculated group with corresponding HS mimetics. On the 
contrary, treatment of RSV inoculated groups with HS 259 or HS 267 resulted in 
higher (p < 0.0001) eosinophil numbers compared to Vero E6 cell lysate 
inoculated groups treated with HS 259 or HS 267. 
In addition, no significant difference in neutrophil numbers was observed 
between saline treatments of, Vero E6 cell lysate (negative control) or UV-RSV 
(additional negative control) inoculated groups (Figure 5.10 D). In addition, 
treatment of Vero E6 or UV-RSV inoculated group with HS mimetics (applies for 
all six tested HS mimetics) showed no significant difference in neutrophil 
numbers between groups. Positive control resulted in no change in neutrophil 
numbers present in blood compared to the negative control. Treatment of Vero 
E6 cell lysate inoculated groups with HS 230 (negative HS control), HS 254 
(positive HS control), HS 228, HS 259, HS 267 or HS 424 resulted in no change 
in neutrophil numbers compared to negative control (Figure 5.10 D). In addition, 
treatment of RSV inoculated groups with HS 230 (negative HS control), HS 254 
(positive HS control), HS 228, HS 259, HS 267 or HS 424 resulted in no change 
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Figure 5.10. Differential leul^ocyte count in blood following heparan 
sulfate (HS) treatment of respiratory syncytial virus (RSV) infection in vivo 
Wild type BALB/c mice were infected with Vera E6 cell lysate (white bar), ultraviolet-inactivated 
RSV (UV-RSV) (grey bar) or RSV (black bar) (5 x 10^  plaque forming units (pfu)/mouse) on day 
0. On days 1-4, mice received daily treatment of saline or HS mimetics (228, 230, 254, 259, 267 
and 424) at 10 mg/mL/kg concentration by intraperitoneal injections (100 |JL). On day 5, mice 
were euthanised and blood was collected by cardiac puncture. Total number of leukocytes was 
determined by haemocytometer count of 5 |JL of blood mixed with 95 pL of methylene blue. 
Differential leukocyte counts was done through a light microscope (Nikon) analysis of May-
Grunwald and Giemsa stained blood smears on a glass slides. Monocyte (A), lymphocyte (B), 
eosinophil (C) and neutrophil (D). Data are represented as mean (n = 5) ± standard deviation. HS 
compounds 230 (negative) and 254 (positive) were used as HS mimetic controls. Data were 
analysed using TWO-way ANOVA with Tukey's multiple comparison test (GraphPad Prism) (**", 
p < 0.0001 compared to Vero E6 cell lysate inoculated and saline treated group (negative 
control); mm, p < 0.0001 compared to RSV inoculated, saline treated group; ++, p < 0.005 and 
++++, p < 0.0001 compared to corresponding Vero E6 cell lysate inoculated HS treated group). 
5.3.3.5 Lung histopathology following HS mimetics treatment 
of RSV infection 
Following treatment (saline or HS) of Vero E6 cell lysate (negative 
control), UV-RSV (additional negative control) or RSV inoculated BALB/c mice, 
lungs were assessed for airways mucus occlusion, degree of parenchymal 
pneumonia, peribronchial infiltrates, quality of peribronchial infiltrates, 
perivascular infiltrates, histopathological score, number of goblet cells and 
eosinophil tissue infiltrates. 
5.3.3.5.1 Descriptive analysis 
Lung samples recovered from Vero E6 cell lysate or UV-RSV (histology 
images not shown) inoculated mice treated with saline (Figure 5.11 A (i and ii) 
were characterised by clear alveoli (square) and absence of inflammatory 
infiltrates around bronchioles and blood vessels. In contrast, five days post RSV 
inoculation saline treated group (Figure 5.11 A (iii and iv) lung samples showed 
signs of inflammatory response characterised by parenchymal pneumonia 
(square), airway mucus occlusion (arrow head) and extensive infiltration 
dominated by an excess of lymphocytes and macrophages surrounding both 
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bronchioles (thin arrow) and pulmonary blood vessels (thick arrow). The arrow 
heads indicate airways occlusion and the circles show the presence of goblet 
cells within bronchi. HS 230 (negative HS control) treatment of Vero E6 cell 
lysate inoculated mice resulted in minimal parenchymal pneumonia (square) 
and mild inflammatory infiltrates present around bronchioles (thin arrows) and 
blood vessels (thick arrow). However, treatment with HS 254 (positive HS 
control) of Vero E6 cell lysate inoculated mice showed no signs of parenchymal 
pneumonia (square) or inflammatory infiltrates around bronchioles (thin arrows) 
or blood vessels (thick arrow). Treatment with HS compounds, HS 228, HS 259, 
HS 267 and HS 424 of Vero E6 cell lysate inoculated mice was characterised 
by minimal parenchymal pneumonia (square) and mild infiltration dominated by 
lymphocytes and macrophages surrounding both, bronchioles (thin arrows) and 
pulmonary blood vessels (thick arrows) (Figure 5.11 D, E, F and G (i and ii)). 
Treatment with compound HS 230 (negative HS control) of RSV 
inoculated mice (Figure 5.11 B (iii and iv)) induced medium parenchymal 
pneumonia (square) and airway occlusion (arrow head) with goblet cells present 
within bronchioles (circle). However, treatment of RSV inoculated mice with 
compound 254 (positive HS control) was characterised by mild-medium 
parenchyma, mild airway mucus occlusion, moderate perivascular (thick 
arrows) and peribronchiolar infiltrates (thin arrows) (Figure 5.11 C (iii and iv)). 
Treatment of RSV inoculated mice with compound 228 was also characterised 
by mild-moderate parenchyma (square), mild airway mucus occlusion (arrow 
head) with the presence of several goblet cells (circle), moderate perivascular 
infiltrates (thick arrows) and moderate peribronchiolar infiltrates (thin arrows) 
(Figure 5.11 D (iii and iv)). Finally, treatment with compounds HS 259, HS 267 
and HS 424 of RSV inoculated mice (Figure 5.11 B (iii and iv)) resulted in 
moderate parenchymal pneumonia (square) and airway occlusion (arrow head) 
with goblet cells present within bronchioles (circle) and moderate perivascular 
(thick arrows) and peribronchiolar infiltrates (thin arrows). 
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Figure 5.11. Effect of heparan sulfate (HS) treatment on respiratory 
syncytial virus (RSV) infected mice lung histology 
Wild type (WT) BALB/c mice were infected intranasally with Vera E6 cell lysate (i and ii) or RSV 
(5 X 105 plaque forming units (pfu)/mouse) on day 0 (iii and iv). On days 14, mice received daily 
treatment of saline (A) or HS mimetics: 230 (negative HS control) (B), 254 (positive HS control) 
(C), 228 (D), 259 (E), 267 (F) and 424 (G) at 10 mg/mL/kg concentration by intraperitoneal 
injections (100 |JL). Lungs were collected on day 5 and processed for histology using periodic 
acid Schiff (PAS) stain. Arrows, squares and circles indicate the different signs of inflammation in 
mice as described in the text. Magnification (i and ii) was 100X and (iii and iv) 400X including the 
eyepiece. Images are representative of each group (n = 5). 
5.3.3.5.2 Numerical (score) analysis 
No significant difference was observed between negative control and 
UV-RSV (histology images not shown) inoculated groups treated with saline 
(additional negative control) (Figure 5.12), in terms of scores allocated to airway 
mucus occlusion (A), peribronchial infiltrates (C), quality of peribronchial 
infiltrates (D), perivascular infiltrates (E), goblet cell count (G) and eosinophil 
tissue infiltrates (H). The only difference found between these two groups was 
that UV-RSV inoculated groups treated with saline had greater parenchymal 
pneumonia (p < 0.05) and combined HPS score (p < 0.0001) compared to Vero 
E6 cell lysate Inoculated group treated with saline (Figure 5.12 B and F). 
Saline treatment of RSV inoculated groups resulted in a significant 
increase in scores (p < 0.05) allocated to all eight assessed measurements 
(Figure 5.12, A-H) compared to the negative control. Similarly, treatment of 
Vero E6 cell lysate inoculated group with HS 230 (negative HS control), induced 
a significant increase (p < 0.005) in airway occlusion (A), parenchymal 
pneumonia (B) and combined HPS score (F) when compared to the negative 
control, however, no change was observed for peribronchial infiltrates (C), 
quality of peribronchial infiltrates (D), perivascular infiltrates (E), goblet cell 
count (G) and eosinophil tissue infiltrates (H) (Figure 5.12). In addition, 
treatment of Vero E6 cell lysate inoculated group with HS 254 (positive HS 
control), has induced significant increase (p < 0.05) in airway occlusion (A), 
peribronchial infiltrates (C), quality of peribronchial infiltrates (D) and combined 
HPS score (F) compared to the negative control; while no change was observed 
for parenchymal pneumonia (B), perivascular infiltrates (E), goblet cell count (G) 
and eosinophil tissue infiltrates (H) following HS 254 treatment of the Vero E6 
cell lysate inoculated group compared to negative control (Figure 5.12). 
Furthermore, treatment of Vero E6 cell lysate inoculated groups with HS 
259, HS 267 or HS 424 resulted in an increase (p < 0.05) in airway occlusion 
(A), parenchymal pneumonia (B) (for HS 228 as well), peribronchial infiltrates 
(C) and quality of peribronchial infiltrates (D) compared to the negative control 
(Figure 5.12). Treatment with HS 228 of Vero E6 cell lysate inoculated groups 
showed no difference in airway occlusion (A), peribronchial infiltrates (C) and 
quality of peribronchial infiltrates (D) compared to the negative control. Also, 
treatment with compounds HS 259, HS 267 or HS 424 of Vero E6 cell lysate 
inoculated groups showed greater (p < 0.0001) combined HPS (5-7 out of 17) 
compared to the negative control (1 out of 17) (Figure 5.12 F). Treatment with of 
Vero E6 cell lysate inoculated groups with HS 228 showed no difference in 
combined HPS (score out of 17) compared to the negative control. There was 
no significant difference in goblet cell count following the HS (applies to all six 
HS mimetics) treatment of Vero E6 cell lysate compared to the negative control. 
Treatment with HS 267 and HS 424 of Vero E6 cell lysate inoculated groups 
induced an increase (p < 0.05) in eosinophil tissue infiltrates compared to the 
negative control (Figure 5.12 H). 
Treatment of RSV inoculated groups with HS 230 (negative HS control) 
resulted In an increase (p < 0.05) in airway mucus occlusion (A), peribronchial 
infiltrates (C), quality of peribronchial infiltrates (D) and perivascular infiltrates 
(E) compared to HS 230 treated Vero E6 cell lysate inoculated groups (Figure 
5.12). Parenchymal pneumonia score remained the same following treatment of 
RSV inoculated groups with HS 230 (negative HS control) compared to HS 230 
treated Vero E6 cell lysate inoculated group (Figure 5.12 B). Treatment of RSV 
inoculated group with HS 254 induced no change in airway mucus occlusion 
compared to HS 254 treated Vero E6 cell lysate inoculated groups; while 
parenchymal pneumonia (B), peribronchial infiltrates (C), quality of peribronchial 
infiltrates (D) and perivascular infiltrates (E) scores increased (p < 0.05) 
following treatment of RSV inoculated groups with HS 254 (positive HS control) 
compared to HS 254 treated Vero E6 cell lysate inoculated group (Figure 5.12). 
In contrast, treatment of RSV inoculated groups HS 228 and HS 259 has 
resulted in an increase (p < 0.05) in airway mucus occlusion compared to the 
corresponding HS treated Vero E6 cell lysate inoculated groups (Figure 5.12 A). 
However, treatment with HS 267 and HS 424 induced no change in airway 
mucus occlusion compared to the corresponding HS treated Vero E6 cell lysate 
inoculated groups. Parenchymal pneumonia score (B), peribronchial infiltrates 
(C), quality of peribronchial infiltrates (D) and perivascular infiltrates (E) only 
increased (p < 0.05) following the treatment of RSV inoculated groups with HS 
228 while these remained unchanged following the treatment of RSV inoculated 
groups with HS 259, HS 267 and HS 424 compared to the corresponding HS 
treated Vero E6 cell lysate inoculated groups (Figure 5.12). HS treatment of 
(except for HS 424) RSV inoculated groups induced an increase (p < 0.0001) in 
the HPS combined score compared to the corresponding MS treated Vero E6 
cell lysate inoculated group. In contrast, treatment with HS 424 of RSV 
inoculated groups had resulted in a reduced (p < 0.0001) combined HPS score 
compare to the HS 424 treated Vero E6 cell lysate inoculated group (Figure 
5.12 F). Goblet cell count increased (p < 0.05) following the treatment of RSV 
inoculated groups with HS 228 and HS 259 compared to corresponding HS 
treated Vero E6 cell lysate inoculated groups (Figure 5.12 G). However, goblet 
cell count remained unchanged following the treatment of RSV inoculated 
groups with HS 267 compared to HS 267 treated Vero E6 cell lysate inoculated 
group. Treatment of RSV inoculated group with HS 424 has resulted in a 
decrease (p < 0.05) in a number of goblet cells compared to its corresponding 
HS treated Vero E6 cell lysate inoculated group (Figure 5.12 G). Treatment of 
RSV inoculated group with HS mimetics had no effect on eosinophil tissue 
infiltration compared to the corresponding HS treated Vero E6 cell lysate 
inoculated group (Figure 5.12 H). 
Treatment with HS 230 of RSV inoculated group resulted in no effect on 
any of the eight pathological measurements compared to the positive control. 
Treatment of RSV inoculated group with HS 424 resulted in a decrease (p < 
0.05) in parenchymal pneumonia (B), quality of peribronchial infiltrates (D) and 
combined HPS score (F) compared to the positive control (Figure 5.12). 
Treatment with compounds HS 254 (positive HS control), HS 259, HS 267 or 
HS 424 of RSV inoculated groups showed lower (p < 0.0001 combined 
histopathological score (5-9 out of 17) compared to saline treated RSV 
inoculated control (positive control) (11 out of 17). In contrast, treatment of RSV 
inoculated group with HS 228 did not reduce combined HPS score compared to 
the positive control (11 out of 17). Additionally, treatment of RSV inoculated 
group with HS 254 (positive HS control) resulted in a reduction (p < 0.05) of 
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F igure 5 .12 . H i s t o p a t h o l o g i c a l s c o r e ( H P S ) a s s e s s m e n t of m ice lungs 
f o l l o w i n g h e p a r a n su l fa te ( H S ) m i m e t i c s t r e a t m e n t of resp i ra tory syncyt ia l 
v i rus ( R S V ) in fect ion 
Wild type BALB/c mice were inoculated with either Vero E6 lysate (white bar), ultraviolet-
inactivated RSV (UV-RSV) (grey bar) or RSV (black bar) and then treated with saline or HS 
mimetics (228, 230, 254, 259, 267 or 424). On day 5 post inoculation, lungs were collected and 
processed for histopathology. Lungs were analysed for: A) Airways mucus occlusion, B) 
Parenchymal pneumonia, C) Peribronchial infiltrates, D) Quality of peribronchial infiltrates, E) 
Perivascular infiltrates, F) Combined HPS and G) Goblet cell count. Data are represented as 
mean (n = 5) ± standard deviation. HS 230 (negative) and HS 254 (positive) were used as HS 
mimetic controls. Data were analysed using ONE-way ANOVA with Tukey's multiple comparison 
test (GraphPad Prism) (*, p < 0.05, p < 0.005, p < 0.001 and p < 0.0001 compared to 
Vero E6 cell lysate inoculated and saline treated group (negative control); #, p < 0.05 and ####, p 
< 0.0001 compared to RSV inoculated, saline treated group; +, p < 0.05, ++, p < 0.005, +++, p < 
0.001 and ++++, p < 0.0001 compared to corresponding Vero E6 cell lysate inoculated HS 
treated group). 
5.3.4 Prophylactic HS treatment of RSV infection in 
vivo 
5.3.4.1 Weight and RS V clinical scores 
There were no significant changes in weights for Vero E6 cell lysate 
(negative control), UV-RSV (additional negative control) or RSV inoculated mice 
(data not shown). RSV inoculated mice showed signs of RSV infection as 
described in the section 2.12.2 (RSV clinical scores); reaching a maximum 
score of 4. There was no significant difference in the clinical scores recorded for 
Vero E6 cell lysate, UV-RSV or RSV inoculated HS treated groups (data not 
shown). 
5.3.4.2 Effect of HS prophylactic treatment on viral titres 
following RSV infection In vivo 
No viral titres were recovered following the RSV immunohistochemistry 
plaque assay analysis of Vero E6 cell lysate (negative control-data not shown) 
or UV-RSV (additional negative control-data not shown) inoculated lung 
samples treated with saline. Treatment of RSV inoculated groups with HS 230 
(negative HS control) and 254 (positive HS control) did not inhibit RSV infection 
compared to saline treatment of RSV inoculated groups (positive control) 
(Figure 5.13). Prophylactic treatment of the RSV inoculated group with HS 228 
(carboxyl reduced mucosal heparin), HS 259 (fucoidan), HS 267 (lambda 
carrageenan (200kDa) or HS 424 (mucosal heparin with glycol split (3kDa) 
induced a significant reduction (p < 0.05) in RSV titres compared to the positive 
control (Figure 5.13). Treatment of RSV inoculated group with compounds HS 
228, HS 259, HS 267 and HS 424 also inhibited RSV infection significantly (p < 
0.05) compared to the treatment of RSV inoculated group with HS 230 
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Figure 5.13. Prophylactic lieparan sulfate (HS) treatment of respiratory 
syncytial virus (RSV) infection induced reduction in titres in vivo 
Starting 48 hours prior to intranasal inoculation and continuing daily for 4 days after, wild type 
BALB/c mice received treatment with saline or HS mimetics (228, 230, 254, 259, 267 and 424) at 
10 mg/mUkg concentration by intraperitoneal injections (100 pL). On day 0, mice were infected 
by intranasal inoculation with RSV (black bar) (5 x 10^ plaque forming units (pfu)/mouse). On day 
5, mice were euthanised and samples collected. Titres are represented as pfu/gram of lung 
tissue. Data are represented as mean (n = 5) ± standard deviation. HS 230 (negative) (white bar) 
and 254 (positive) (light grey bar) used HS mimetic controls. Data were analysed using a ONE-
way ANOVA with Tukey's multiple comparison test (GraphPad Prism). 
5.3.4.3 Leukocyte population in a bronchoaiveolar iavage fiuid 
(BALF) 
Analysis of the leukocyte population present in BALF revealed a 
significantly lower (7.5 x 10" macrophages/mL of BALF) number of 
macrophages present in BALF, following the Vero E6 cell lysate (negative 
control) or UV-RSV (additional negative control) inoculation of saline treated 
groups when compared to the RSV inoculated and saline treated group (21 x 
10" macrophages/mL of BALF) (p < 0.0001) (Figure 5.14 A). Treatment of the 
Vero E6 cell lysate inoculated groups with HS 230 (negative HS control) or HS 
254 (positive HS control) induced no change in the number of macrophages 
present in BALF compared to negative control. Treatment of Vero E6 cell lysate 
inoculated groups with HS 228 or HS 267 also induced no change in a number 
of macrophages compared to the negative control. However, reduction in 
macrophage numbers present in BALF was observed following treatment of 
Vero E6 cell lysate inoculated groups with HS 259 (p < 0.0001) compared to 
negative control. In contrast, treatment of Vero E6 cell lysate inoculated group 
with HS 424 resulted in significant increase in macrophages present in BALF (p 
< 0.0001) compared to negative control (Figure 5.14 A). Interestingly, treatment 
of RSV inoculated group with HS 230 (negative HS control) or HS 254 (positive 
HS control) induced an increase in a number of macrophages (p < 0.001) 
compared to the corresponding HS treated Vero E6 cell lysate inoculated 
groups (Figure 5.14 A). Also, treatment of RSV inoculated groups with HS 228 
or HS 267 resulted in an increase (p < 0.0001) in the number of macrophages 
compared to the corresponding HS treated Vero E6 cell lysate inoculated 
groups. In contrast, treatment of RSV inoculated group with HS 259 did not 
induce a change in macrophage numbers while treatment of RSV inoculated 
group with HS 424 induced a decrease (p < 0.0001) in macrophage numbers in 
BALF compared to corresponding Vero E6 cell lysate inoculated controls 
(Figure 5.14 A). HS treatment of RSV inoculated group resulted in no change in 
macrophage numbers present in BALF compared to positive control. 
Lymphocyte BALF analysis revealed no difference in a number of 
lymphocytes present following Vero E6 cell lysate (negative control) or UV-RSV 
(additional negative control) inoculation of saline treated groups compared to 
the RSV inoculated and saline treated group (positive control) (Figure 5.14 B). 
In addition, treatment of Vera E6 cell lysate inoculated groups with any of the 
HS compounds: HS 230 (negative HS control), HS 254 (positive HS control), 
HS 228, HS 259, HS 267 or HS 424 resulted in no change in lymphocyte 
numbers compared to the negative control. Additionally, treatment of RSV 
inoculated groups with HS 230 (negative HS control), HS 254 (positive HS 
control), HS 259, HS 267 and HS 424 induced no change in lymphocyte 
numbers compared to both, positive control and corresponding HS treated Vero 
E6 cell lysate inoculated groups (Figure 5.14 B). Treatment of RSV inoculated 
groups with HS 228 induced an increase (p < 0.0001) in the number of 
lymphocyte infiltrates compared to both, positive control and corresponding HS 
228 treated Vero E6 cell lysate inoculated group (Figure 5.14 B). 
Saline treatment of Vero E6 (negative control) and UV-RSV (additional 
negative control) inoculation resulted in no change in eosinophil numbers 
compared to the saline treatment of RSV inoculated group (positive control) 
(Figure 5.14 C). Treatment of Vero E6 cell lysate inoculated groups with any HS 
mimetic compound (HS 230 (negative HS control), HS 254 (positive HS 
control), HS 228, HS 259, HS 267 or HS 424) did not induce change in 
eosinophil numbers present in BALF compared to negative controls. Treatment 
with HS 230 (negative HS control) of RSV inoculated groups also resulted in no 
change in the number of eosinophils in BALF compared to HS 230 treated 
group following Vero E6 cell lysate inoculation. In contrast, treatment of the 
RSV inoculated group with HS 254 (positive HS control) resulted in an increase 
(p < 0.005) in eosinophil numbers compared to the HS 254 treatment of the 
Vero E6 cell lysate inoculated group (Figure 5.14 C). Treatment of RSV 
inoculated groups with HS 228 and HS 424 resulted in a significant increase (p 
< 0.0001) in eosinophil numbers compared to both, corresponding HS treatment 
of RSV inoculated groups and positive controls (Figure 5.14 C). Treatment of 
RSV inoculated groups with HS 267 also induced an eosinophil influx (p < 0.05) 
compared to HS 267 treatment of RSV inoculated groups (Figure 5.14 
C).Treatment of RSV inoculated group with 259 did not induce any change to 
eosinophil numbers compared to positive controls (Figure 5.14 C). 
Furthermore, no significant difference in neutrophil numbers was 
observed between saline treatments of, Vero E6 cell lysate (negative control) or 
UV-RSV (additional negative control) inoculated groups (Figure 5.14 D). In 
addition, treatment of Vero E6 or UV-RSV inoculated group with HS mimetics 
(applies for all six tested HS mimetics) showed no significant difference in 
neutrophil numbers between groups. Positive control resulted in no change in 
neutrophil numbers present in BALF compared to the negative control. 
Treatment of Vero E6 cell lysate inoculated groups with HS 230 (negative HS 
control), HS 254 (positive HS control), HS 228, HS 259, HS 267 or HS 424 
resulted in no change in neutrophil numbers compared to negative control. In 
addition, treatment of RSV inoculated groups with HS 230 (negative HS 
control), HS 254 (positive HS control), HS 228, HS 259, HS 267 or HS 424 
resulted in no change in neutrophil numbers compared to positive control. 
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Figure 5.14. Differential leukocyte count in bronchoalveolar lavage fluid 
(BALF) following heparan sulfate (HS) prophylactic treatment of 
respiratory syncytial virus (RSV) infection in vivo 
Starting 48 hours prior to intranasal inoculation and continuing daily for 4 days after, wild type 
BALB/c mice received a treatment of saline or HS mimetics (228, 230, 254, 259, 267 and 424) at 
10 mg/mL/kg concentration by intraperitoneal injections (100 pL). Mice were infected with Vero 
E6 cell lysate (white bar), ultraviolet-inactivated RSV (UV-RSV) (grey bar) or RSV (black bar) (5 x 
105 plaque forming units (pfu)/mouse) on day 0. On day 5, mice were euthanised and BALF was 
collected by lavage with PBS. BALF was used for differential leukocyte counts though cytospin 
preparations. Following May-Grunwald and Giemsa staining of the BALF cytospins, leukocyte 
differential counts were performed using a light Nikon microscope and macrophage (A), 
lymphocyte (B), eosinophil (C) and neutrophil (D) counts were determined. Data are represented 
as mean (n = 5) ± standard deviation. HS compounds 230 (negative) and 254 (positive) were 
used as HS mimetic controls. Data were analysed using TWO-way ANOVA with Tukey's multiple 
comparison test (GraphPad Prism) (**", p < 0.0001 compared to Vero E6 cell lysate inoculated 
and saline treated group (negative control); mm, p < 0.0001 compared to RSV inoculated, saline 
treated group; +, p < 0.05, ++, p < 0.005, +++, p < 0.001 and ++++, p < 0.0001 compared to 
corresponding Vero E6 cell lysate inoculated HS treated group). 
5.3.4.4 Differential analysis of leukocyte population in blood 
Analysis of the leukocyte population present in blood revealed no change 
in the number of monocyte infiltrates present, following Vero E6 cell lysate 
(negative control) or UV-RSV (additional negative control) inoculation of saline 
treated groups compared to saline treatment of RSV inoculated group (positive 
control) (Figure 5.15 A). Treatment of Vero E6 cell lysate inoculated groups with 
HS 230 (negative HS control) or HS 254 (positive HS control) also induced no 
change in monocyte infiltrates in blood compared to the negative control. In 
addition, treatment of Vero E6 cell lysate inoculated groups with HS 228, HS 
259, HS 267 or HS 424 induced no change in monocyte infiltrates in blood 
compared to the negative control. Also, treatment of RSV inoculated groups 
with HS 230 (negative HS control) or HS 254 (positive HS control) induced no 
change in monocyte infiltrates in blood compared to both, the corresponding HS 
treatment of Vero E6 cell lysate inoculated groups and positive control. Finally, 
treatment of RSV inoculated groups with HS 228, HS 259, HS 267 or HS 424 
also induced no change in monocyte infiltrates in blood compared to both, the 
corresponding HS treatment of Vero E6 cell lysate inoculated groups and 
positive control. 
Lymphocyte blood analysis revealed no significant change in lymphocyte 
numbers following Vero E6 cell lysate (negative control) or UV-RSV (additional 
negative control) inoculation of saline treated groups compared to the positive 
control (Figure 5.15 B). However, treatment of Vero E6 cell lysate inoculated 
groups with HS 230 (negative HS control) or HS 254 (positive HS control) 
resulted in an increase (p < 0.0001) in lymphocyte numbers compared to the 
negative control. In addition, treatment of Vero E6 cell lysate inoculated groups 
with HS 228, HS 259, HS 267 and HS 424 induced an increase (p < 0.0001) in 
a number of lymphocytes compared to the negative control. On the contrary, 
treatment of RSV inoculated group with HS 230 (negative HS control) resulted 
in a decrease (p < 0.0001) in lymphocyte numbers compared to HS 230 
treatment of Vero E6 cell lysate inoculated groups. Treatment of RSV 
inoculated group with HS 254 (positive HS control) did not Induce any change to 
lymphocyte numbers present in blood compared HS 254 treatment of Vero E6 
cell lysate inoculated group. In contrast, treatment of RSV inoculated group with 
HS 228 resulted in a decrease (p < 0.0001) in lymphocyte numbers compared 
to HS 228 treatment of Vero E6 cell lysate inoculated groups. In addition, 
treatment of RSV inoculated group with HS 267 has resulted in an increase (p < 
0.0001) in lymphocyte numbers compared to the Vero E6 cell lysate inoculated 
group treated with HS 267. Treatment of RSV inoculated groups with HS 259 or 
HS 424 did not induce any change in lymphocyte numbers present in blood 
compared to the corresponding HS treatment of Vero E6 cell lysate inoculated 
groups (Figure 5.15 C). Finally, treatment with HS mimetics (HS 259, HS 267 
and HS 424) following RSV inoculation has resulted in an increase (p < 0.0001) 
in lymphocytes present in blood compared to the lymphocyte numbers 
recovered from the positive control samples. 
Vero E6 (negative control) and UV-RSV (additional negative control) 
inoculation of saline treated groups did not have any effect on eosinophil 
infiltrates into blood compared to the positive control (Figure 5.15 C). No 
change in eosinophil numbers were observed following HS 230 (negative HS 
control) or HS 254 (positive HS control) treatment of the Vero E6 cell lysate 
inoculated groups compared to the negative control. Treatment with all HS 
compounds (except HS 267) of Vero E6 cell lysate inoculated groups did not 
induce a change in eosinophil numbers compared to the negative control. In 
contrast, treatment of the Vero E6 cell lysate inoculated group with HS 267 has 
resulted in an increase (p < 0.0001) in eosinophil numbers compared to the 
negative control. HS 230 (negative HS control) or HS 254 (positive HS control) 
treatment of RSV inoculated groups did not have any effect on eosinophil 
numbers in blood compared to both, the corresponding HS treatment of Vero 
E6 cell lysate inoculated groups and positive control. Additionally, treatment 
with all HS compounds (except HS 267) of RSV inoculated groups did not 
induce a change in eosinophil numbers compared to both, corresponding HS 
treatment of Vero E6 cell lysate inoculated groups and positive control. Also, 
treatment of the RSV inoculated group with HS 267 resulted in higher (p < 
0.0001) eosinophil numbers compared to both, Vero E6 cell lysate inoculated 
group treated with HS 267 and positive control (Figure 5.15 C). 
Finally, no significant difference in neutrophil numbers was observed 
between saline treatments of, Vero E6 cell lysate (negative control) or UV-RSV 
(additional negative control) inoculated groups (Figure 5.15 D). In addition, 
treatment of Vero E6 or UV-RSV inoculated group with HS mimetics (applies for 
all six tested HS mimetics) showed no significant difference in neutrophil 
numbers between groups. Positive control resulted in no change in neutrophil 
numbers present in blood compared to the negative control. Treatment of Vero 
E6 cell lysate inoculated groups with HS 230 (negative HS control), HS 254 
(positive HS control), HS 228, HS 259, HS 267 or HS 424 resulted in no change 
in neutrophil numbers compared to negative control. In addition, treatment of 
RSV inoculated groups with HS 230 (negative HS control), HS 254 (positive HS 
control), HS 228, HS 259, HS 267 or HS 424 resulted in no change in neutrophil 
numbers compared to positive control. 
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Figure 5.15. Dif ferent ial leukocyte coun t in b lood fo l low ing heparan 
sul fate (HS) prophy lac t ic t reatment o f respi ra tory syncyt ia l v i rus (RSV) 
in fec t ion in vitro 
At 48 hours prior to intranasal inoculation and then dally for 4 days after, mice received a 
treatment with intraperitoneal injections (100 |JL) of saline or HS mimetics (228, 230, 254, 259, 
267 and 424) at 10 mg/mL/kg concentration. Wild type BALB/c mice were inoculated with Vero 
E6 cell lysate (white bar), ultraviolet-inactivated RSV (UV-RSV) (grey bar) or RSV (black bar) (5 x 
105 plaque forming units (pfu)/mouse) on day 0. On day 5, mice were euthanised and blood was 
collected by cardiac puncture. Differential leukocyte counts were done by light microscope 
(Nikon) analysis of May-Grunwald and Giemsa stained blood smears on glass slides. Monocyte 
(A), lymphocyte (B), eosinophil (C) and neutrophil (D) counts were determined. Data are 
represented as mean (n = 5) ± standard deviation. HS compounds 230 (negative) and 254 
(positive) were used as HS mimetic controls. Data were analysed using TWO-way ANOVA with 
Tukey's multiple comparison test (GraphPad Prism) (*"* , p < 0.0001 compared to Vero E6 cell 
lysate inoculated and saline treated group (negative control); mm, p < 0.0001 compared to RSV 
inoculated, saline treated group; ++++, p < 0.0001 compared to corresponding Vero E6 cell lysate 
inoculated HS treated group). 
5.3.4.5 Lung histopathology following prophylactic treatment 
of RSV infection with HS mimetics 
Treated (saline or HS) and inoculated (Vero E6 cell lysate (negative 
control), UV-RSV (additional negative control) or RSV) BALB/c mice lungs were 
assessed for airways mucus occlusion, degree of parenchymal pneumonia, 
peribronchial infiltrates, quality of peribronchial infiltrates, perivascular infiltrates, 
HPS, number of goblet cells and eosinophil tissue infiltrates. 
5.3.4.5.1 Descriptive analysis 
The lungs from Vero E6 cell lysate or UV-RSV (histology images not 
shown) inoculated groups treated with saline (Figure 5.16 A (i and ii)) were 
characterised by clear alveoli (square) and no inflammatory infiltrates present 
around bronchioles and blood vessels. In contrast, five days post RSV 
inoculation saline treated group (Figure 5.16 A (iii and iv) lungs showed signs of 
inflammatory response characterised by parenchymal pneumonia (square), 
ainways mucus occlusion (arrow head) and extensive infiltration. Infiltrates were 
dominated by lymphocytes and macrophages, which surrounded both 
bronchioles (thin arrow) and pulmonary blood vessels (thick arrow). The arrow 
heads indicates ainway occlusion and the circles show the presence of goblet 
cells within bronchi. HS 230 (negative HS control) treatment of Vero E6 cell 
lysate inoculated groups resulted in minimal parenchymal pneumonia (square) 
and mild inflammatory infiltrates present around bronchioles (thin arrows) and 
blood vessels (thick arrow) (Figure 5.16 B (i and ii)). Treatment with HS 254 of 
Vero E6 cell lysate inoculated groups showed no signs of parenchymal 
pneumonia (square), or inflammatory infiltrates around bronchioles (thin arrows) 
and blood vessels (thick arrow) (Figure 5.16 C (i and Ii)). Treatment with HS 
compounds, HS 228, HS 259, HS 267 and HS 424 of Vero E6 cell lysate 
inoculated mice was characterised by minimal parenchymal pneumonia 
(square) and mild infiltration dominated by lymphocytes and macrophages 
surrounding both, bronchioles (thin arrows) and pulmonary blood vessel 
infiltrates (thick arrows) (Figure 5.16 D, E, F and G (i and ii)). 
Treatment with compound HS 230 (negative HS control) of RSV 
inoculated groups (Figure 5.16 B (iii and iv)) induced moderate parenchymal 
pneumonia (square) and airways occlusion (arrow head) with goblet cells 
present within bronchioles (circle). Treatment with compound 254 (positive HS 
control) of RSV inoculated group was characterised by mild-moderate 
parenchyma, mild airway mucus occlusion, moderate perivascular (thick 
arrows) and peribronchial infiltrates (thin arrows) (Figure 5.16 C (iii and iv)). 
Treatment with compound HS 228 of RSV inoculated group was also 
characterised by mild-moderate parenchyma (square), mild airway mucus 
occlusion (arrow head) with several goblet cells present (circle), moderate 
perivascular (thick arrows) and peribronchial infiltrates (thin arrows) (Figure 5.16 
D (iii and iv)). Finally, treatment with compounds HS 259, HS 267 and HS 424 
of RSV inoculated group (Figure 5.16 B (iii and iv)) resulted in moderate 
parenchymal pneumonia (square) and airway occlusion (arrow head) with 
goblet cells present within bronchioles (circle), as well as, moderate 
perivascular (thick arrows) and pehbronchial infiltrates (thin arrows). 
Vero EG cell lysate RSV 
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Figure 5.16. Effect of prophylactic heparan sulfate (HS) treatment on 
respiratory syncytial virus (RSV) infected mouse lung histology 
Starting 48 hours prior to intranasal inoculation and continuing daily for 4 days after, wild type 
BALB/c mice received a treatment of saline (A) or HS mimetics: 230 (negative HS control) (B), 
254 (positive HS control) (C), 228 (D), 259 (E), 267 (F) and 424 (G) at 10 mg/mL/kg concentration 
by intraperitoneal injections (100 |JL). Mice were infected with Vero E6 cell lysate (i and ii) or RSV 
(5 X IQs plaque forming units (pfu)/mouse) on day 0 (iii and iv). Lungs were collected on day 5 
and processed for histology using periodic acid Schiff (PAS) stain. Arrows, squares and circles 
indicate the different signs of inflammation in mice as described in the text. Magnification (i and ii) 
was 100X and (iii and iv) 400X including the eyepiece. Images are representative of each group 
(n = 5). 
5.3.4.5.2 Numerical (score) analysis 
No difference between Vero E6 cell lysate inoculated saline treated 
(negative control) and UV-RSV (additional negative control-histology images not 
shown) saline treated (additional negative control) (Figure 5.17) groups were 
observed in terms of scores allocated to airway mucus occlusion (A), 
peribronchial infiltrates (C), quality of peribronchial infiltrates (D), perivascular 
infiltrates (E), goblet cell count (G) or eosinophil tissue infiltrates (H). The only 
difference found between these two groups was that the UV-RSV inoculated 
saline treated group had greater parenchymal pneumonia (p < 0.05) and 
combined HPS score (p < 0.0001) compared negative controls (Figure 5.17 B 
and F). Saline treatment of RSV inoculated groups (positive control) induced a 
significant increase in (p < 0.05) ainway occlusion (A), parenchymal pneumonia 
(B), peribronchial infiltrates (C), quality of peribronchial infiltrates (D), 
perivascular infiltrates (E) and combined HPS score (F) compared to the 
negative controls (Figure 5.17, A-F). In addition, treatment of Vero E6 cell lysate 
inoculated group with HS 230 (negative HS control) or HS 254 (positive HS 
control) induced a significant increase (p < 0.05) in airway occlusion (A), 
parenchymal pneumonia (B), pehbronchial infiltrates (C), quality of peribronchial 
infiltrates (D) and combined HPS score (F) compared to the negative control. 
However, no change was observed for perivascular infiltrates (E), goblet cell 
count (G) and eosinophil tissue infiltrates (H) following HS 230 or HS 254 
treatment of the Vero E6 cell lysate inoculated group compared to the negative 
control (Figure 5.17). 
Treatment of Vero E6 cell lysate inoculated groups with HS 228, HS 259, 
HS 267 or HS 424 resulted in a significant increase (p < 0.001) in ainway mucus 
occlusion compared to the negative control (Figure 5.17 A). Treatment of Vero 
E6 cell lysate inoculated groups with HS 228, HS 259, HS 267 and HS 424 
resulted in a significant increase (p < 0.005) in parenchymal pneumonia score 
compared to negative control (Figure 5.17 B). Additionally, treatment of Vero E6 
cell lysate inoculated groups with HS 228, HS 267 and HS 424 resulted in an 
increase (p < 0.005) in peribronchial infiltrates compared to negative controls 
(Figure 5.17 C). Treatment of Vero E6 cell lysate inoculated groups with HS 
228, HS 259, HS 267 and HS 424 resulted in an Increase (p < 0.05) in quality of 
peribronchial infiltrates compared to negative control (Figure 5.17 D). In 
contrast, treatment of Vero E6 cell lysate inoculated groups with HS 228, HS 
259, HS 267 and HS 424 did not induce any change to perivascular infiltrates 
compared to negative controls (Figure 5.17 E). Treatment with compounds HS 
228, HS 259, HS 267 and HS 424 of Vero E6 cell lysate inoculated groups had 
greater (p < 0.0001) combined HPS (score out of 17) compared to negative 
control (Figure 5.17 F). There was no change in goblet cell count and eosinophil 
tissue Infiltrates following HS treatment of Vero E6 cell lysate Inoculated groups 
compared to negative control. 
Treatment of RSV inoculated groups with HS 230 (negative HS control) 
or 254 (positive HS control) did not induce change to any of the eight 
histopathological measurements assessed in this study compared to the 
corresponding HS treatment of Vero E6 cell lysate inoculated groups. 
Additionally, RSV inoculation of HS (HS 228, HS 259, HS 267 or HS 424) 
treated groups did not have any effect on ainway mucus occlusion compared to 
the corresponding HS treatment of Vero E6 cell lysate inoculated groups. RSV 
inoculation of HS 228, HS 259 and HS 424 treated groups also did not have any 
effect on parenchymal pneumonia compared to the corresponding HS treatment 
of Vero E6 cell lysate inoculated groups. However, RSV inoculation of HS 267 
treated groups has exacerbated (p < 0.001) parenchymal pneumonia compared 
to HS 267 treatment of Vero E6 cell lysate inoculated group. RSV inoculation of 
HS 228 and HS 424 treated groups did not have any effect on peribronchial 
infiltration compared to the corresponding HS treatment of Vero E6 cell lysate 
inoculated groups. However, RSV inoculation of HS 259 and HS 267 treated 
groups has induced an increase (p < 0.05) in peribronchial infiltrate numbers 
compared to the corresponding HS treatment of Vero E6 cell lysate inoculated 
groups. RSV inoculation of HS 228, HS 267 and HS 424 treated groups did not 
have any additional effect on quality of peribronchial infiltration compared to the 
corresponding HS treatment of Vero E6 cell lysate inoculated groups. However, 
RSV inoculation of HS 259 treated groups has resulted in an increase (p < 0.05) 
in quality of peribronchial infiltration compared to the corresponding HS 
treatment of Vero E6 cell lysate inoculated groups. RSV inoculation of HS 228, 
HS 267 and HS 424 treated groups did not have any effect on perivascular 
infiltration compared to the corresponding HS treatment of Vero E6 cell lysate 
inoculated groups. However, RSV inoculation of HS 259 treated groups has 
induced (p < 0.05) perivascular infiltration compared to the corresponding HS 
treatment of Vero E6 cell lysate inoculated groups. Also, treatment with 
compounds HS 254, HS 259, HS 267 and HS 424 of RSV inoculated groups 
induced an increase (p < 0.0001) in combined HPS compared to the 
corresponding HS treated Vero E6 cell lysate inoculated groups. However, 
there was no change in goblet cell count following HS treatment (except HS 
254) of RSV inoculated groups compared to corresponding HS treatment of 
Vero E6 cell lysate inoculated groups. Treatment of RSV inoculated group with 
HS 254 (positive HS control) resulted in an increase (p < 0.0001) in goblet cell 
count compared to the HS 254 treated Vero E6 cell lysate inoculated group 
(Figure 5.17 G). However, there was no change in eosinophil tissue influx 
following HS treatment of RSV inoculated groups compared to corresponding 
HS treatment of Vero E6 cell lysate inoculated groups. 
Finally, treatment of RSV inoculated groups with HS mimetics (HS 228, 
HS 259, HS 267 or HS 424) did not have any additional effect on airway mucus 
occlusion (A), parenchymal pneumonia (B), peribronchial infiltration (C), quality 
of peribronchial infiltrates (D), perivascular infiltrates (E), goblet cell count (G) 
and eosinophil tissue infiltrates (H) compared to the positive control. All HS 
treated (except for HS 267) RSV inoculated groups showed no change in HPS 
combined score compared to the saline treatment of RSV inoculated group 
(positive control). In contrast, treatment with HS 267 of RSV inoculated groups 
resulted in an increase (p < 0.0001) in combined HPS score compare to the 
positive control (Figure 5.17 F). 
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Figure 5.17. Histopathological score (HPS) assessment of mice lungs 
following prophylactic heparan sulfate (HS) mimetics treatment of 
respiratory synovial virus (RSV) infection 
Starting 48 hours prior to intranasal inoculation and continuing daily for 4 days after, wild type 
BALB/c mice received a treatment with saline or HS mimetics (228, 230, 254, 259, 267 or 424) at 
10 mg/mL/kg concentration by intraperitoneal injections (100 |JL). Mice were Inoculated with Vero 
E6 lysate (white bar), ultraviolet-inactivated RSV (UV-RSV) (grey bar) or RSV (black bar) on day 
0. On day 5 post inoculation, lungs were collected and processed for histopathology. Lungs were 
analysed for: A) airway mucus occlusion, B) parenchymal pneumonia, C) peribronchial infiltrates, 
D) quality of peribronchial infiltrates, E) perivascular infiltrates, F) combined HPS, G) goblet cell 
count and H) eosinophil tissue infiltrates. Data are represented as mean (n = 5) ± standard 
deviation. HS compounds 230 (negative) and 254 (positive) were used as HS mimetic controls. 
Data were analysed using ONE-way ANOVA with Tukey's multiple comparison test (GraphPad 
Prism) (*, p < 0.05, p < 0.001 and p < 0.0001 compared to Vero E6 cell lysate inoculated 
and saline treated group (negative control); +, p < 0.05, ++, p < 0.005, and ++++, p < 0.0001 
compared to corresponding Vero E6 cell lysate inoculated HS treated group). 
5.4 DISCUSSION 
While there is an ample of evidence demonstrating that the binding of 
RSV to cultured cells involves an interaction between the viral envelope 
glycoproteins (G and F) and the cell surface HSPGs (Bourgeois et al., 1998; 
Escribano-Romero et al., 2004; Feldman et al., 2000; Feldman et al., 1999; 
Hallak et al., 2000a; Harris and Werling, 2003; Karger et a!., 2001; Krusat and 
Streckert, 1997; Martinez and Melero, 2000; Techaarpornkul et al., 2002), only 
recently has the cellular protein nucleolin been identified as a specific receptor 
for RSV (Tayyari et al., 2011). Tayyarl et al. (2001) proposed that RSV binds to 
the cell surface proteoglycans to allow the RSV fusion protein to interact with 
nucleolin (Tayyari et al., 2011). The interactions between the RSV and the cell 
surface HSPGs are required for the RSV attachment and entry into the host 
cell, and therefore, represent a valid target for the inhibition of RSV infection. 
An effective and inexpensive treatment against RSV is urgently required, 
especially since motavizumab, a variant of palivizumab, which was expected to 
replace palivizumab for the prevention of RSV infection in infants, was recently 
denied approval by the U.S. Food and Drug Administration (FDA) due to 
concerns about safety and allergic reactions (Donalisio et al., 2012). Currently, 
no vaccine for RSV is available as previous vaccine attempts have failed to 
elicit a long-lasting protective immune response (Castilow et al., 2008) and the 
approval of a new RSV vaccine is not expected before 2020 (Donalisio et al., 
2012). Considering the high burden of RSV disease worldwide on both the 
population and healthcare systems, further antiviral research and development 
is critical (Storey, 2010). 
A key limitation of previous studies examining the RSV interaction with 
GAGs is that all studies to date have been performed in vitro only. Therefore, a 
key focus of this chapter was to elucidate the role of HS mimetics in viral 
inhibition in vitro and in vivo, testing the anti-viral activity of 53 HS mimetics in 
vitro while facilitating the selection of 6 HS mimetics for in vivo testing. This 
extensive HS mimetics assessment included compounds from five, chemically 
and structurally different groups: group 1- heparins and modified heparins 
(12kDa), group 2- low molecular weight heparins (3kDa and 5kDa) and 
enoxaparin with/without glycol split, group 3- fucoidans and modified fucoidan, 
group 4- carrageenans and group 5- other HS compounds. 
It is important to note that HS compounds cytotoxicity on the Vera E6 
cells was the only cytotoxicity assay performed. As no cytotoxicity was detected 
following the HS mimetic incubation with Vero E6 cells, it was concluded that 
any changes observed in terms of viral load recovery would likely be due to HS 
effect on RSV viral load as opposed to the cell death in the presence of HS 
mimetics and RSV. In addition, positive infection control (RSV infected Vero E6 
cells with saline treatment) was used in all of the Chapter 5 experimental work. 
Therefore, all HS treated and RSV infected Vero E6 results were compared to 
the positive infection control. Furthermore, if there was any cell death due to 
RSV infection, it was taken into account by using the positive infection control 
and comparing all of RSV infected and HS treated samples to it. 
Following the incubation of RSV with HS mimetics in vitro for 10 minutes 
(condition A), 20 out of 53 tested HS mimetic compounds were found to induce 
80-100% RSV inhibition (p < 0.005); with 11 out of those 20 showing over 90% 
RSV inhibition (Figure 5.4). Findings from this study demonstrate HS mimetics 
antiviral potential against RSV. The best performing compound in this study was 
HS 267 (lambda carrageenan), achieving 100% (p < 0.0001) RSV inhibition at 
all three HS mimetic concentrations. These results are in agreement with 
previous studies reporting that pre-incubation of RSV with certain GAGs (e.g. 
heparin) inhibited virus infectivity (Krusat and Streckert, 1997; Martinez and 
Melero, 2000). The mechanism behind the viral inhibition exhibited by tested HS 
compounds could involve an interaction of HS mimetics with RSV glycoproteins 
(G or F) and the formation of an RSV glycoprotein-HS complex. This complex 
could inhibit RSV binding to the HS at the cell surface, resulting in a reduction of 
RSV cell infectivity. The proposed mechanism requires further investigation to 
elucidate the interaction between HS mimetics and RSV, providing a better 
understanding, which could be utilised in vaccine design. 
Furthermore, the hypothesis that HS mimetics may bind to the negatively 
charged sulfate and carboxyl groups of the GAG chains on the cell surface was 
tested by pre-incubating HS mimetics with Vero E6 cell monolayer for 10 
minutes (condition B). Findings indicate that 20 out of 53 tested HS mimetic 
compounds inhibited RSV infection at a rate of 80-100% (p < 0.0001) (Figure 
5.5). Moreover, six out of these 20 HS mimetics induced over 90% RSV 
inhibition following the pre-incubation of HS mimetics with the Vero E6 cell 
monolayer. The best performing compound under this testing condition was 
again HS 267 (lambda carrageenan), achieving 100% (p < 0.0001) RSV 
inhibition at all three HS mimetic concentrations. Previous studies examining 
the effect of HEp-2 cells pre-treatment with GAGs (condition B), prior to RSV 
inoculation, have also shown that this treatment approach results in reduced 
binding efficiency of RSV infection (Donalisio et a!., 2012; Donalisio et al., 2010; 
Hallak et al., 2000b). The efficacy of this treatment condition suggests the 
potential for the development of a specific and targeted RSV inhibiting 
therapeutic while rendering the GAGs unavailable for RSV glycoprotein binding. 
A short incubation of RSV with the Vero E6 cells (condition C), resulted 
in 21 out of 53 tested HS mimetic compounds inducing 80-95% RSV inhibition 
(Figure 5.6). Ten out of these 21 HS mimetics showed over 90% RSV inhibition. 
Results from this study suggest that HS mimetics may be able to compete with 
RSV for the HS interaction on the cell surface of the Vero E6 cells as long as 
RSV pre-incubation with the cell monolayer is kept to a very short period (e.g. 
10 minutes). A longer incubation period (1 hour - condition D) had detrimental 
effect on viral inhibition. Nevertheless, the best performing compound under 
condition C was HS 267 (lambda carrageenan), achieving 95% (p < 0.0001) 
RSV inhibition at 5 (jg/mL. Previous studies have shown that sulfated 
polysaccharides can mimic HS chains and interact with viral glycoproteins, 
blocking viral attachment to cell surface HS through competitive inhibition 
(Rusnati and Urbinati, 2009; RusnatI etal., 2009). Similarly, studies have shown 
SB105-A10 (peptide-derlvatised dentridimer) exerts antiviral activity by 
competing with glycoprotein G or F for binding to cell surface HS (Donalisio et 
al., 2012). Other studies have also shown that pre-incubatlon of RSV with 
heparin inhibited virus Infectivity (Krusat and Streckert, 1997; Martinez and 
Melero, 2000). 
Under the final testing condition, pre-incubation of RSV with the Vero E6 
cell monolayer for 1 hour (clinically the most relevant condition), resulted in 15 
out of 53 HS mimetic compounds inducing 50-90% RSV inhibition at 100 pg/mL 
(Figure 5.7). These results suggest the HS mimetics have an ability to compete 
with RSV for interaction with HS on the cell surface as well as reduce RSV 
replication by inhibiting cell-to-cell spread. The best performing compound 
under this condition was HS 424 (mucosal heparin with glycol split SkDa), 
achieving 65% (p < 0.0001) RSV inhibition at the highest HS concentration of 
100 |jg/mL. As sulfated polysaccharides have been studied extensively as 
broad-range antiviral compounds, some of them [e.g. heparin (Hallak et a!., 
2000b), chondroitin sulfate (Hallak et al., 2000a), and dextran sulfate (Kimura et 
at., 2004)] have already been shown to inhibit RSV successfully. To elucidate 
the mechanism underlying conditions C and D, more work is required to gain a 
better understanding of resulting competitive inhibition as well as potential ways 
to enhance HS efficacy while reducing cell-to-cell spread of the virus. Broader 
analysis should involve assessment of HS-RSV glycoprotein and HS-cell 
surface interactions, as these are part of an overarching HS driven RSV 
inhibition mechanism of competitive inhibition. 
Taken together, the in vitro HS mimetic studies have generated a list of 
compounds with great antiviral potential. The best performing compounds 
across all four conditions are outlined in Table 5.3 demonstrating compounds 
that achieved viral inhibition between 50-100%, depending on a testing 
condition. Furthermore, in vitro results demonstrate significant RSV inhibition 
achieved following a pre-treatment of the virus with HS mimetics, pre-treatment 
of the cells with HS mimetics and HS treatment of RSV infection. Results from 
chapter 5 in vitro studies are in an agreement with those of Hallak et ai. (2000) 
who reported that RSV infection was reduced significantly by pre-treatment of 
the virus with soluble GAGs, pre-treatment of the cells with GAG-binding 
molecules, pre-treatment of the cells with GAG-destroyIng enzymes or in cells 
genetically deficient in GAGs (Hallak et al., 2000a). Krusat and Streckert (1997) 
also showed that pre-incubation of virus with heparin, or enzymatic digestion of 
cell surface GAGs, inhibited virus infectivity. 
Table 5.3. List of the best performing heparan sulfate (HS) mimetics in vitro under four testing conditions, arranged in 
descending order, from most viral inhibition to least viral inhibition 
Condition A Condition B Condition C Condition D 
465, 466, 494, 495, 496, 497, 
502, 267, 500, 229, 266, 499, 
501,259, 511 A, 510,424, 498, 
511B, 512D, 416 
466, 495, 497, 500, 267, 494, 
499, 266, 511 A, 496, 229, 465, 
498, 502, 510, 259,416,5120, 
501 
266 
394, 419, 418,408, 106, 486, 
448, 384, 201,483,217, 481, 
218,254 
51 IB, 424, 419, 217, 486, 201 259,424 
204, 228, 109 106,218, 408,384, 448, 394, 418, 512E,481, 254 
254,408,267, 416, 481,494, 
242, 511A, 448, 512E, 418, 
511B, 384, 106, 419, 483, 241, 
510, 333, 332 
512E, 331,PI-88, 205,207, 81, 
332 109, 204, 228, PI-88, 483 
81, 486, 238, 502, 394, 217, 
496, 495, 465, 331, 51D, 201 424 















The best performing compounds list across four testing conditions: A (respiratory syncytial virus (RSV) 10 minute pre-lncubation witti HS), B (HS mimetic 10 
minute pre-incubation with cell surface), C (short RSV pre-incubation with cell surface) and D (1 hour RSV pre-incubation with cell surface). Colours denote 
different degrees of inhibition, in 10% increments, from 50-100%. 
An analysis of the large data set generated from the in vitro HS mimetic 
revealed a novel trend emerging. In vitro studies showed that all group 3 
(fucoidans and modified fucoidan) and group 4 (carrageenans) HS mimetic 
compounds induced over 80% RSV inhibition under conditions A (RSV 10 
minute pre-incubation with HS) and B (HS mimetic 10 minute pre-incubation 
with cell surface) (Table 5.4), demonstrating a potential Involvement of these 
compounds at earlier stages of viral infection, e.g. attachment. These findings 
suggest that group 3 (fucoidans and modified fucoidan) and group 4 
(carrageenans) may be good candidates for prophylactic RSV treatment. In 
addition, as demonstrated previously, there was a significant difference in viral 
inhibition observed following a short and long RSV incubation with the cell 
monolayer. Keeping these results in mind, the most effective HS mimetic group 
under condition D (1 hour RSV pre-incubation with cell surface; the most 
clinically relevant condition) was group 2 (low molecular weight heparins (3kDa 
and 5kDa) and enoxaparin with/without glycol split) followed by group 1 
(heparins and modified heparins (12kDa). This finding indicates the importance 
of heparin modified compounds in RSV competitive inhibition while also 
highlighting the potential importance of HS mimetic size (3 or 12kDa) in 
successful viral inhibition. Although, almost all HS mimetics in group 3 and 
group 4 performed the best under conditions. A, B and C, these groups 
performed poorly under condition D. Results suggest that groups 1 and 2 are 
the most suited for competitive RSV inhibition and cell-to-cell spread, while 
groups 3 and 4 are the best suited to inhibit RSV by interacting with the cell 
surface HS and RSV glycoproteins. The proposed and arising trends should be 
investigated further with some HS compounds showing a great potential for 
prophylactic treatment while others appear to be the best suited for post RSV 
infection treatment. 
Table 5.4. The average respiratory syncyt ia l v i rus (RSV) inhibi t ion across 
f ive heparan sulfate (HS) mimet ic groups 
Percentage of HS compounds that achieved an average RSV 











Group 1 63.6 27.3 81.8 36.4 
Group 2 61.5 38.5 92.3 53.8 
Group 3 100.0 100.0 85.7 14.3 
Group 4 100.0 100.0 100.0 20.0 
Group 5 47.1 41.2 76.5 23.5 
Five HS mimetic groups: group 1- heparins and modified heparins (12l<Da), group 2- low 
molecular weight heparins (3kDa and 5kDa) and enoxaparin with/without glycol split, group 3-
fucoidans and modified fucoidan, group 4- carrageenans, and group 5-other HS compounds. 
Four testing condition in vitro: Conditions A (RSV 10 minute pre-incubation with HS), B (HS 
mimetic 10 minute pre-incubation with cell surface), C (short RSV pre-incubation with cell 
surface) and D (1 hour RSV pre-incubation with cell surface). Data is represented as an average 
RSV inhibition and expressed in percentages. Average RSV inhibition differed across the four test 
conditions; hence, data presented for condition A is above 80%, condition B above 80%, 
condition C above 50% and condition D above 50%. 
It is important to note that some HS compounds performed best at the 
highest (100 pg/mL) and/or lowest (5 pg/mL) HS concentrations, whilst other 
were unaffected by the change in HS concentration (Figures 5.4-5.7). 
Unexpectedly, in vitro study analysis revealed that 10 out of 53 tested HS 
compounds achieved an average of 65-90% RSV inhibition across the four test 
conditions at the lowest, 5 pg/mL, HS concentration. Similar findings were also 
observed following amantadine antiviral treatment of influenza A virus, which 
blocks the influenza A M2 protein ion channels (Jefferson et a!., 2004). The 
proton channel formed by M2 protein, transports protons from the endosome to 
the inside of the influenza A virion (Hay etal., 1985; Pinto etal., 1992; Wang et 
a!., 1993). As a weakly basic substance, amantadine binds protons in the 
endosome itself, thereby making them impossible to flow inside the virion. This 
way, both the interaction of the matrix M1 protein and release of the virion 
nucleus into the host cell environment, are prevented (Hay etal., 1985; Pinto et 
al., 1992; Wang et al., 1993). This process has been found to be the most 
effective at lower concentrations of amantadine (e.g. 1 |jg/mL) (Nguyen et a!., 
2009). In contrast, high concentrations of amantadine are believed to contribute 
to enhanced viral replication, with amantadine, itself, becoming a source of 
protons, leading to an increase in proton flow towards the virion while enabling 
viral uncoating and viral replication (Nguyen etal., 2009; Nguyen etal., 2012). 
A similar mechanism may be behind HS-induced RSV inhibition at low 
HS concentrations. However, until recently, none of the RSV glycoproteins were 
known as a proton-selective ion channel proteins; which is a main characteristic 
of influenza A M2 protein. The role played by SH protein during RSV infection is 
still unknown and SH ion channel potential was not Investigated until few years 
ago. Gan et al. (2008) have provided experimental evidence that the 
transmembrane domain of SH protein forms pentameric a-helical bundles that 
form cation-selective ion channels in planar lipid bilayers (Gan et al., 2008). 
This suggests that SH may act as a proton-selective ion channel protein, 
transporting protons from the outside to the inside of the RSV virion. At low 
concentrations, HS mimetics could bind protons while inside the SH-proton 
channel, thereby making it impossible for protons to flow inside the virion. As a 
result, RSV uncoating would be blocked and viral replication would be inhibited 
(Figure 5.18). In contrast, in some instances high concentrations of HS 
mimetics have resulted in enhanced viral replication in vitro. This finding could 
be a result of HS mimetics acting as protons themselves at high concentrations, 
with an increase in proton flow towards the virion enabling viral uncoating and 
viral replication. This study highlights the importance of dose dependant viral 
inhibition and the need to evaluate a range of concentrations, including lower 
concentrations. Drugs performing well at lower concentrations have the 
potential to control tissue toxicity and any drug related side effects; much 
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Figure 5.18. Proposed mechanism of heparan sulfate (HS) mimetics 
induced inhibition of respiratory syncytial virus (RSV) replication at low 
HS concentration 
RSV small hydrophobic (SH) protein acts as a proton-selective ion channel protein, transporting 
protons (H+) to the inside of the RSV virion. At low concentrations HS mimetics bind protons while 
Inside the SH-proton channel, thereby blocking the protons from entering the virion, inhibiting 
uncoating and release of free ribonucleoprotelns Into the cytoplasm. Adapted from (FocosI, 2001-
2013). 
Previous studies have shown that mucosal heparin, dextran sulfate, 
fucoidan and/or lambda carrageenan have good antiviral activity against RSV, 
hepatitis C, human T-lymphotropic virus type-1, HIV, influenza A and Newcastle 
disease virus (Araya et a!., 2011; Crim et al., 2007; Elizondo-Gonzalez et a!., 
2012; Hayashi et al., 2013; Ito et al., 1987; Malhotra et al., 2003; Mori et al., 
2012). Furthermore, studies have found that fucoidans and carrageenans can 
exhibit the antioxidant activity and that this is related to the molecular weight 
and sulfate content of fucoidan. The in vitro model suggested that the ratio of 
sulfate content/fucose was an effective indicator to antioxidant activity of the 
samples (Rocha de Souza et al., 2007; Wang et al., 2008). As antioxidants are 
the compounds, which terminate the attack of reactive species and reduce the 
risk of diseases, the fact that fucoidans exhibit this activity is a very positive role 
in decreasing the effect of RSV infection on lung pathology. In conjunction with 
in vitro results detailed in table 5.5 and the current literature on relevant in vitro 
studies, six HS mimetic compounds were selected for testing in an in vivo 
mouse model. The compounds selected were: HS 230 (desulfated mucosal 
heparin-negative HS control), HS 254 (dextran sulfate- positive HS control), HS 
228 (variation of mucosal heparin), HS 259 (fucoidan), HS 267 (lambda 
carrageenan) and HS 424 (variation of mucosal heparin). Table 5.5 summarises 
the in vitro RSV inhibition levels across all four tested conditions and at all three 
concentrations of the selected compounds. These compounds, excluding the 
negative and positive HS control, represent a selection of four chemically (e.g. 
sulfation, carboxylation) and structurally (e.g. open or closed ring, size 
difference (3 or 200kDa) different compounds which may provide insight into the 
importance of these characteristics in viral inhibition. This study is the first to 
assess HS mimetics antiviral potential against RSV in vivo. 
Table 5.5. In vitro inhibition levels of selected HS mimetics for in vivo 
study across all four conditions 



















5 |jg/mL 8 59 74 91 100 93 
20 |jg/mL 8.5 74 63 99 100 89 
100 |jg/mL 22 97 70 98 100 74 
Condition 
B 
5 pg/mL 2 80 65 96 67 72 
20 |jg/mL 0 78 78 98 100 78 
100 |jg/mL 4 76 76 96 100 87 
Condition 
C 
5 pg/mL -8.7 57 83 85 97 67 
20 |jg/mL 13 76 39 91 72 79 
100 Mg/mL 0 83 74 87 92 65 
Condition 
D 
5 pg/mL -19.5 2.1 24 22 53 22 
20 pg/mL -24 0 0 22 35 30 
100 pg/mL -11 83 63 25 52 65 
Greyed out areas denote the best RSV inhibition levels for the corresponding HS compounds at 
the specified concentration under the specified test condition. 
In vivo post (therapeutic) RSV infection treatment with HS 228 (carboxyl 
reduced mucosal heparin) and HS 259 (fucoidan) has resulted in a statistically 
significant reduction (p < 0.05) in RSV titres compared to the RSV inoculated 
saline treated group (positive control) (Figure 5.8). These results demonstrate 
HS 228 and HS 259 antiviral activity against RSV and potential involvement in 
competitive as well as cell-to-cell spread inhibition. It is hypothesised that these 
compounds could be used as therapeutic candidates utilising a proposed 
mechanism of competitive inhibition previously described. These results are in 
agreement with earlier in vitro studies which have demonstrated the importance 
of HS compounds in RSV inhibition, with compounds such as heparan sulfate, 
dextran sulfate, heparin and chondroitin sulfate B inducing effective RSV 
inhibition (Hallak et at., 2000a; Hallak et al., 2007; Hallak et a!., 2000b; Karger 
et al., 2001). In addition, a study using dengue virus and flavlviral encephalitis 
mouse model found that PI-88 (a mixture of highly sulfated, 
monophosphorylated mannose oligosaccharides) had a significant and 
beneficial effect in disease outcome (Lee etal., 2006). 
Although, post RSV infection treatment with HS mimetics resulted in only 
two HS compounds effectively reducing RSV infection, their performance in vivo 
is in agreement with previously suggested trend extrapolated from the HS in 
vitro studies (previously described in Tables 5.4 and 5.5). HS 228 
(decarboxylated mucosal heparin) belongs to group 2 of HS mimetics tested in 
vitro. Group 2 HS mimetics were found to perform, on average, better under 
condition D in vitro (RSV pre-incubation with a cell monolayer for 1 hour) which 
is closely related to post RSV infection HS treatment in vivo, in terms of 
experimental set up. The in vitro proposed trend translated well to in vivo study 
showing that HS 228 (group 2 HS mimetic) induced a reduction in RSV titres 
following post RSV infection treatment with HS 228. However, HS 259 
(fucoidan) belongs to group 3 of HS mimetics tested in vitro. Group 3 HS 
mimetics were proposed to perform the best under conditions A (RSV 10 minute 
pre-incubation with HS mimetics) and B (HS mimetic 10 minute pre-incubation 
with cell surface), while not so well under C (short RSV pre-incubation with cell 
surface) and D (1 hour RSV pre-incubation with cell surface). In vivo HS 259 
performed well, inducing statistically significant reduction in viral tires following 
post RSV infection HS 259 treatment; however this unexpected result, 
demonstrates that some HS compounds individual antiviral effect may deviate 
from the group classification proposed by in vitro findings. HS 254 (group 5), HS 
267 (group 4) and HS 424 (group 2) did not induce statistically significant 
reduction in viral titres. Based on the in vitro study proposed trend, this was an 
expected result for HS 254 and HS 267, however it was unexpected finding for 
HS 424 which belongs to group 2 of HS mimetics and was predicted to be more 
effective. A plausible explanation for this finding could be related to HS 424 
chemical structure. HS 424 has a glycol split and there is a lot to be noted about 
a glycol split modification on any compound. Firstly, most of the attempts to 
modulate protein binding and biological properties of heparin have been made 
by the modulation of the sulfation patterns of the GAG backbone and enhance 
of chain flexibility of the GAG by the glycol splitting of C2-C3 bonds of 
nonsulfated GIcA and IdoA residues. Both the degree of sulfation (charge 
density) and the appropriate distribution of N-sulfate and N-acetyl groups 
(charge distribution) along the heparin molecule is determinant in its biological 
properties (VIodavsky et al., 2007). For example, the strongest protein binding 
was observed for 'fully sulfated' heparin and extra-sulfate groups potentiated 
this interaction. IdoA-containing sequences are considered to facilitate the 
appropriate orientation of substituents for the suitable interaction (Casu et a/., 
2002a; Casu et ai., 2002b). Additional local flexibility was obtained by glycol 
splitting that act as flexible joints along the heparin chain were conformation 
changes can be induced by the protein interaction. Chain flexibility is thought to 
play a key role in heparin-protein interactions (Ritchie et ai., 2011). The most 
important result of glycol split modification is that glycol split of heparin 
drastically reduces the anticoagulant activity normally associated with heparin. 
(Conrad and Guo, 1992; VIodavsky et ai., 2007). Taking all of these findings 
together, the benefits of glycol split are apparent and maybe HS 424 inactivity is 
simply a result of HS 424 inability to act as a treatment for RSV infection. 
However, HS 424 structure may be more favourable for prophylactic treatment. 
On the other hand, prophylactic HS treatment of the RSV inoculated 
group, with HS 228 (carboxyl reduced mucosal heparin), HS 259 (fucoidan), HS 
267 (lambda carrageenan (200kDa) or HS 424 (mucosal heparin with glycol 
split (3kDa) induced a statistically significant reduction (p < 0.05) of RSV viral 
titres compared to the positive control (Figure 5.13). Prophylactic treatment with 
HS mimetics resulted in all tested compounds demonstrating their antiviral 
potential by, either, HS mimetic interaction with the HS at the cell surface or HS 
mimetics interaction with RSV glycoproteins. Cliaracterising the proposed 
mechanisms could help determine which of the tested HS mimetic has the 
potential to become prophylactic RSV infection treatment candidate. These 
results are supported by chapter 5 in vitro findings, with each of the tested HS 
mimetics also performing very well in vivo. Condition B (HS mimetic 10 minute 
pre-incubation with cell surface) experimental set up is equivalent to the one for 
prophylactic HS treatment of RSV infection. Enhanced RSV inhibition achieved 
following prophylactic treatment of RSV infection is possibly due to the HS 
mimetics interaction with the cell surface HS where HS mimetics were not 
required to compete for the binding site, it was available to them prior to RSV 
infection. Structurally, HS 259 and HS 267 belong to groups 3 and 4, 
respectively, and as proposed by in vitro results, these are the best suited for 
prophylactic treatment. HS 254 belongs to group 5 of HS mimetics, which 
remained uncharacterised; however, in the in vivo model, HS 254 appears to be 
promising prophylactic treatment candidate. Finally, HS 228 and HS 424 belong 
to group 2 of HS mimetics, which was found to perform the best as a 
therapeutic for RSV infection during an in vitro study, however, in vivo, HS 228 
and HS 424 were found to perform well as prophylactic candidates against RSV 
infection. As suggested earlier HS 424 efficacy as prophylactic compound may 
be due to its open ring structure, however HS 228 has proven to be HS 
compound performing well as a therapeutic treatment following RSV infection 
and as prophylactic treatment of RSV infection. HS 228 should be tested further 
in vivo at different concentrations to elucidate its antiviral ability against RSV. 
Table 5.6 compares the in vitro and in vivo findings. It outlines RSV 
inhibition levels induced by HS 230, HS 254, HS 228, HS 259, HS 267 and HS 
424 following their in vivo treatment of RSV infection compared to condition D in 
vitro and prophylactic in vivo HS treatment of RSV infection compared to 
condition B in vitro. The comparison of in vitro and in vivo results is possible as 
the in vitro concentration of 100 pg/mL is equivalent to the 10 mg/mL/kg HS 
concentration used in vivo. The result analysis revealed an emerging trend from 
the in vitro study allowing prediction of HS mimetic inhibition of RSV in vivo by 
taking a 50% of its in vitro inhibition value. This trend could be used to 
determine the most suited compound for in vivo study based on its in vitro 
results, hence reducing the number of compounds required for in vivo testing. In 
contrast, in vitro anti-flaviviral effectiveness of the HS mimetics did not reliably 
predict their in vivo therapeutic activity (Lee et al., 2006) suggesting that caution 
must be exercised when eliminating compounds at the in vitro stage. 
Table 5.6. Comparison of in vitro and in vivo RSV inhibition 
Average RSV inhibition levels (%) 
Test 
condit ions 


















10 mg/mL/kg -1.7 0 37 38 24 19 





10 mg/mL/kg 0 37 54 52 52 48 
100 pg/mL 4 76 76 96 100 87 
Post RSV infection treatment with HS mimetics resulted in measured 
immune response in BALF (Figure 5.9) and blood (Figure 5.10), leading to 
reduction in combined HPS (Figure 5.12). The measured immune response 
observed here, suggests HS mimetics immunomodulatory effect on RSV viral 
load while preventing immune overreaction. These results are supported by 
findings that sulfated polysaccharides, have been shown to possess 
immunomodulatory activities that may be of potential application in stimulating 
the immune response or in controlling immune cell activity to mitigate 
associated negative effects such as inflammation (Chen etai., 2008; Parish et 
al., 2001). Fucoidans and carrageenans specifically have been found to be 
involved in immune modulation, playing a very positive role in inflammation 
(Blondin et al., 1994; Senni et al., 2006). Therefore, further investigation into the 
mechanism behind this immune modulation is required to gain better 
understanding of, the HS effect on the immune response and targeted immune 
response using HS mimetics. 
Prophylactic treatment of RSV infection demonstrates for the first time 
that prophylactic treatment with HS mimetics results in a similar immune 
response as observed following the RSV re-infection in the absence of HS 
mimetics (chapter 4). Consequently, it can be hypothesised that prophylactic 
HS treatment induces innate immune response, which is followed by adaptive 
immune activation once RSV inoculation is administered. This study has not 
characterised which adaptive immune cells are present following the 
prophylactic HS treatment of RSV infection; as such, this hypothesis is solely 
based on an increase in lymphocyte numbers, in BALF and blood. These 
results also differ from those observed in a previous section on post RSV 
Infection HS treatment, where a decrease in lymphocyte numbers present in 
BALF was observed (Figure 5.14). Finally, prophylactic treatment of RSV 
infection with HS 259 and HS 267 resulted in significant increase (p < 0.0001) in 
combined HPS compared to the positive control; while HS 288 prophylactic 
treatment of RSV infection resulted in a decrease (p < 0.05) in combined HPS 
compared to the positive control (Figure 5.17). This finding contributes to ever 
growing evidence that an increase in eosinophil infiltration In BALF does not 
contribute to combined HPS. HS 228 prophylactic treatment of RSV infection 
resulted in an increase in eosinophil numbers present in BALF while it reduced 
combined HPS. This is a novel finding demonstrating HS mimetics effect on 
RSV infection in vivo and Immune modulation. 
In addition, in vivo findings indicate for the first time that HS may have a 
direct effect on immune response even in the absence of viral infection. A pre-
primed immune response may lead to more efficient viral clearance and may be 
a useful treatment for infants and elderly who may be highly susceptible to viral 
infection and could benefit from already activated immunity. Also, groups like 
HIV patients, medical staff working in infectious disease units and 
immunodeficient patients (e.g. lacking IgA) could benefit from this treatment, as 
it can be administered as a preventative measure. Currently, some therapies 
are already in use as prophylactic treatments for asthma, multiple sclerosis and 
other diseases. XOLAIR (omallzumab) Is a monoclonal antibody targeting 
circulating IgE, preventing them from making a contact with its receptor on the 
effector cell. XOLAIR is recommended for people with allergic asthma who still 
have asthma symptoms even though they are taking inhaled steroids and It 
seems to work well (Norman et a!., 2013). Also, the therapy of relapsing-
remitting multiple sclerosis is also based on the use of immune-modulating 
treatments with drugs such as, IFN-|3, glatiramer acetate, natallzumab etc. 
(Clerico et al., 2008). As demonstrated, immune modulating treatment is widely 
used and HS mimetics pose as potential immune modulating candidate to be 
used in RSV Infection while HS production costs are kept low. 
It has been reported that efficient RSV infection requires the intact G 
protein (Kwilas et al., 2009). However, most laboratory-derived RSV stock, 
including the stock used in this study, is propagated through Vero cells which, 
according to Kwilas et al. (2009), results In the formation of truncated G protein 
(Kwilas et al., 2009). The truncated form of the G protein is believed to be 
dysfunctional in terms of viral attachment to the cell surface HS based on the in 
vitro findings (Kwilas et al., 2009). This loss of attachment function is believed to 
also result in poor infection initiation in vivo, potentially negatively impacting on 
both animal experiments and attenuated-vaccine studies with volunteers 
(Kwilas et al., 2009). This limitation was not directly addressed in this present 
study, however it should be noted that RSV infection in the mouse model was 
achieved and this was consistent with other studies using a laboratory derived 
viral stock (Tripp et al., 2000; Waris et al., 1996). Currently there are no in vivo 
studies that have compared truncated and non-truncated virus forms, therefore, 
repeating the in vivo studies using a virus with a non-truncated form of G 
protein, would be required to assess the effect on viral attachment and RSV 
interaction with GAGs. 
In conclusion, this is the first HS mimetic study that has examined and 
reported on 53 HS mimetic compounds antiviral activity against RSV in vitro. In 
addition, this study is the first to perform in vivo studies with HS mimetics using 
RSV mouse model, and compare post RSV infection HS treatment with 
prophylactic HS treatment of RSV infection. Together, findings from in vitro and 
in vivo studies demonstrate the antiviral potential of HS mimetics against RSV. 
HS 228 was found to be the best performing compound, both, as post RSV 
infection HS treatment and prophylactic treatment of RSV infection, while 
reducing RSV disease pathology. In addition, HS mimetics were found to 
activate an immune response even in the absence of viral infection, suggesting 
their potential in pre-emptive immune activation and immune modulation. The 
development of an effective and safe RSV vaccine has remained elusive to 
date, making HS mimetics true contenders in this race. 
Chapter 6. GENERAL DISCUSSION AND CONCLUSIONS 
6.1 INTRODUCTION 
In 2010, RSV was found to be responsible for the majority of 2.8 million 
infantile lower respiratory tract infections (Lozano et al., 2012). The virus infects 
nearly all children by three years of age and is a leading cause of infant 
hospitalisation and childhood wheezing (Hall et al., 2009; Shay et al., 1999). 
Globally, RSV accounts for 6.7% of deaths among infants, one month to one 
year old, which is more than any other single pathogen except malaria (Lozano 
et al., 2012). The only intervention currently available is passive administration 
of the licensed monoclonal antibody palivizumab (Beeler and van Wyke 
Coelingh, 1989; Johnson et al., 1997). However, this treatment is very 
expensive and is reserved for high risk patients only. Therefore, controlling RSV 
has remained a formidable challenge and more work is urgently required, to 
understand the role of innate and adaptive immunity in RSV infection and in the 
development of new therapeutics. 
6.2 RESEARCH OUTCOMES 
6.2.1 Effect of RSV infection on eosinophil biology 
Since, the first FI-RSV vaccine trial yielded disastrous results with young 
recipients, pulmonary eosinophilia elicited in response to primary RSV infection 
became the hallmark of RSV disease (Chin et al., 1969; Fulginiti et al., 1969; 
Rosenberg et al., 2009; van Hagen et al., 1999). Subsequent FI-RSV studies 
have led to the conclusion that eosinophils contribute to the pathological 
cascade of RSV disease and their presence was deemed undesirable (Graham 
etal., 2000; Hancock etal., 1996; Openshaw etal., 2001; Tripp etal., 2000; van 
Hagen et al., 1999; Varga et al., 2001). In the late 1990s, several studies have 
focused on elucidating the beneficial role of eosinophils in viral infection 
(Adamko et al., 1999; Domachowske et al., 1998a; Phipps et al., 2007; 
Rosenberg and Domachowske, 2001) which was further elucidated in the 
chapter 3 in vitro study. 
Eosinophil treatment with RSV has resulted in eosinophil activation as 
evaluated by degranulation, activation and migration assays. The eosinophil 
degranulation study revealed RSV-induced increase in MBP release (Figure 
3.3) suggesting that MBP release results from the targeted activation of 
eosinophils as opposed to a cellular degeneration process. Moreover, RSV 
treatnnent of eosinophils also resulted in increased eosinophil activation (Figure 
3.5) and activation of the eosinophil cytoskeleton, as illustrated by a-tubulin and 
F-actin (Figure 3.6 and 3.7). These results suggest that eosinophil migration 
and recruitment may also result from a targeted response as opposed to a 
nonspecific immune response. Together these findings contribute to the 
hypothesis that an effective viral clearance may be determined by the activation 
of targeted cellular response when and where required. This approach would 
yield controlled immune response with a very specific purpose - viral clearance. 
Earlier studies are in agreement with chapter 3 degranulation findings as high 
levels of ECP were also found present in the lung epithelial tissue culture 
(Olszewska-Pazdrak et a!., 1998b) and nasopharyngeal secretions of human 
infants (Saito et al., 1997). Similarly, RSV-induced eosinophil activation results 
confirm finding by Phipps et al. (2007) who also showed an increase in EPO as 
a result of RSV activation of eosinophils (Phipps et al., 2007), demonstrating 
RSV-induced eosinophil activation. The current migration study is the first to 
report on the RSV-induced activation of the eosinophil cytoskeleton. 
The RSV kinetics study revealed the potential for eosinophils to induce 
viral inhibition, with a reduction in viral titres observed over 0-24 hours period 
(Figure 3.4). In contrast, previous studies have revealed that RSV can infect 
human eosinophils while PVM was shown to infect murine eosinophils (Dyer et 
al., 2009; Kimpen et al., 1996); however, this was not the case following a 
treatment of murine eosinophils with RSV. This contradictory in vitro finding 
could be a result of incompatibility between RSV as a human respiratory 
pathogen and murine eosinophils. However, the mechanism that provides 
protection for mouse eosinophils against RSV infection, may offer a novel 
insight into prevention of human infection and as a result, it should be explored 
further. Finally, RSV treatment of eosinophils has demonstrated for the first time 
that RSV has detrimental effect on eosinophil morphology overtime (0, 3, 6, 12, 
18 and 24 hours) (Figure 3.1 and Figure 3.2). This was confirmed by the 
continuous release of cytotoxic proteins and loss of cellular integrity over the 24 
hour incubation period. Previous findings by Phipps et al. (2007) are in 
agreement with described RSV-induced eosinophil morphological changes, as 
Phipps et al. (2007) have also showed that a ten minute treatment of 
eosinophils with ssRNA results in eosinophil morphological changes as 
demonstrated by a loss of eosinophil crystal core content (Phipps et a!., 2007). 
Current study demonstrates for the first time that RSV treatment has an 
increasingly detrimental effect on eosinophil morphology over time, with 
apoptosis becoming a hallmark of RSV-induced effect on eosinophil structure at 
24 hours post incubation. This finding supports chapter 3 results highlighting 
that eosinophil response to RSV is a targeted response to viral infection, with 
focus on viral clearance through the release of eosinophil cytotoxic proteins. 
6.2.2 The role of innate and adaptive immunity in RSV 
infection and re-infection 
RSV infection in the first two years of life is believed to lead to long-term 
deficiencies in protective immunity to RSV (Welliver, 2003). Inadequate 
immunity in response to RSV re-infection leads to limited viral clearance 
(Welliver et al., 2008) characterised by the infiltration of NK cells and 
subsequent recruitment of helper CD4* and cytotoxic CDS'" lymphocytes to the 
site of infection (Olson et al., 2008; Olson and Varga, 2007; Stevens et al., 
2009). Although RSV-specific CD8'' T cells can provide protection against 
infection, the effect is short-lived (Connors et al., 1991; Kulkarni et al., 1995). 
Therefore, further investigation into long lasting RSV adaptive immune 
response is urgently required, leading to more effective vaccine development. 
Primary infection and re-infection study results confirm eosinophil 
involvement in RSV clearance as demonstrated by a reduction in viral titres 
following RSV infection of eosinophil overproducing mice (IL-5 Tg BALB/c) 
(Figures 4.2 and 4.7). Previous studies by Phipps et al. (2007) had also 
demonstrated accelerated RSV clearance from the lungs of the IL-5 Tg BALB/c 
(Phipps et al., 2007). Our current studies imply that eosinophil antiviral activity 
may be modulated through the availability of T cells and/or T cell counterparts 
such as ILC2 cells in the immune system. This was especially evident with Rag 
27" mice, lacking T and B cells, where eosinophil recruitment was regulated by 
the CD2 expressed on the T cell surface. The absence of T cells in the Rag 27" 
humanised model has resulted in a reduced eosinophil recruitment into the 
BALF and blood following RSV infection and re-infection. In addition, this issue 
appears somewhat overcome in the IL-5 Tg Rag 27" mice, through the 
eosinophil regulation via most likely, ILC2 cells IL-5 production. Recent study by 
Roediger et al. (2013) has shown that both NK and ILC2 cell express CD2, 
required for eosinophil recruitment (Roediger et al., 2013). Adoptive transfer of 
CD4'' cell into adaptive immunity deficient mice induced a reduction in RSV 
infection (Figure 4.7). An increase in eosinophil tissue infiltration was observed 
following CD4''adoptive cell transfer, correlating to the viral clearance observed 
(Figure 4.11). These results suggest that CD4'' cells are required for eosinophil 
recruitment following RSV re-infection, demonstrating eosinophil potential to 
assist in viral clearance. Although the adoptive transfer of CD4'' cells assisted in 
RSV re-infection viral titres reduction, their presence was found to exacerbate 
RSV disease as demonstrated by an increase in combined HPS. RSV disease 
pathology observed appears to be due to CD4^ cell transfer as oppose to 
eosinophil tissue infiltration. This is in agreement with previous antibody 
depletion study of mouse lymphocytes which revealed that the CD4'' and CDS'" 
T lymphocyte contribute individually to clearing of the RSV infection, but that 
both also contribute to disease, especially CDS"^  T cells (Graham et al., 1991). 
Furthermore, several studies have shown that RSV infection alters functionality 
of T lymphocytes (Fulton et al., 2008; Gray et al., 2005) resulting in inadequate 
immune response and low T lymphocyte numbers. The impaired function of T 
lymphocytes in the lung during virus infection has been proposed to be the 
consequence of virus-induced changes in the lung environment (Gray et al., 
2005) as well as virus- induced immune evasion tactics (Lotz and Peebles, 
2012; Moreau et al., 2003). Future RSV immunisation strategies should strive to 
achieve a balanced Immune response. 
6.2.3 HS treatment of RSV infection 
It is well documented that the interaction between RSV and cell surface 
HSPGs are required for RSV attachment and entry into host cells, consequently 
it is a preferential target for the development of antiviral compounds against 
RSV (Feldman et al., 2000). It is not clear, however, what type of GAGs and 
GAG components are involved, whether the important GAGs are on the virus 
(Bourgeois et al., 1998) or the target ceil (Krusat and Streckert, 1997), and the 
magnitude of their contribution to the infection (Hallak et al., 2000a). 
Nevertheless, an effective and inexpensive treatment against RSV is urgently 
required. In 2012, motavizumab, a variant of palivizumab, was denied approval 
by the U.S. FDA due to concerns about safety and allergic reactions (Donalisio 
et al., 2012). Currently, no vaccine for RSV is available. Considering the high 
burden of RSV disease worldwide on both the population and healthcare 
systems, further antiviral research and development is critical (Storey, 2010). 
HS mimetics have a great potential as antiviral candidates. Unlike previously 
tested drugs, which were found to be unsafe and very expensive, HS mimetics 
are highly effective against RSV as demonstrated by current study findings and 
with no/low cellular toxicity and the low cost of production. Therefore, HS 
mimetics could be the antiviral therapeutics that we have been waiting for the 
last six decades. 
The incubation of RSV with HS mimetics in vitro for 10 minutes (condition 
A), pre-incubation of HS mimetics with Vero E6 cell monolayer for 10 minutes 
(condition B) and a short incubation of RSV with the Vero E6 cells (condition C) 
have resulted in 20 out of 53 tested HS mimetics inducing 80-100% RSV 
inhibition {p < 0.005) (Figures 5.4-5.6). The best performing compound under 
conditions A, B and C was HS 267 (lambda carrageenan), inducing 90-100% 
RSV inhibition. These results are in agreement with previous studies who 
reported that pre-incubation of RSV with certain GAGs (e.g. heparin) inhibited 
virus infectivity (Krusat and Streckert, 1997; Martinez and Melero, 2000) as well 
as that HEp-2 cells pre-treatment with GAGs, prior to RSV inoculation, results in 
reduced efficiency of RSV infection (Donalisio et al., 2012; Donalisio et al., 
2010; Hallak et al., 2000b). These results suggest that there may be a 
mechanism behind the interaction of HS mimetics with RSV glycoproteins (G or 
F) with formation of RSV glycoprotein - HS complex resulting in reduction of 
RSV cell infectivity. In addition, HS mimetics interaction with HS on the cell 
surface may involve HS mimetic binding to the HS on the cell surface. 
Consequently the cell surface HS would become unavailable for RSV 
glycoprotein interaction resulting in RSV inhibition. The proposed mechanisms 
require further research to elucidate the exact interaction between HS mimetics 
and RSV as well as HS mimetics and HS on the cell surface; enabling a more 
specific and targeted RSV inhibition and production of therapeutic and/vaccine 
candidates with much specified role. Under final testing condition, pre-
incubation of RSV with the Vero E6 cell monolayer for 1 hour (clinically the most 
relevant condition, condition D), resulted in 15 out of 53 HS mimetic compounds 
inducing 50-90% RSV inhibition (Figure 5.7). The best performing compound 
under condition D was HS 424 (mucosal heparin with glycol split 3kDa), which 
induced 90% RSV inhibition. Previous studies have shown that sulfated 
polysaccharides can mimic HS chains and interact with viral glycoproteins, 
blocking viral attachment to cell surface HS through competitive inhibition 
(Rusnati and Urbinati, 2009; Rusnati et al., 2009). Other studies have also 
shown that pre-incubation of RSV with heparin Inhibited virus infectivity (Krusat 
and Streckert, 1997; Martinez and Melero, 2000). These results demonstrate 
HS mimetic antiviral potential, specifically in competitive RSV inhibition. 
Characterisation of the best performing compounds is essential for the 
elucidation of HS mimetics with competitive inhibition potential are fully 
elucidated in vivo followed by clinical trials if found to be successful as RSV 
antiviral therapeutics. 
It is important to note that some HS compounds performed best at the 
highest (100 MQ/mL) and/or lowest (5 pg/mL) HS concentrations, whilst other 
were unaffected by change In HS concentration (Figures 5.4-5.7). In vitro study 
analysis revealed that 10 out of 53 tested HS compounds achieved an average 
of 65-90% RSV inhibition across the four test conditions at the lowest, 5 pg/mL, 
HS concentration. It was proposed that a mechanism behind RSV inhibition 
following a HS treatment at low HS concentrations involved a proton-selective 
ion channel protein. In 2008, Can et al. (2008) provided experimental evidence 
that the transmembrane domain of SH protein forms pentameric a-helical 
bundles that form cation-selective ion channels in planar lipid bilayers (Gan et 
al., 2008). This suggests that SH may act as a proton-selective ion channel 
protein, transporting protons from the outside to the inside of the RSV vihon. At 
low concentrations, HS mimetics could bind protons while inside the SH-proton 
channel, thereby making it impossible fOor protons to flow inside the virion. As a 
result, RSV uncoating would be blocked and viral replication would be inhibited 
(Figure 5.18). In contrast, in some instances high concentrations of HS 
mimetics have resulted in enhanced viral replication in vitro. This finding is 
hypothesised to be a result of HS mimetics acting as protons themselves at 
high concentrations, with an increase in proton flow towards the virion enabling 
viral uncoating and viral replication. The current study highlights the importance 
of dose dependant viral Inhibition and the need to evaluate a range of 
concentrations, including lower concentrations essential in development of any 
therapeutic. Figure 6.1 summarises proposed mechanisms of RSV inhibition 
discussed so far. 
Figure 6.1. Heparan sulfate (HS) mimetics inhibition of respiratory 
syncytial virus (RSV) infection initiation 
A) HS mimetics blocl< the influx of protons (H-" ions) through the SH (small hydrophobic protein) -
proton channel, Inhibiting uncoating and release of free ribonucleoproteins into the cytoplasm; B) 
HS mimetics interaction with the RSV G attachment protein, preventing virus binding to the 
glycosaminoglycans (GAGs) on the cell surface; and C) HS mimetics bind to GAGs on the cell 
surface blocking the virus interaction with GAGs on the cell surface. 
In vivo post (therapeutic) RSV infection treatment with HS 228 (carboxyl 
reduced mucosal heparin) and HS 259 (fucoidan) resulted in a statistically 
significant reduction (p < 0.05) in RSV titres compared to the RSV inoculated 
saline treated group (positive control) (Figure 5.8). These results demonstrate 
HS 228 and HS 259 antiviral role in RSV infection with potential involvement in 
competitive and cell-to-cell spread inhibition. Prophylactic HS treatment of RSV 
inoculated group, with HS 228 (carboxyl reduced mucosal heparin), HS 259 
(fucoidan), HS 267 (lambda carrageenan (200 kDa)) or HS 424 (mucosal 
heparin with glycol split (3kDa)) induced a statistically significant reduction (p < 
0.05) of RSV viral titres compared to the positive control (Figure 5.13). This 
finding demonstrates HS mimetic antiviral potential again and it could be a 
result of either, HS mimetic interaction with the HS at the cell surface or the 
interaction of HS mimetics with RSV glycoproteins. Characterising the proposed 
mechanisms could help determine which of the tested HS mimetics have the 
potential to become prophylactic RSV infection treatment candidates. These 
results are in agreement with previous in vitro studies which have demonstrated 
the importance of HS compounds in RSV inhibition, with compounds such as 
heparan sulfate, dextran sulfate, heparin and chondroitin sulfate B inducing 
effective RSV inhibition (Hallak et ai., 2000a; Hallak et a!., 2007; Hallak et al., 
2000b; Kargeref a/., 2001). In addition, a study using dengue virus and flaviviral 
encephalitis mouse model found that PI-88 (a mixture of highly sulfated, 
monophosphorylated mannose oligosaccharides) had a significant and 
beneficial effect in disease outcome (Lee etal., 2006). 
Leukocyte recruitment results contribute to the growing evidence that an 
increase in eosinophil infiltration in BALF (following prophylactic HS treatment) 
or in blood (following post RSV infection HS treatment) does not contribute to 
the combined HPS. Post RSV infection HS treatment with HS 259, HS 267 and 
HS 424 has resulted in a reduced (p < 0.0001) combined HPS compared to the 
positive control (Figure 5.12) while HS 228 prophylactic treatment of RSV 
infection resulted in a reduced combined HPS. This novel finding supports the 
antiviral role of HS mimetics in RSV infection in vivo, as well as highlighting their 
potential role in immune modulation. A pre-primed immune response may 
contribute to more effective viral clearance in high-risk patients such as infants 
and the elderly. Also, HIV patients, medical staff working in infectious disease 
units and immune-deficient patients (eg. lacking IgA) could benefit from this 
treatment, as HS mimetics could be administered as a preventative measure. 
Currently, there are some therapies that are used as prophylactic treatments 
(for asthma, multiple sclerosis etc.). XOLAIR (omalizumab) is a monoclonal 
antibody targeting circulating IgE, preventing IgE from making a contact with its 
receptor on the effector cell. XOLAIR is recommended for people with allergic 
asthma who have atopic symptoms even though they are taking inhaled 
steroids (Norman et ai., 2013). As demonstrated by the current studies, the use 
of HS mimetics as prophylactic therapeutics may provide a low cost and high 
efficacy treatment of RSV infection as well as prevention of subsequent ainways 
disease. 
In conclusion, this is the first HS mimetic study that has examined and 
reported on the anti-viral activity of 53 HS mimetic compounds in vitro against 
RSV. In addition, this study is the first to perform in vivo studies with HS 
mimetics using RSV mouse model, and compare post RSV infection HS 
treatment with prophylactic HS treatment of RSV infection. Together, findings 
from in vitro and in vivo studies demonstrate the anti-viral potential of HS 
mimetics against RSV with HS 228 characterised as the best performing 
compound for post RSV infection HS treatment and prophylactic treatment of 
RSV infection, while reducing RSV disease pathology. In addition, HS mimetics 
were found to activate immune response even in the absence of viral infection, 
suggesting their potential in pre-emptive immune activation and immune 
modulation. 
6.2.4 Vaccine candidates and therapeutic agents on 
the edge of success 
Major barriers to vaccine development to date have included: the early 
age of primary RSV infection; the capacity of RSV to evade innate immunity; the 
failure of RSV-induced adaptive immunity to prevent re-infection; the history of 
RSV vaccine-enhanced disease; and the lack of an animal model fully 
permissive to human RSV infection (Graham, 2011). These biological 
challenges, safety concerns, and practical issues, have significantly impeded 
RSV vaccine development progress (Graham, 2011). Nevertheless, recently the 
pre-fusion state of RSV F protein was identified as a target of most RSV-
neutralising activity in human sera; however, its metastability has hindered 
characterisation. To overcome this obstacle, a study has identified prefusion-
specific antibodies that were substantially more potent than the prophylactic 
antibody palivizumab (McLellan et al., 2013). This finding could potentially lead 
to successful vaccine development in the near future. In addition, a clinical-
stage biopharmaceutical company, Okairos, has evaluated its RSV vaccine 
candidate in well-established preclinical models and found that it stimulates 
both a strong neutralising antibody and a robust T-cell response (Okairos, 
2014). Okairos' vaccine candidate has also been shown to provide complete 
protection against RSV infection in challenge experiments in both cotton rats 
and neonatal calves, as well as having an excellent safety profile, both before 
and after challenge (Okairos, 2014). 
Unfortunately, all of these vaccine candidates are antibody based and 
just like previously mentioned XOLAIR (omalizumab), their application may be 
limited to a certain age. Currently XOLAIR can be used only in children over 12 
years of age, which is beyond the age of the high risl< RSV patients (1 month- 2 
years). Also, the production of these therapeutics remains costly as previously 
seen with palivizumab and therefore their application is likely to be highly 
restrictive and out of reach of the general community. 
In contrast, the therapeutic use of HS mimetics has the potential to 
overcome the issues faced by previous monoclonal antibody-based vaccines. 
Firstly, HS mimetics are cheap and easy to produce. Results from this thesis 
demonstrate that HS mimetics induce viral clearance, in vitro and in vivo. In 
addition, HS mimetic have been shown to Induce an immune response even in 
the absence of viral infection, suggesting that they may have a role in immune 
modulation. The fact that HS mimetics have the potential to be used in antiviral 
treatment is supported by patent submitted in 2013 for iota-carrageenan HS 
compound. In early 2013 a patent titled "Antiviral composition comprising a 
sulfated polysaccharide: iota-carrageenan" was submitted by Marinomed 
Biotechnologie GmbH and published on 27th of May 2013. In their patent 
Marinomed Biotechnologie GmbH suggest that iota-carrageenan can be used 
as an active antiviral ingredient in medication for the prophylactic or therapeutic 
treatment of a symptom, condition or disease caused by or associated with an 
infection by a respiratory virus selected from the group consisting of 
paramyxovirus (human parainfluenza virus (HPV) type 1, HPV type 2, HPVtype 
3, HPV type 4 and RSV), human influenza A virus, and adenovirus of subtype 
B. Their results show that iota-carrageenan reduces plaque formation of 
parainfluenza virus 3 in Hep-2 cells by 75% inhibition at lOOpg/ml. Also, iota-
carrageenan pre-treatment of HeLa cells results in 65% reduction of plaque 
formation of parainfluenza virus 3 at 400 pg/ml. Finally, they also show that iota-
, kappa-, lambda-carrageenan and fucoidan induce reduce plaque formation of 
influenza A H5N1 virus in epithelial cells by 80% inhibition at 400 pg/ml (IFI 
CLAIMS Patent Services, 2012). These findings are supported by chapter 5 in 
vitro results where lambda- and iota-carrageenans were found to perform very 
well across all four testing conditions with approximately 60-100% RSV 
inhibition achieved. The in vivo analysis provided by the current studies further 
illustrates the anti-viral potential of HS mimetics. In summary, the in vivo results 
revealed HS 228 (carboxyl reduced mucosal heparin) as the best performing 
compound in vivo following by HS 424 (mucosal heparin with glycol split 
(3kDa)). Further in vivo analysis of HS mimetics is required to elucidate their 
vaccine and therapeutic potential. 
6.3 CONCLUSIONS 
RSV is an important viral pathogen that causes significant morbidity, 
utilisation of health care resources, and impact on secondary disease 
processes. While there are significant biological and historical barriers that have 
delayed vaccine development, continued evaluation of new vaccine and 
therapeutic candidates, such as HS mimetics, indicate the potential for a safe 
and efficacious therapeutic treatment to reduce the disease burden induced by 
RSV. Research to-date highlights that the success of any therapeutic will hinge 
on the generation of an appropriate immune response within the patient, hence, 
continued research towards understanding the innate and adaptive immune 
responses Involved in RSV infection and re-infection is essential. 
Findings from this thesis have advanced current understanding and 
knowledge regarding RSV infection specifically in terms of the role of 
eosinophils in RSV infection, innate and adaptive immune responses to RSV as 
well as potential therapeutic candidates against RSV. The role of eosinophils in 
RSV infection has been expanded on with study findings suggesting that RSV is 
unable to infect mouse eosinophils and that RSV infection induces eosinophil 
activation resulting in eosinophil-mediated and targeted immune response. 
Innate and adaptive immune studies of RSV infection and re-infection advanced 
current knowledge on eosinophil antiviral potential under both experimental 
conditions. Furthermore, eosinophil recruitment is believed to be regulated 
through the expression of CD2 on the T cell surface. Limited eosinophil 
recruitment in the Rag 27" model following RSV infection and re-infection is 
suggestive of T cell regulation. However, this regulation does not seem to be 
limited to T cells only, as recent study by Roediger et al. (2013) has shown that 
both NK and ILC2 cell express CD2, required for eosinophil recruitment 
(Roediger et ai., 2013). As both of these cells are present in the Rag 27" model, 
it is possible that the delay in the eosinophil recruitment observed following RSV 
infection and re-infection of IL-5 Tg Rag 27" mice, is a result of NK and ILC2 
regulation of eosinophil recruitment in the absence of T cells. This novel finding 
could be immune cell regulation, instrumental in the early stages of life when 
dealing with underdeveloped immunity. In vitro and in vivo studies using HS 
mimetics reported for the first time data from over 53 HS mimetic compounds 
demonstrating HS treatment results in RSV inhibition following a pre-incubation 
of RSV with HS mimetics, pre-incubation of HS mimetics with cell surface or 
pre-incubation of RSV with cell surface. HS mimetics also showed antiviral 
potential in vivo as a therapeutic and prophylactic treatment of RSV infection. 
Also, a mechanism for RSV inhibition at low HS mimetic concentrations was 
proposed to utilise interaction between using RSV SH protein and HS mimetics. 
Finally, novel findings that HS mimetics induce immune response in the 
absence of viral infection suggest their potential in immune modulation. 
In conclusion, novel HS mimetics have been identified as potential 
prophylactic or post-infection therapeutic candidates for RSV infection. HS 
mimetics have been shown to have the potential to inhibit viral attachment 
directly or to induce an immune modulation response, further inhibiting the viral 
infection. A modulated immune response could be used to induce a targeted 
antiviral response with eosinophils demonstrating a therapeutic role in RSV 
infection and re-infection. However, in the absence of effective immunisation 
against RSV, the focus needs to remain on reducing prenatal and 
environmental risk factors, including prematurity, smoking and improved 
hygiene practices. In the meantime, search for RSV vaccine and effective 
therapeutic agent continues. 
6.4 FUTURE WORK 
Following the investigations described in this thesis, there are a number 
experiments that should be undertaken as part of the future work. As RSV, 
human respiratory pathogen was found to be unable to infect murine 
eosinophils, it was suggested that a mechanism that offers protection for mouse 
eosinophils against RSV infection should be examined further. Although, mouse 
and human eosinophils are similar, these cells generate different responses to 
RSV infection. To elucidate this mechanism, a FACS analysis of the eosinophil 
(human and mouse) cell surface receptors following the RSV treatment should 
be undertaken. This may identify a cell surface receptor(s) present and used by 
one type of eosinophil in eosinophil-RSV interaction that enables RSV infection. 
Moreover, the contribution of eosinophils to RSV clearance appears to 
be of high importance and the modulation of eosinophil recruitment may be the 
key to RSV inhibition. HS mimetics, in the absence of viral infection, have been 
found to induce immune modulation. Several experiments could assess this 
finding and fine-tune the immune response. Initially, an in vitro migration study 
can be done to assess the effect of HS mimetics on leukocyte chemotaxis. In 
addition, real time migration study can be performed using a TAXIScan machine 
examining eosinophil migration towards HS mimetics as an agonist. 
Furthermore, a dose dependant HS mimetics study could be performed to 
characterise the ability of HS mimetics to induce greater viral inhibition at lower 
concentrations as observed in in vitro studies. 
As CD4'' adoptive transfer into IL-5 Tg Rag 2 /" BALB/c mice has resulted 
in the reduction of viral load, it would be useful to assess: if CD4'' adoptive 
transfer into Rag 2-/- BALB/c; and CDS"' adoptive transfer into Rag 27- and IL-5 
Tg Rag 2i- BALB/c mice would also, result in the same viral titre reduction. In 
addition, 004"^ and CDS"^  adoptive transfer effect on lung pathology in response 
to RSV infection. This would be of interest as cells are believed to 
contribute to more RSV disease pathology compared to the CD4'' cells. 
Furthermore, as eosinophils have been found to be regulated by T cells and 
potentially T cell innate counterparts, the focus of future studies should be on 
elucidating the cell population involved in the regulation process. Furthermore, 
any future work should also utilise assays described in chapter 3 
(degranulation, activation and chemotaxis) which could assist in elucidating the 
difference in eosinophil response observed between primary and secondary 
RSV infection. 
As mentioned in chapter 5, it is imperative to understand the interaction 
between RSV, HS mimetics and/ or HS at the cell surface, so this knowledge 
can be used and applied to vaccine and therapeutic designs. Therefore, wild 
type RSV could be assessed for its ability to utilise HS-mediated viral replication 
by performing an in vitro attachment experiments. These experiments would 
involve characterising RSV G or F protein interaction with HS at the cell surface 
by removing RSV receptors one at the time using WT BALB/c model and 
blocking RSV receptors. If results were promising from this study the next step 
should involve investing into developing genetically modified BALB/c mice 
lacking specific RSV receptors. Similar approach could be applied while 
characterising HS mimetics and cell surface HS interaction using WT BALB/c 
model and blocking the cell surface receptors one at a time in vivo. These 
experiments would facilitate a better understanding of RSV attachment and 
fusion requirements, and hence, enable the development and characterisation 
of novel HS mimetics to inhibit RSV to target cell binding. In parallel, expanding 
on previous studies by Gan et al. (2008) through a series of structural studies 
aimed to characterise SH potential as cation-transport channel protein, w^ould 
be worthwhile in elucidating the role of SH protein in RSV infection as well as 
RSV and HS interaction. 
The HS mimetic studies, in vitro and in vivo, have generated a number of 
potential therapeutic/vaccine candidates. It was beyond the scope of this study 
to test all the candidates in vivo; however, future work should focus on 
characterising more HS mimetic compounds, specifically group 1 - modified 
mucosal heparins (~12kDa) with a glycol split (HS 204, HS 205), group 2 -
modified mucosal heparin (3kDa) (HS 331, HS 332) and group 5 - other HS 
compounds (HS 238, HS 241, HS 242, PI-88 and Suramin) as these were found 
to be the most efficient at lower concentrations of 5 and/or 20 pg/mL across all 
four testing conditions. Therefore, these compounds should be tested further in 
vitro at 1 pg/mL and 0.1 pg/mL concentrations to assess if their RSV antiviral 
efficacy can be improved at these concentrations. These compounds should be 
tested in an in vivo model, as many of them are promising anti-RSV candidates. 
Furthermore, as HS mimetics were delivered i.p. in the in vivo studies, it is 
important to assess how much of the HS dose would actually make it to its 
destination, lungs. There appears to be several experimental approaches 
available and future work should focus on answering this crucial question 
arising from the chapter 5 findings. Experiments proposed could entail 
monoclonal antibody detection of HS present in lungs (David et al., 1992), 
fluorophore labelling (Skidmore et a!., 2009) and/or radioactive isotope 
labelling. All of these would enable quantification of HS present in lungs. 
Finally, it is worth repeating some of the studies presented in this thesis 
using RSV clinical isolates, to address the importance of truncated G protein. 
Clinical isolates express full length G protein and studies using these isolates 
could help alleviate any doubt inferred by G protein truncation following the RSV 
derivation in the laboratory. 
APPENDICES 
APPENDIX 1 
Buffered Distilled Water 
Sorensons Buffer 
• Solution A: 0.2 M sodium di-hydrogen orthophosphate 
(MW = 156 g/mol) =3.12 g in 100 ml distilled water 
• Solution B: 0.2 M di-sodium hydrogen orthophosphate 
(anhydrous) (MW 142) = 2.83 g in 100 ml distilled water 
pH 6.8 Stock Solution: 25.5 ml Solution A and 24.5 ml Solution B 
Make up to 100ml with distilled water. 
Working Solution: 50 ml Stock pH 6.8 diluted to 1 litre with distilled 
water. 
APPENDIX 2 
Transmission Electron Microscopy Protocol 
1. Primary fixation: 2% giutaraldehyde in 0.1 M sodium cacodylate for 2 hours 
2. Buffer washes: 2 x 0.1IVI Sodium cacodylate for 15 minutes each 
3. Secondary fixation: 1 % Osmium textroxide for 1.5 hours 
4. Buffer washes: 2 x 0.1 IVI Sodium cacodylate for 15 minutes each 
5. Samples were rinsed in distilled water twice for 5 minutes each 
6. Dehydration in acetone 
• 15 minutes each in 30, 50, 70, 90, 95% acetone and then 3 x 100% 
acetone 
7. Embedded in Spurr's resin as follows: 2 hours in 50:50 - resin: acetone, 2 
hours in 100% resin, overnight in 100% resin, 2 hours in 100% resin, 
overnight in fresh 100% resin to embed at 70°C 
8. Sections approximately 80nm thick were cut 
• Sections were stained with 2% uranyl acetate and Reynold's lead citrate 
9. Samples were photographed using a Hitachi H7000 transmission electron 
microscope at 75k\/ 
Appendix 3 
Negative control ^ ^ ^^ 
UV-RSV V 
0.1 MM PMA 
RSV 
Figure A.1. Respiratory syncytial virus (RSV) induced eosinophil 
degranulation - dot blot membrane 
Freshly isolated eosinophils from interleukin-5 transgenic BALB/c mice were incubated with Vero 
E6 cell lysate (untreated eosinophils; negative control), ultraviolet-inactivated RSV (UV-RSV) 
(additional negative control), 0.1 pM phorbol myristate acetate (PMA) (positive control) or RSV at 
multiplicity of infection of 1 for 4 hours and assessed for eosinophil degranulation using major 
basic protein as a degranulation marker. Dots represent five individual samples tested for each 
sample type. 
APPENDIX 4 
Heparan sulfate cytotoxicity study 
Control 81 106 109 111 229 238 241 242 254 486 510 511A 511B 512D 512E Pl-88Sutainin 
Figure A.2. Heparan sulfate (HS) treatment results in no cellular toxicity 
Assay was prepared in 96-well plate with 6000 Vero E6 cells seeded per well. Once adhered to 
the plate, Vero E6 cell were treated with saline (negative control- white bar) or HS mimetics 
(black bar) at 100 pg/mL final concentration. Following the 24 hour incubation at 37°C, cells were 
analysed for signs of cellular toxicity using AlamarBlue assay. Samples are represented as a total 
of viable cells (n = 4) ± standard deviation. Data was analysed using ONE-way ANOVA with 
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Figure A.3. Heparan sulfate (HS) in vitro (Condition A) treatment of 
respiratory syncytial virus (RSV) infection 
The assay was carried out in 24-well flat bottom plate. Group 1 (heparins and modified heparins ( -
12kDa)) (A), Group 2 (low molecular weight heparins (LMWH) (5kDa and 3kDa) and enoxaparin 
with/without glycol split) (B), Group 3 (fucoidans and modified fucoidan) (C), Group 4 
(carrageenans) (D) and Group 5 (other) (E) HS mimetics were tested at 100, 20 or 5 Mg/mL. 
Briefly, 100 [jl/well of HS mimetics was incubated with RSV (200 plaque forming units/well) for 10 
minutes at 37°C and 5% CO2. Following the incubation, HS with RSV mixture was added to Vero 
E6 cell monolayer and allowed to incubate for 1 hour at 37°C and 5% CO2. Plate was processed 
by immunostaining RSV plaque assay (section 2.10). Data are represented as a mean of RSV 
plaques recovered (n = 4) ± standard deviation. HS compounds 230 (negative) and 254 (positive) 
were used as HS mimetic controls. For each graph, the controls HS 230, HS 254 and RSV results 
are presented in boxed area for comparison. Data were analysed using a ONE-way ANOVA with 
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Figure A.4. Heparan sulfate (HS) in vitro (Condition B) treatment of 
respiratory syncytial virus (RSV) infection 
The assay was carried out in 24-well flat bottom plate. Group 1 (heparins and modified heparins 
(~12kDa)) (A), Group 2 (low molecular weight heparins (LMWH) (5kDa and 3kDa) and 
enoxaparin with/without glycol split) (B), Group 3 (fucoidans and modified fucoidan) (C), Group 4 
(carrageenans) (D) and Group 5 (other) (E) HS mimetics were tested at 100, 20 or 5 pg/mL and 
100 [jl/well of HS mimetics was incubated with Vero E6 cell monolayer for 10 minutes at 37°C 
and 5% CO2. Following the incubation, RSV (200 plaque forming units/well) was added to Vero 
E6 cell monolayer with HS mimetics and allowed to incubate for 1 hour at 37°C and 5% CO2. 
Plate was processed by immunostaining RSV plaque assay (section 2.10.). Data are represented 
as a mean of RSV plaques recovered (n = 4) ± standard deviation. HS 230 (negative) and 254 
(positive) were used as HS mimetic controls. For each graph, the controls HS 230, HS 254 and 
RSV results are presented in boxed area for comparison. Data were analysed using ONE-way 
ANOVA with Tukey's multiple comparison test (GraphPad Prism) ( * " , p < 0.001 and " * * , p < 
0.0001). 
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Figure A.5. Heparan sulfate (HS) in vitro (Condition C) treatment of 
respiratory syncytial virus (RSV) infection 
The assay was carried out in 24-well flat bottom plate. RSV (200 plaque forming units/well) was 
added to Vero E6 cell monolayer and allowed to incubate for 10 minutes at 37°C and 5% CO2. 
Following the incubation, 100 pl/well of Group 1 (heparins and modified heparins (~12kDa)) (A), 
Group 2 (low molecular weight heparins (LMWH) (5kDa and 3kDa) and enoxaparin with/without 
glycol split) (B), Group 3 (fucoidans and modified fucoidan) (C), Group 4 (carrageenans) (D) and 
Group 5 (other) (E) HS mimetics were added at 100, 20 or 5 pg/mL to Vero E6 cell monolayer 
treated with RSV and incubated for 1 hour at 37°C and 5% CO2. Plate was processed by 
immunostaining RSV plaque assay (section 2.10.). Data are represented as a mean of RSV 
plaques recovered (n = 4) ± standard deviation. HS 230 (negative) and 254 (positive) were used 
as HS mimetic controls. For each graph, the controls HS 230, HS 254 and RSV results are 
presented in boxed area for comparison. Data were analysed using ONE-way ANOVA with 
Tukey's multiple comparison test (GraphPad Prism) (*, p < 0.05,*", p < 0.001 and p < 
0.0001). 
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Figure A.6. Heparan sulfate (HS) in vitro (Condition D) treatment of 
respiratory syncytial virus (RSV) infection 
The assay was carried out in 24-well flat bottom plate. RSV (200 plaque forming units/well) as 
added to Vero E6 cell monolayer and allowed to incubate for 1 hour at 37°C and 5% CO2. 
Following the incubation, 100 pl/well of Group 1 (heparins and modified heparins (~12kDa)) (A), 
Group 2 (low molecular weight heparins (LMWH) (5kDa and 3kDa) and enoxaparin with/without 
glycol split) (B), Group 3 (fucoidans and modified fucoidan) (C), Group 4 (carrageenans) (D) and 
Group 5 (other) (E) HS mimetics were added at 100, 20 or 5 pg/mL to Vero E6 cell monolayer 
treated with RSV. Plate was processed as per immunostaining RSV plaque assay (Section 2.7.). 
Data are represented as a mean of RSV plaques recovered (n = 4) + standard deviation. HS 230 
(negative) and HS 254 (positive) were used as HS mimetic control. For each graph, the controls 
HS 230, HS 254 and RSV results are presented in boxed area for comparison. Data were 
analysed using ONE-way ANOVA with Tukey's multiple comparison test (GraphPad Prism) (**, p 
<0.005 and "** , p < 0.0001). 
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